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Abstract 
Colorectal cancer (CRC) incidence and mortality among Alaska Native people are the 
highest of any ethnic or racial group in the United States. First-degree relatives (FDRs), 
which include parents, siblings, and children of CRC patients, are at increased risk. There 
is a paucity of data on predictors of screening adherence among Alaska Native FDRs, and 
the extent to which screening outreach is occurring within the Alaska Tribal Health 
System (ATHS) for FDRs. There is also a lack of data available on barriers and 
facilitators to increasing screening outreach efforts in this population. This study assessed 
the prevalence of CRC screening outreach to FDRs at Alaska tribal health organizations 
(THOs), use of family history information, barriers to CRC screening, and potential tools 
to improve CRC screening throughout the Alaska Tribal Health System (ATHS). The 
study also included a process evaluation of the Alaska Native CRC Family Outreach 
Program (2000-2012) based in Anchorage, Alaska. The process evaluation investigated 
the program’s formation, evolution, and successes and challenges through a series of key 
informant interviews with program stakeholders. Lastly, an outcome evaluation was 
conducted of the Alaska Native CRC Family Outreach Program to assess predictors of 
screening adherence and results of screening among Alaska Native FDR program 
participants. The study found that CRC screening outreach was common in the ATHS, 
but significant barriers still exist. These barriers were especially notable for outreach to 
FDRs, including a lack of dedicated staff and resources. Key results of the process 
evaluation of the Alaska Native CRC Family Outreach Program included an incremental 
approach that led to a unique outreach program and revealed the need for dedicated staff 
to provide culturally competent patient navigation. Challenges identified included 
differing FDR outreach responses, health system data access and coordination, and 
relying on unstable grant funding for program sustainability. The outcome evaluation of 
the Alaska Native CRC Family Outreach Program found despite increasing programmatic 
outreach and FDR screening rates, a large proportion of Alaska Native FDRs were still 
due for screening. This was especially true among rural-dwelling and older FDRs. This 
study found that overall, CRC screening and awareness are increasing among the Alaska 
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Native population, including among FDRs. However, many Alaska Native FDRs remain 
unscreened. There is a critical need for more research into FDR barriers and facilitators to 
CRC screening, as well as how the ATHS can more systematically promote screening 
among this increased-risk population and reduce morbidity and mortality due to this 
preventable disease.  
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CHAPTER 1 
 
General Introduction 
 
Over the past four decades colorectal cancer (CRC) pathogenesis has been increasingly 
well elucidated. Epidemiological data outlining the demographic factors associated with 
colorectal cancer have also become available, included both protective and risk factors. 
Screening for colorectal cancer has come to be regarded as a primary method to both 
prevent colorectal cancer as well as find it early in the disease progression, resulting in 
reduced morbidity and mortality.  
 
Anatomy  
The human digestive system, also called the gastrointestinal system, processes food for 
energy in the upper portion (esophagus, stomach and small intestine). In the lower 
gastrointestinal system, water and mineral nutrients from digested food are absorbed and 
solid waste (stool) is formed that passes from the body through the colon and rectum (see  
Figure 1-1a). The colon, also called the large intestine or bowel, is about 5-6 feet long 
and is divided into four sections: the ascending colon, the transverse colon, the 
descending colon, and the sigmoid colon, which joins the rectum, which is the final 5-6 
inches of the digestive system.  
Figure 1-1a. Anatomy of human colon. Source: www.medicalinfo-3n.blogspot.com.  
Figure 1-1b. Colorectal cancer disease progression. Source: National Cancer 
Institute.  
Colorectal Cancer Pathogenesis 
2 
Colorectal cancer can start anywhere within the colon or rectum. Most colorectal cancers 
begin as polyps, small precancerous growths in the interior lining of the large intestine 
which progress very slowly into cancers (see Figure 1-1b).1 Anatomic sub-sites for 
colorectal cancer are based on the International Classification of Diseases for Oncology 
codes for broad categories: proximal colon (codes C18.0 and C18.2-C18.5), distal colon 
(codes C18.6 and C18.7), rectum (codes C19.9 and C20.9), and other (codes C18.1, 
C18.8, C18.9, and C26.0).2 The average time from progression of a polyp to cancer is 10 
to 15 years.3 Certain kinds of polyps, called adenomatous polyps or adenomas, are 
precancerous lesions formed from glandular structures in colon epithelial tissue and are 
the most likely to become cancer, though fewer than 10% of adenomas actually progress 
to cancer.1 These types of polyps are common, and an estimated one-third to one-half of 
all individuals will eventually develop adenomas.4 The vast majority (96%) of colorectal 
cancers are adenocarcinomas: “adeno-”, meaning “gland”, and “carcinoma”, meaning a 
malignant tumor evolving from epithelial tissue.5 Colorectal cancers are classified by 
stages in the progression of the disease process. In Stage 1 the cancer has not spread to 
nearby tissue (in situ cancer). In Stage 2 the cancer has spread to other tissues, but not to 
the lymph nodes (local). In Stage 3 the cancer has spread to the lymph nodes (regional), 
and in Stage 4 it metastasizes to other organs in the body via the lymph system (distant). 
 
Disease Progression 
If found early when the disease is still at the local stage, the 5-year survival rate is 90%. 
If the disease has spread to the regional and distant stage at the time of diagnosis the 5-
year survival rates are 70% and 12% respectively. Overall about 39% of colorectal cancer 
patients are diagnosed with localized-stage disease.4 Colorectal cancers and some 
precancerous adenomas sometimes intermittently bleed resulting in small amounts of 
blood in the stool. Symptoms of colorectal cancer may include bleeding from the rectum,  
 
blood in the stool or in the toilet after having a bowel movement, dark- or black-colored 
stools, a change in the shape of the stool, cramping pain in the lower stomach, a feeling 
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of discomfort or an urge to have a bowel movement when there is no need to have one, 
new onset of constipation or diarrhea that lasts for more than a few days, or unintentional 
weight loss.4 However, colorectal polyps and early stage colorectal cancers usually do not 
cause symptoms, and in the absence of screening, they may go undetected until an 
individual presents at a symptomatic advanced stage. 
 
Incidence and Mortality  
 
United States Demographic Characteristics 
Colorectal cancer mortality data in the United States (U.S.) is available from the National 
Center for Health Statistics (NCHS). Colorectal cancer incidence data comes primarily 
from the Surveillance, Epidemiology, and End Results (SEER) program of the National 
Cancer Institute. These data sources provide long-term trends on colorectal cancer in the 
United States. Cancer cases are classified according to the International Classification of 
Diseases for Oncology.6 All incidence and death rates in these data sources are age-
standardized to the 2000 U.S. standard population and expressed per 100,000 persons.7 
 
In the United States alone, an estimated 102,480 (72%) cases of colon and 40,340 (28%) 
cases of rectal cancer were expected to occur in 2013, with an estimated 51,710 deaths, 
accounting for 9% of all new cases of cancer and 9% of all cancer deaths in the country.7 
Colorectal cancer is the third most common cancer in both men and women and the 
second most common cancer for males aged 40 to 79.7 Rates of the disease vary widely 
by U.S. geographic area, with death rates tending to be lower in the Western states and 
higher in the South and Midwest. Incidence rates tend to be higher in the Midwest and 
Northwest regions of the country (see Figure 1-2).4, 8  
4 
            
Figure 1-2. Age-adjusted colorectal cancer incidence and death rates per 100,000 
population, U.S., 2007.9  
 
Nationally, colorectal cancer incidence and mortality rates are highest among African 
American men and women, while rates are lower among the other major racial/ethnic 
groups (Asian American/Pacific Islander, Hispanic/Latino, and American Indian/Alaska 
Native) than rates among Non-Hispanic Whites.4 Among American Indian and Alaska 
Native people overall incidence and death rates of colorectal cancer are similar to the 
United States White population.7 However, American Indian and Alaska Native people 
are a heterogeneous population, and rates of colorectal cancer among American Indian 
and Alaska Native groups vary considerably throughout the United States.  
 
Alaska Native Demographic Characteristics 
Cancer is the leading cause of death among Alaska Native (AN) people. Data collected as 
part of the Alaska Native Tumor Registry demonstrate that colorectal cancer is the 
second leading cause of cancer mortality behind lung among Alaska Native people and 
the leading incident cancer.10-12 For the period, 2004-2008, the Alaska Native age-
adjusted colorectal cancer mortality and incidence was about twice that of U.S. Whites 
(see Figure 1-3);13 a trend which also held for the period, 2005 to 2009, in which the 
colorectal cancer incidence rate in Alaska Native men and women was two times the rate 
in U.S. Whites (84 vs. 43/100,000).9, 14 Alaska Native colorectal cancer incidence and 
mortality rates are also about twice those of all Alaskans.4, 7  
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Figure 1-3: Five-year average annual age-adjusted cancer incidence rates, Alaska 
Native people, 1969-2008 and U.S. Whites, 1974-2008.  
 
In sum, the colorectal cancer incidence and mortality rate among Alaska Native people is 
the highest of any ethnic or racial group in the U.S.15 Furthermore, Alaska Native people 
experience the highest colorectal cancer incidence rate of all Native American groups 
with the rate varying five-fold between Alaska Native people (102.6 per 100,000) and 
American Indians from the Southwest U.S  (21.0 per 100,000) (see Figure 1-4).15-17 
 
Figure 1-4: CRC incidence rates by select Indian Health Service Region Contract 
Health Service Delivery Area (CHSDA) counties, 1999-2004. NHW=non-Hispanic 
Whites.16 
 
Colorectal cancer screening efforts at Alaska tribal health organizations statewide have 
documented identification of adenomatous polyps in 30% to 50% of patients. This stands 
in contrast to a national study of Medicare beneficiaries that reported an average polyp 
rate of 24%.18 For the most recent period (2005 to 2009) for which data are available 
there were 301 cases of invasive and 36 cases of in situ colorectal cancer diagnosed 
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among Alaska Native people (154 men and 147 women).14 Unlike national trends, the 
rates of colorectal cancer were similar for Alaska Native men and women, and colorectal 
cancers occurred proportionally in the same regions of the colon (41% in the proximal 
colon, 29% in the distal colon, and 28% in the rectum) as the U.S. White population.  
 
Age-specific rates of colorectal cancer are higher among Alaska Native people as 
compared with U.S. Whites for all age groups, especially for Alaska Native people aged 
70 to 79 (see Figure 1-5). Age-specific incidence rates for Alaska Native people are 
double those of U.S. Whites for ages 30 to 39 (11.3 vs. 5.6/100,000) and 40 to 49 (45.1 
vs. 19.8/100,000).14 The Alaska Native colorectal cancer in situ rate was four times 
higher than among U.S. Whites. As for invasive cancers, the incident rate was two times 
lower for localized colorectal cancer among Alaska Native people as compared with U.S. 
Whites, but twice as high for regional and distant cancers, which are the more advanced 
and difficult to treat cancers. An analysis of diagnosis by colorectal cancer stage found 
that 59% of Alaska Native colorectal cancers were diagnosed beyond the local stage. 
However, at each stage of diagnosis, the five-year relative survival rate was similar 
between Alaska Native and U.S. White populations. 
 
Figure 1-5: Age-specific CRC incidence rates and stage at diagnosis, Alaska Native 
People and U.S. Whites, 2005-2009.14   
 
Incidence and Mortality Trends  
In the United States overall, colorectal cancer mortality rates have declined 30% over the 
past two decades; from 2000-2009, colorectal cancer declined 3.0% annually.7 Long-term 
incidence rates have also been declining in men and women, with an increase in the 
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incidence of the disease for men during 1975-1985, declines during 1985-1995 for men 
and women, a short non-significant increase from 1995-1998, and then marked declines 
from 1998-2006 for both sexes.7 
 
In the 1950s, cancer ranked low among causes of death among Alaska Native people. 
Over the last 50 years cancer has increased to now ranking as the leading cause of death 
among Alaska Native people. In contrast to the declining United States death rate from 
colorectal cancer, the Alaska Native colorectal cancer death rate has not been declining.19 
The incidence of colorectal cancer has significantly increased in the Alaska Native 
population since 1969.15, 16 Data from the most recent period available from the Alaska 
Native Tumor Registry (2005 to 2009) show that the Alaska Native incident rate appears 
to be declining from the 1990s. However, this decreasing trend was not  statistically 
significant, and colorectal cancer continues to account for the greatest cancer burden 
among Alaska Native people.14  
 
Colorectal Cancer Screening  
Declining trends in colorectal cancer incidence and mortality among adults 50 years and 
older have been largely attributed to increases in colorectal cancer screening.2, 4, 9, 20, 21 
Screening has the potential to prevent colorectal cancer by detection and removal of 
precancerous polyps in the colon and rectum, as well as detecting cancer at earlier, more 
treatable stages.3, 22, 23 The evidence for screening effectiveness is primarily based on 
large prospective randomized controlled trials with guaiac-based fecal occult blood tests 
(gFOBT) ,which demonstrated significant reductions in colorectal cancer mortality of 
15% to 33%, and large randomized controlled trials with flexible sigmoidoscopy which 
found that flexible sigmoidoscopy reduced colorectal cancer incidence by 32% and 
mortality by 28%.24, 25  
 
The primary goal of colorectal cancer screening is cancer prevention, and the long lead-
time from precancerous polyp to colorectal cancer presents a window of opportunity for 
8 
screening and intervention.26 It has been estimated that if all precancerous polyps were 
identified and removed before becoming cancerous, colorectal cancer incidence and 
mortality could be reduced by 76% to 90% and 70% to 90%, respectively.3, 27 This also 
has profound implications for healthcare systems in the form of unrealized financial 
savings.28 The United States spends roughly $14 billion each year on colorectal cancer 
treatment.29-31 In 2006 alone, an estimated $288,468 in productivity was lost per 
colorectal cancer death.9 As the United States population ages, the economic burden of 
this disease among individuals aged 65 and older is estimated to increase by 50-89% 
through 2020.29 If United States cost estimates are projected for Alaska Native people, 
the treatment costs alone for 100 persons with colorectal cancer would be more than $10 
million annually.29, 30 
 
The United States Healthy People 2020 target for colorectal cancer screening is 70.5%,32 
and the Centers for Disease Control and Prevention (CDC) National Colorectal Cancer 
Control Program (CRCCP) has set a goal to increase colorectal cancer screening rates 
from about 64% to 80% among adults aged 50 years and older by 2014.  
 
Screening Methods 
Accepted colorectal cancer screening options include tests that primarily detect cancer 
(stool tests) and those are more likely to detect cancer and precancerous growths, 
including flexible sigmoidoscopy, colonoscopy, computed tomography colonography 
(also known as virtual colonoscopy), and double-contrast barium enema. Although all 
these screening tests are nationally recommended, there are significant advantages and 
disadvantages to each test in terms of patient discomfort, time requirements, invasiveness 
of test, and recommended intervals and required follow-up. These tests may be used 
alone or in combination to improve the sensitivity of the test or if the initial test cannot be 
completed.  
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Fecal Occult Blood Tests 
Fecal occult blood tests (FOBTs) detect blood in the stool resulting from colorectal 
cancer and some precancerous adenomas.33 Studies have reported specificities of guaiac-
based fecal occult blood test for detecting advanced neoplasia from 63% to 97% and of 
immunochemical fecal occult blood tests from 62% to 99%.34-49 Patients collect stool 
samples for the fecal occult blood test using a specimen collection stick and spreading it 
on the fecal occult blood test card. Patients then return the fecal occult blood test cards to 
their provider or to a laboratory for evaluation. Positive fecal occult blood tests require 
colonoscopic follow-up to rule out presence of polyps or cancer. Guaiac-based fecal 
occult blood test (gFOBT) detects the heme portion of hemoglobin. However, bleeding 
from upper intestinal tract lesions, including erosions or ulcers from Helicobacter pylori 
(H. pylori) infection or non-steroidal anti-inflammatory medications, as well as the 
presence of non-human heme from ingesting red meat or ingesting foods with peroxidase 
activity (e.g. spinach), can cause false positive results. Ingestion of vitamin C may cause 
false negative tests. Dietary and medication restrictions are therefore necessary for 
maximizing the accuracy of guaiac-based fecal occult blood tests.  
 
The immunochemical FOBT (iFOBT) detects the globin portion of human hemoglobin. 
As globin is degraded as it transits the upper intestinal tract, the immunochemical fecal 
occult blood test is more specific for lower intestinal bleeding. Therefore, dietary and 
medication restrictions are not required with the immunochemical fecal occult blood test. 
For these reasons the immunochemical fecal occult blood test has been shown to have 
better specificity and equal or better sensitivity than guaiac-based fecal occult blood tests 
for the detection of colorectal neoplasms.48-52 However, because hemoglobin degrades 
during colon transit, commonly used fecal blood tests, such as guaiac-based fecal occult 
blood test or immunochemical fecal occult blood test, are proportionately less sensitive 
for colorectal cancer on the right side of the colon.53, 54 There has been a growth in the 
number of commercially available versions of the guaiac-based fecal occult blood test 
10 
and immunochemical fecal occult blood test on the market, which vary in their sensitivity 
and specificity for colorectal cancer.  
 
Endoscopy (Flexible Sigmoidoscopy and Colonoscopy) 
Compared with stool tests, endoscopy (flexible sigmoidoscopy or colonoscopy) requires 
specially trained providers, is resource intensive, and requires patients to undergo 
invasive bowel preparation and screening procedures. However, endoscopy can prevent 
cancer by detecting and even removing precancerous polyps from the colon and 
rectum.33, 55, 56 For flexible sigmoidoscopy, a short thin flexible lighted tube with a 
camera (sigmoidoscope) is inserted into the rectum to check for polyps or cancer inside 
the rectum and the sigmoid colon (the lower third of the colon). The procedure is usually 
performed without sedation and requires minimal bowel cleansing (laxatives). Although 
sigmoidoscopy does not examine the entire colon, approximately 60-80% of patients with 
significant findings in the colon will be identified with this test.24, 55 Flexible 
sigmoidoscopy requires much less time and preparation than a colonoscopy, but if a 
tumor or polyp is found during the exam then a follow-up colonoscopy is necessary.  
 
In a colonoscopy, a longer thin flexible lighted tube with a camera lens is inserted into 
the rectum. This scope can be advanced through the entire colon all the way to the 
ileocecal valve, located at the juncture between the colon and the small intestine (ileum). 
The colonoscope can check for polyps or cancer similarly to flexible sigmoidoscopy, but 
is the only method that can also remove polyps during the procedure. However, both 
sedation and a full bowel preparation are necessary for colonoscopy, and it has the 
highest risk of complications, including bowel tears or bleeding. Because of the sedation 
used during the exam, patients are generally not allowed to go home without an escort, 
such as a friend or family member who can watch over them after the screening exam. 
Tumor and polyp removal methods include clipping, burning with a laser, and/or lassoing 
the polyp and cutting it off from the wall of the colon. Tissue biopsies are sent to a 
pathology laboratory for histological sub-typing. Depending on the severity of the polyp, 
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different surveillance follow-up intervals may be recommended. In recent years 
endoscopy quality assurance standards, including adenoma detection rate, complications 
rate, bowel preparation quality, cecal intubation rate (for colonoscopy), and colonoscope 
withdrawal time have started to be used by providers to provide benchmarking for quality 
improvement and more consistency of screening endoscopic procedures.57-59 
 
Other Screening Tests 
Double-contrast barium enema (DCBE), a radiological examination of the colon, does 
not require sedation but requires a full bowel preparation, and a follow-up colonoscopy is 
necessary if abnormalities are detected. Computed tomographic (CT) colonography uses 
low dose radiation to obtain an interior view of the colon using special x-ray equipment 
linked to a computer. The bowel-cleansing regimen for CT colonography is similar to 
that of a colonoscopy, and if abnormalities are detected then a follow-up colonoscopy is 
necessary.  
 
Biologically, only a small proportion of precancers bleed but they all exfoliate cells into 
stool. A new screening test in development detects the colorectal cancer genetic 
molecular markers exfoliated in stool (stool DNA, or sDNA test). Due to the genetic 
heterogeneity of colorectal neoplasia, multiple DNA markers need to be assayed. 
However, early clinical studies suggest high sensitivity (85%-96%) and specificity (87%-
91%) for both colorectal cancer and pre-cancerous polyps, and the sDNA test has been 
endorsed by the American Cancer Society.24, 60 This test requires a single stool collection, 
no dietary or medication restrictions, can be sent through the mail, and subjected to 
freezing with no loss of test performance.61-63 
 
Screening Methods for Alaska Native People 
Colorectal cancer screening using conventional guaiac-based fecal occult blood test has 
been discouraged among Alaska Native populations due to a high prevalence of H. pylori 
infection, which affects up to 75% of Alaska Native populations living in rural areas.64-66 
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H. pylori can cause erosions, ulcers, hemorrhagic gastritis, and less commonly mucosa-
associated lymphoid tissue lymphoma (MALT) and adenocarcinoma of the stomach40, 64, 
67, 68 all of which can cause upper gastrointestinal bleeding and false positive tests with 
gFOBT. Accurate use of the guaiac-based fecal occult blood test is further complicated 
by the Alaska Native diet, which tends to be high in red meat, causing further excessive 
false positive guaiac-based fecal occult blood tests and poor specificity of the test.69, 70 
Haverkamp et al. (2011) found that Alaska had the lowest percent (54%) of tribal 
providers nationally that reported using fecal occult blood tests for colorectal cancer 
screening.71 The high prevalence of H. pylori infection and its association with false 
positive guaiac-based fecal occult blood test results have led to a reliance on endoscopy, 
particularly colonoscopy, as the preferred colorectal cancer screening method in this 
population.67, 72 Although flexible sigmoidoscopy is available at several tribal health 
facilities statewide, colonoscopy is the primary screening method used throughout 
Alaska.73 Some reasons for this are the high false positive fecal occult blood test rate, the 
high incidence and mortality of colorectal cancer among Alaska Native people, a high 
number of colorectal cancers on the right side of the colon, which cannot be detected by 
flexible sigmoidoscopy, and a national trend towards using colonoscopy for screening.14, 
72, 74 
 
Recommended Screening Intervals 
Recommended colorectal cancer screening intervals vary by test, and have changed over 
time due to advances in clinical practice and research. Being screened at the 
recommended frequency increases the likelihood that colorectal cancer can be detected at 
an earlier, more curative stage, with less extensive treatment and recovery time for the 
patient.4 The first formal guidelines for colorectal cancer screening in average-risk adults 
were issued by the American Cancer Society (ACS). In 1997 under the sponsorship of a 
consortium of gastroenterology societies, a panel was convened by the United States 
Agency for Health Care Policy and Research to create a set of clinical practice guidelines 
for colorectal cancer screening for persons aged ≥50 which also included 
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recommendations for high-risk individuals.75 Those guidelines were then updated in 2003 
to reflect advances in the research literature, including not rehydrating fecal occult blood 
tests, decreasing the screening interval for double contrast barium enema, recommending 
colonoscopy for diagnostic follow up and for screening patients with a family history of 
hereditary nonpolyposis colorectal cancer, and providing guidance on appropriate time 
intervals for surveillance after positive findings.76 Guidelines for surveillance after 
screening have been updated, most recently in 2012.77 
 
In 2008 the United States Preventive Services Task Force (USPSTF) convened to review 
the previous guidelines and recent scientific literature  as a collaboration between the 
American Cancer Society, the American College of Radiology and the U.S. Multi-
Society Task Force on Colorectal Cancer (a consortium representing the American 
College of Gastroenterology, the American Society of Gastrointestinal Endoscopy, the 
American Gastroenterological Association, and representation from the American 
College of Physicians). The USPSTF published a set of guidelines that recommends 
routine colorectal cancer screening for average-risk men and women, ages 50-75, using 
annual high-sensitivity guaiac-based fecal occult blood tests or immunochemical fecal 
occult blood tests; flexible sigmoidoscopy every five years combined with high-
sensitivity fecal occult blood testing every three years; or colonoscopy every ten years. 
Recommendations for double contrast barium enema x-ray and CT colonography are 
every five years. Based on the accumulation of evidence sDNA testing has now been 
included as an acceptable screening option, although the appropriate interval for follow-
up has not yet been established.23, 24 For healthy adults aged 76 to 85 without significant 
comorbidities the USPSTF recommends screening on a case-by-case basis.  
 
Screening Algorithms  
There are many colorectal cancer screening algorithms used as decision support tools for 
providers. International screening decision support tools vary slightly, but all follow the 
same pattern, with risk level determined by the number and type of relatives diagnosed 
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(i.e. first- or second-degree), the age at diagnosis and the presence of other high-risk 
features, i.e. mutation status for cancer predisposing genes if present in the family. These 
algorithms provide guidelines for screening and follow-up care, appropriate risk 
management and stratification of patients, and help protect providers against medical 
liability, such as the CRICO/RMF CRC Screening Algorithm used by Harvard University 
(www.rmf.harvard.edu/~/media/Files/_Global/KC/PDFs/RMFCRC.pdf). An Alaskan 
example is given below (see Figure 1-6) of the Anchorage Neighborhood Health Center 
(ANHC) screening program algorithm which provides no-cost fecal occult blood tests 
and follow-up colonoscopies for low income uninsured patients in Anchorage, Alaska.78  
 
Figure 1-6. Referral flow chart, Anchorage Neighborhood Health Center, 2009.78  
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Screening Adherence  
 
Predictors of Screening Adherence  
There is a wide array of colorectal cancer screening methods available, and research on 
patient preference and adherence has found many different patterns of use by geography, 
race/ethnicity, sex, and age group. Lower income and education, and being from a racial 
minority group have been found to be barriers to colorectal cancer screening, even among 
insured populations or populations for whom cost barriers are removed.4, 79-81 Cultural 
differences also play a role. One study of ethnically diverse focus group participants 
found that Hispanic men in the study were reluctant to get screening due to 
embarrassment and fear of exposure. African American men reported a general mistrust 
of physicians and the medical system, and Chinese men preferred to use Eastern forms of 
medicine over Western medical care.82 A study of American Indian people living in the 
U.S. Midwest found that tribal cultural barriers related to colorectal cancer screening 
relate to lack of American Indian or Alaska Native healthcare providers or patient 
navigators, non-culturally-specific education, and lack of preventive care.83 In some areas 
elders may primarily speak their own native language instead of English, such as on the 
Navajo reservation and in western Alaska, which may also decrease uptake of colorectal 
cancer screening.83 
 
Because there are several nationally recommended colorectal cancer screening tests, each 
of which varies by frequency, accuracy, preparation required, and discomfort and cost, 
patients may have trouble determining which screening test to select. Jones et al. (2010) 
found that patients who were confused about screening tests were significantly more 
likely to be non-adherent to screening than those who were not confused, and those who 
discussed two or more options with their clinician were more likely to be confused about 
which test to undertake.84 Many barriers and facilitators are also screening test-specific 
such as fear of pain associated with colonoscopy, or discomfort with collecting stool 
samples.85 Additional barriers to screening are lack of health insurance, out-of-pocket 
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costs, and lack of awareness of the importance/benefits of colorectal cancer screening.4, 
86-88 Overall, provider recommendation, especially primary care providers, has been 
found across studies to be a major facilitator of screening adherence.79, 89-92  
 
Many other factors also place a role in screening adherence, which screening tests 
patients elect, and at what age they choose to get screened, including fear/embarrassment, 
personal/social circumstances, specific screening method-related concerns, difficulty 
understanding test instructions, preference for screening tests other than the one offered 
by a provider, language issues, and being up-to-date with other cancer screening 
exams.87-89, 93-99 One survey reported that 31% of respondents in the United States would 
choose not to be screened for colorectal cancer even when their preferred screening test 
was offered.100 Furthermore, data from the National Health Interview Survey (NHIS), the 
National Cancer Institute Health Information National Trends Survey (HINTS), and other 
studies point to associations between colorectal cancer knowledge, awareness, and 
intention to screen with screening receipt.101-104 Results from the 2005 National Health 
Interview Survey showed that the most commonly reported reason for not have a 
colorectal cancer screening was “never thought about it.”105  
 
Theoretical Constructs Related to Screening Adherence 
Several theoretical constructs may influence colorectal cancer screening behavior 
including salience and coherence, perceived susceptibility, self-efficacy, and social 
influence.106, 107 Cultural background, cancer beliefs, screening perceptions and cues to 
action all inform an individual’s sense of their perceived risk and benefit of screening 
(see Figure 1-7 below). 
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Figure 1-7. Theoretical model of CRC screening in underserved populations. 
Adapted from Indian Health Services Clinical Rounds presentation by David 
Perdue, MD, MSPH, American Indian Cancer Foundation, March, 2013. 
 
Theoretically based studies have the advantage of using systematic approaches to 
examine screening adherence. The Stages of Change theory (pre-contemplation, 
contemplation, preparation, action, and maintenance) evidenced in the Transtheoretical 
Model (TTM: behavior changes occur in stages on a continuum rather than as a single 
discrete event) has been used to model colorectal cancer screening behaviors in different 
sub-populations,93, 108 as has the Health Belief Model (HBM: perceived benefits, 
perceived barriers, perceived risk and perceived severity).109-114 For example, one study 
used the Health Belief Model, along with elements of the TTM to investigate if 
individuals were more likely to obtain colorectal cancer screening if they perceived 
themselves to be susceptible to colorectal cancer, perceived the consequences of 
colorectal cancer to be severe, perceived many benefits of colorectal cancer screening, 
and perceived barriers to screening as relatively low.111 The authors found that among 
siblings of patients with colorectal cancer, adherence and stage of adoption were 
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significantly related to perceived benefits, barriers and susceptibility. Barriers to 
screening decreased as stage progressed from pre-contemplation to maintenance. 
Constructs from the TTM were more associated with screening than the HBM and dual 
process models among this group of mostly Caucasian, middle class, well-educated 
siblings of colorectal cancer patients.111  
 
Another study used the TTM to identify perceived benefits and barriers of fecal occult 
blood tests, sigmoidoscopy and colonoscopy among first-degree relatives (FDRs) of 
colorectal cancer patients to determine if they differed by stage of screening adoption 
(pre-contemplation, contemplation, and action).93 The authors used the TTM to identify 
pros and cons (similarly to the Health Belief Model’s benefits and barriers) to understand 
how changes in perceived benefits, barriers, and movement across stages led to behavior 
change around colorectal cancer screening (fecal occult blood test, sigmoidoscopy, and 
colonoscopy) among a group of mostly Caucasian middle class FDRs living in the U.S. 
Midwest. Benefits identified by this group of FDRs included finding cancer early, 
decreasing colorectal cancer mortality risks, freedom from worry about colorectal cancer 
and reassurance of being cancer-free. Most of the FDRs agreed with benefits of 
screening. Despite this fact, the majority was still in the pre-contemplation stage (had 
never thought about getting screened themselves). The study found that more than 64% 
of FDRs were in pre-contemplation, 15% were contemplating and 21% were in action for 
colonoscopy. Age was not related to colonoscopy stage of adoption. Participants in the 
action stage were more than twice as likely as pre-contemplators to believe in the benefits 
of colonoscopy to help find colorectal cancer early. Pre-contemplators cited barriers 
including healthcare provider not recommending screening (94%), colonoscopy being too 
embarrassing or painful (49%), and that they did not need it because they had no 
symptoms (45%). Interestingly, contemplators were twice as likely as pre-contemplators 
to report that they were afraid to have a colonoscopy because they might find out that 
something was wrong.93 However, the study had a cross-sectional design and so was 
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unable to examine within-individual changes in benefits and barriers across stages over 
time, which would require a more longitudinal framework. 
Although theoretical constructs have been used to help inform research on screening 
adherence, much is still not understood about the social processes and settings that 
influence colorectal cancer screening behavior, especially for sociodemographic 
subpopulations, such as Alaska Native people.  
 
Alaska Native Predictors of Screening Adherence  
In addition to the predictors of screening adherence mentioned above, additional barriers 
experienced by Alaska Native people, including geographic barriers and cost of travel 
may play a role in underutilization of colorectal cancer screening.72 Southcentral 
Foundation (SCF), a tribal health organization based in Anchorage, Alaska, conducted 
telephone interviews in 2010 with a small group of Alaska Native men and women ages 
50-75 about barriers and facilitators to colorectal screening by either flexible 
sigmoidoscopy or colonoscopy. These results were shared with tribal leadership but are 
not yet published or available for external review. However, similar barriers as national 
studies were reported in the study conclusions. Of note was that there was no difference 
in the barriers reported by both screened and unscreened individuals; therefore, further 
as-yet unrecognized factors may play a role in why Alaska Native individuals choose to 
obtain or not obtain colorectal cancer screening. 
 
Screening Prevalence  
 
United States Colorectal Cancer Screening Trends 
Although colorectal cancer incidence and mortality can be reduced substantially through 
screening and early detection, the United States colorectal cancer screening rate remains 
far lower than other screen-detectable cancers including breast and cervical cancer.115 
Nationally, as of 2010, a total of 65.4% of Americans aged 50 to 75 years reported being 
up-to-date with colorectal cancer screening, where “up-to-date” means the respondent 
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had a fecal occult blood test (FOBT) during the previous year, a sigmoidoscopy within 
the previous five years and a FOBT within the previous three years, or a colonoscopy 
within the previous ten years.9 This represents an increase in the screening rate from 
2002, when only 51.9% of Americans were screened as recommended, which was even 
lower (40.9%) in 1997.9 However, 22 million people in the United States are still not up-
to-date with recommended colorectal cancer screening.9, 105 United States Behavioral 
Risk Factor Surveillance System data (2008) show that screening rates are highest in the 
Northeast region of the country, with Massachusetts reporting the highest screening rate 
in the nation (75.8%), compared with the lowest rate reported in West Virginia (54.7%).9 
The percent of people up-to-date with screening either by FOBT or endoscopy is fairly 
similar among men (54.9%) and women (52.0%).4 Screening prevalence is lower among 
people aged 50 to 64 (49.1%) compared to those 65 years and older (58.1%), and is 
especially low among those who are non-White, who have fewer years of education, who 
lack health insurance coverage, or are recent immigrants. Overall screening rates are 
highest among White non-Hispanics (56.0%), followed by African Americans (48.9%), 
Asians (47.9%), Hispanic/Latinos (37.2%), and American Indian/Alaska Natives 
(33.1%). Screening rates have been increasing nationwide for American Indian/Alaska 
Natives, with Indian Health Service (IHS) data showing a national average of 37% in 
2012 compared with 33% in 2009. Screening rates vary considerably by Indian Health 
Service region from 24% in the Phoenix Area to 55% in Alaska.116  There is an overall 
increasing trend of screening among those with a higher education, with 64.5% of 
Americans with 16 or more years of education reporting have been screened versus 
37.3% of those with 11 or fewer years of education. The contrasts in screening rates are 
especially notable by insurance status: just 19.5% of those without insurance reported 
screening, compared with 55.7% of those with health insurance. Likewise, those who 
were born in the United States (55.0%) or who had been in the United States for ten years 
or more (41.9%) were more likely to be screened than those who had been in the United 
States less than ten years (28.0%).4  
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Over the past decade, patterns of use of colorectal cancer screening methods have shifted 
(see Figure 1-8), with declines in the use of flexible sigmoidoscopy and stool blood tests, 
increases in the use of colonoscopy, and a phasing out of double contrast barium enema 
(DCBE) as a first-step screening test.117, 118  Endoscopy (primarily colonoscopy) is 
currently the predominant screening modality in the United States; 62% of United States 
Behavioral Risk Factor Surveillance System (2008) respondents aged 50 to 75 years 
reported lower endoscopy within the past ten years.9 However, although colonoscopy 
usage has been increasing rapidly among nearly all population subgroups, there are 
differences in usage rates. An analysis by Klabunde et al. (2011) of data from the 2000, 
2003, 2005, and 2008 National Health Interview Survey found that Hispanics reported 
less colonoscopy use than non-Hispanic Whites did.118 Similar patterns were observed for 
people with less than an high school education (versus those with more than an high 
school education); recent immigrants (versus individuals born in the United States); 
people with family income <200% of Federal Poverty Level (versus those with family 
income >500% of Federal Poverty Level); the uninsured (versus people with health 
insurance coverage); those with no usual source of care (versus individuals who reported 
having a usual source of care); and people who had no physician visits in the past year 
(versus those with two or more visits).118 
 
Figure 1-8. CRC screening data from BRFSS. Percentage of respondents aged 50--
75 years who reported receiving a fecal occult blood test (FOBT) within 1 year 
and/or a lower endoscopy within 10 years and Healthy People 2020 (HP 2020) target 
--- Behavioral Risk Factor Surveillance System (BRFSS), United States, 2002, 2004, 
2006, 2008, and 2010.9 
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These overall trends in endoscopy use have led to studies which have noted that demand 
for endoscopic colorectal cancer screening could outstrip supply at current rates of 
increase.119, 120 In 2000, the Centers for Disease Control and Prevention (CDC) conducted 
a nationwide study to determine if there was enough capacity in the United States to meet 
the rising demand for endoscopic screening, called the Survey of Endoscopic Capacity 
(SECAP I). The survey found that there was capacity to screen United States residents 
using fecal occult blood tests with follow-up colonoscopies, but not using colonoscopy as 
the first-step screening test. In 2011, the Centers for Disease Control and Prevention 
commissioned SECAP II as a follow up study to determine the colorectal cancer 
screening capacity in the nation and in additional selected states, including Alaska.121 
This study collected data on the current number of flexible sigmoidoscopy and 
colonoscopy procedures performed each year, as well as the additional number of 
procedures (unused capacity) that could be performed each year. A forecasting model 
was developed based on the demographic characteristics of the population in the state and 
the number of screenings that need to be completed among the eligible population. The 
study found that current capacity in Alaska is not adequate to meet the use of screening 
tests based on the current pattern of screening test use (primarily colonoscopy).73  
 
A further issue is whether colonoscopy is being performed more frequently than national 
guidelines would suggest, leading to increased social and financial costs. Several 
nationally representative studies of physicians who perform colonoscopy have found that 
more frequent surveillance intervals for asymptomatic average-risk patients, or older 
patients, than national recommendations is common, particularly for hyperplastic polyps 
and low-risk lesions such as small adenomas, which has further implications for overall 
screening capacity nationwide.122, 123 
 
Alaska Native Colorectal Cancer Screening Trends 
Screening rates among the Alaska Native population are lower than U.S. White rates, but 
have been steadily increasing, from 29% in 2000 to 58% of age-appropriate Alaska 
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Native people being up to date with colorectal cancer screening (colonoscopy in last 10 
years or flexible sigmoidoscopy in last 5 years) in 2012 (Alaska Tribal Health System 
(ATHS) Government Results and Performance (GPRA) data, 2000-2012). Data from the 
Alaska Behavioral Risk Factor Surveillance System (BRFSS) in 2011 showed that 68.1% 
of Alaska Native adults reported ever had a sigmoidoscopy or colonoscopy, which was an 
increase from 50% in 2010 and 51.8% in 2008. The 2011 rate is the first time that the 
Alaska Native rate has been above the rate for all Alaskans (65%) and Alaska Whites 
(65%).124 Despite substantial efforts, colorectal cancer screening rates among Alaska 
Native people fall short of the Healthy People 2020 target and the Centers for Disease 
Control and Prevention National Colorectal Cancer Control Program goal. Additionally, 
Alaska Native screening rates vary widely by geographic region, from 33% to 72% 
statewide in 2012.125 The continuing large disparities in colorectal cancer mortality and 
incidence between Alaska Native people and U.S Whites suggest that screening for 
colorectal cancer needs significant improvement.  
 
International Incidence, Mortality, Screening Methods, Intervals, and Rates  
Rates of colorectal cancer vary by country, with Australia/New Zealand, Western Europe 
and North America experiencing the highest incidence of the disease, and African nations 
the lowest. Similarly, colorectal cancer mortality is highest in Central and Eastern 
Europe, and lowest in African nations.126 Incidence has been increasing worldwide; 
colorectal cancer is the third most commonly diagnosed cancer in men and second in 
women. In contrast to the declining mortality seen in the United States, colorectal cancer 
mortality has been increasing worldwide, especially in rapidly developing countries such 
as South America, Eastern Europe, and East Asia, which may be related to the increasing 
adoption of Western dietary and lifestyle practices.126 
 
Countries have differing recommendations for screening methods and follow-up 
intervals.127, 128 Partly this is a reflection of limited resources and more pressing health 
priorities in low- and very-low income countries. But variations are also found among 
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higher income countries. For example while Poland, Germany and Austria screen the 
entire average-risk population via colonoscopy, generally after age 60, Italy provides 
flexible sigmoidoscopy as the primary screening test. Most countries, however, focus on 
annual or biennial guaiac-based fecal occult blood tests or immunochemical fecal occult 
blood tests, and only provide colonoscopies for higher-risk patients and diagnostic 
follow-up.126 Countries also vary as to screening age to begin guaiac-based fecal occult 
blood tests or immunochemical fecal occult blood tests. For example, the Australian 
National Bowel Screening Program currently provides a iFOBT only at ages 50, 55, and 
65.126 One of the most important issues involved in setting up national screening 
programs is that colorectal cancer screening should only be promoted in settings in which 
appropriate follow-up and treatment are available.129 Worldwide, colorectal cancer 
screening remains below 50%, even in countries with national colorectal cancer screening 
programs. However, some individuals in those countries may be obtaining screening 
through providers outside the national screening program, but it is not known to what 
extent this occurs.126  
 
Risk Factors for Colorectal Cancer  
There are many known factors that increase or decrease the risk of colorectal cancer. 
Major risk factors for colorectal cancer include both modifiable lifestyle risk and 
protective factors and non-modifiable factors like age and family history (see Figure 1-
9).4 
 
 
 
 
 
 
 
 
25 
 
 
 Relative Risk 
Factors that increase risk:  
Heredity and Medical History  
   Family history  
      1 first-degree relative 2.2 
      More than 1 relative 4.0 
      Relative with diagnosis before age 45 3.9 
   Inflammatory bowel disease  
      Crohn disease (colon) 2.6 
      Ulcerative colitis  
         Colon 2.8 
         Rectum 1.9 
      Diabetes 1.2 
Other Factors  
   Obesity 1.2 
   Red meat consumption 1.2 
   Processed meat consumption 1.2 
   Smoking 1.2 
   Alcohol consumption 1.1 
  
Factors that decease risk  
   Physical activity (colon)  
      Men 0.8 
      Women  0.7 
   Calcium 0.8 
   Milk consumption 0.9 
Figure 1-9. Summary of major risk factors for colorectal cancer.4 
 
Modifiable Risk Factors 
Modifiable factors that are associated with an increased risk of colorectal cancer include 
physical inactivity, obesity, high consumption of red or processed meats and low 
consumption of fruits and vegetables, tobacco use, and moderate-to-heavy alcohol 
consumption.2, 4, 130-134  Protective factors that may decrease the risk of colorectal cancer 
include aspirin and non-steroidal anti-inflammatory drugs, multivitamin use (including 
supplemental folic acid and calcium, and physical activity, which may decrease the risk 
of colorectal cancer by as much as 50%.2, 135 A Danish prospective cohort study found 
that 25% of colorectal cancer cases could be avoided by maintaining a healthy abdominal 
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weight, being physical active at least 30 minutes per day, eating a healthy diet, not 
smoking, and not drinking excessive amount of alcohol.136 
 
Non-modifiable Risk Factors 
The lifetime risk of being diagnosed with cancer of the colon or rectum is about 5% for 
both men and women in the United States. Both colorectal cancer incidence and death 
rates increase with age; about 90% of new cases and 94% of deaths occur in those aged 
50 and older.4 From birth to age 39 the probability of developing invasive colorectal 
cancer is 1 in 1,212 in men and 1 in 1,236 in women. Among those aged 40 to 59 the 
rates go up considerably to 1 in 106 in men and 1 in 134 in women; among those aged 60 
to 69 the rates are 1 in 71 for men and 1 in 102 for women; at age 70 and older the rates 
are 1 in 24 for men and 1 in 26 for women.7 The median age at diagnosis in the United 
States is 68 years in men and 72 years in women. Overall, rates of colorectal cancer for 
men are about 35% to 40% higher than for women. A personal history of colorectal 
polyps or cancer is associated with developing new colorectal cancers, especially if 
diagnosed at a younger age. Inflammatory bowel disease (IBD), which includes 
ulcerative colitis and Crohn's disease, and type 2 diabetes mellitus are likewise associated 
with a higher risk for developing colorectal cancer.4  
 
 
Figure 1-10. Causes of hereditary susceptibility to colorectal cancer.137 
 
As shown in Figure 1-10, the majority of colorectal cancers (65% to 85%) occur in 
persons with no known cause (i.e., they are considered sporadic). A total of 10% to 30% 
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of cases of colorectal cancer occur in people who have a family member who has had an 
adenomatous polyp or colorectal cancer. This family history may increase colorectal 
cancer risk by influencing adenoma formation or enhancing the formation of new 
lesions.138 A small percentage of colorectal cancers occur as part of an inherited 
syndrome. Approximately 5% are associated with Lynch syndrome (also known as 
hereditary nonpolyposis colorectal cancer or HNPCC) and about 1% are associated with 
familial adenomatous polyposis (FAP). These hereditary conditions cause rapid adenoma 
to carcinoma progression or multiple polyps and carcinoma progression.4 HNPCC is a 
result of germ line mutations in DNA-mismatch repair (MMR) genes, which can be 
inherited from either parent. Tumors with defective MMR are characterized by the 
presence of a particular tumor phenotype, termed microsatellite instability (MSI).139 
Persons with these inherited syndromes have a propensity to develop other tumor types in 
addition to colorectal cancer, including tumors of the endometrial, ovarian, gastric, small 
intestine, brain, ureter, and biliary tract.140 Less than 0.1% are rare colorectal cancer 
syndromes. It is important to note that there is no well-defined threshold between 
sporadic and familial colorectal cancer at this time, and there are likely to be multiple low 
penetrant genes plus environmental factors at work in the pathogenesis of colorectal 
cancer.141, 142  
 
Alaska Native Risk Factors 
The Education and Research Towards Health (EARTH) Study (2004-2006) collected 
chronic disease risk factor data for Alaska Native people in three regions of Alaska 
(southcentral, southwest, and southeast) which provide some baseline information on 
colorectal cancer risk factors among this population. Alaska Native people have many of 
the same colorectal cancer risk factors as the general United States population. Current 
cigarette use among Alaska EARTH Study participants (n=3821) was twice the 
prevalence of the Healthy People 2010 (HP 2010) goal (32% vs. 12%) and current 
smokeless tobacco (ST) (both commercial and homemade) use was markedly higher: 
18% vs. 0.4%. About a quarter (24%) of study respondents were former smokers or 
28 
former ST users (18%) and likely to still be at risk.143 Alaska Behavioral Risk Factor 
Surveillance System (BRFSS) data show that the percent of current smokers and ST users 
among Alaska Native adults is two-fold or greater than among Alaska non-Native 
people.143, 144 
 
Overweight and obesity were likewise high among Alaska EARTH Study participants. 
Based on standard categorization of Body Mass Index (weight in kilograms divided by 
height in meters squared), 42% of participants meet the definition of obesity (BMI 
≥30.0), and 32% were overweight (BMI 25.0 to 25.9). Only one quarter of the study 
population fell in the recommended range for healthy weight and the prevalence of 
obesity among Alaska EARTH study participants exceeded the rate among Alaska non-
Native BRFSS respondents (42% vs. 25%).143 Self-reported fruit consumption (2+ 
servings per day) was about half of HP2010 recommendations (38% vs. 75%) and 
vegetable consumption (3+ servings per day) was likewise lower: only 45% of men and 
52% met the goal.143 The 2009 Alaska Behavioral Risk Factor Surveillance Survey 
(BRFSS) likewise reported similar findings; only 14% of Alaska Native people reported 
eating five or more servings of fruits and vegetables per day, compared to 25% reported 
by Alaska non-Native people.144  
 
Self-reported physical inactivity was also high among Alaska EARTH Study participants; 
only 35% of women and 61% of men reported getting five or more hours of moderate and 
vigorous physical activity. Similarly, Alaska BRFSS data showed that 17% of Alaska 
Native men and women combined met the goal of moderate and vigorous activity as 
defined as moderate activity on 30 or more minutes per day on five or more days per 
week or vigorous physical activity for 20 min or more per day, for three or more days per 
week. This is in comparison with 27% of non-Native Alaska residents who met the 
goal.143 
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Findings from the Alaska EARTH Study and others have reported on the shift in Alaska 
Native diet from wild to store-bought foods, and decreases in overall physical activity as 
well as increasing availability and use of motorized vehicles for hunting and subsistence 
activities.69, 145-149 These trends, along with other colorectal cancer risk factors and the 
aging of the population, will likely continue to contribute to increases in colorectal cancer 
incidence.150 Although these risk factors are shared with other United States populations, 
additional genetic mutations which might predispose Alaska Native people to colorectal 
cancer have been postulated due to the increased rates of colorectal cancer, especially 
among Alaska Native women, and the larger proportion of tumors in the proximal colon 
and tumors of higher grade and severity among Alaska Native colorectal cancer 
patients.139 However, hereditary risk factors like HNPCC do not seem to be unusually 
high in Alaska Native people.14 Furthermore, a study by Boardman et al. (2007) looked at 
evidence of defective DNA mismatch repair (MMR) by testing tumors from colorectal 
cancers from Alaska Native people for altered protein expression (hMLH1, hMSH2, and 
hMSH6) and for the presence of microsatellite instability (MSI).139 Their study did not 
find evidence of an association between tumor stage and MMR status, although they did 
find that colorectal cancers with defective MMR were more frequently seen in the 
proximal colon and among patients presenting at a young age. Overall evidence of 
defective DNA MMR was found in 14% of the colorectal cancers tested, a frequency 
similar to that reported in other population groups.139  Although further research is 
needed to evaluate possible genetic risk factors among Alaska Native people, it is likely 
that increases in body weight, dietary changes, increases in physical inactivity, and 
tobacco use, are strong contributing factors to colorectal cancer in Alaska Native people, 
similarly to what has been described in other United States populations.134  
 
Family History  
Family history is a critical component of colorectal cancer risk stratification.151-153 The 
overall lifetime risk of colorectal cancer in the U.S. is approximately 6%. Persons with a 
history of colorectal cancer or adenomatous polyps in one or more first-degree relatives 
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(FDRs: parents, siblings, or children) are at increased risk. Studies of FDRs of colorectal 
cancer patients in the prospective cohort Nurses' Health Study and the Health 
Professionals Follow-up Study found that FDRs had a 1.7-fold increase in risk of 
colorectal cancer. Furthermore, for persons who had two or more affected first-degree 
relatives or who were younger than age 44 the relative risk (RR) increased substantially. 
This association held  even after adjustment for other known or suspected risk factors for 
colorectal cancer.154 Data from the National Polyp Study which calculated the relative 
risk of colorectal cancer in FDRs compared with spouse controls confirms these findings; 
FDRs are over twice as likely to experience colorectal cancer (relative risk=2.2), 
especially if their family member was affected before age 45 (relative risk=3.9).154-157 If 
the person has one affected FDR the risk is 2-3 fold higher (lifetime risk 12-18%). If a 
person has two FDRs with colorectal cancer or if the FDR was less than age 50 the risk is 
3-4 fold (18-24%). Even having second- and third-degree relatives with colorectal cancer 
can increase the risk of colorectal cancer to a lifetime risk of 9%.76, 156 Furthermore, the 
presence of advanced adenomas (not colorectal cancer) in a FDR is a risk factor for 
colorectal cancer development in their close family members.157, 158  
 
There may also be a synergistic effect increasing the risk for colorectal cancer between 
modifiable risk factors such as diet, alcohol and tobacco use, and having a family history 
of the disease.159 Data from two large cohort studies, the Nurses' Health Study and Health 
Professionals Follow-Up Study, found that the previously reported association between 
heavy alcohol consumption (more than 30 grams per day) and colorectal cancer differs by 
family history; participants with a family history who consumed alcohol had a higher 
incidence of colorectal cancer than those with no family history.160 One study found that 
family history increases the risk of sporadic colorectal cancer in men mainly through its 
interaction with lifestyle exposures, including high beef and alcohol intake.141 FDRs of 
colorectal cancer patients are the largest groups of individuals at increased colorectal 
cancer risk. Overall, it is believed that screening strategies targeting FDRs of affected 
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cases could contribute to the prevention or early detection of 15% to 20% of colorectal 
cancers.158, 161 
 
Recommended Screening Methods and Intervals 
Although the field of molecular epidemiology and genomics is rapidly expanding the 
potential for identifying persons at risk of colorectal cancer; including the discovery of 
new biomarkers, whole genome association studies (GWAs), and expression profiling 
and proteomics;162-165 family history is still one of the most valuable tools which provides 
predictive value to identify individual patients at increased risk of colorectal cancer.166 In 
the early 2000s a number of screening recommendations existed for FDRs, which varied 
on the definition of risk type and frequency of tests recommended, and the age at which 
FDRs should start screening.167-170 However, since then, as the evidence base has grown 
regarding the increased risk for colorectal cancer among this population, 
recommendations have solidified in favor of early screening (pre-age 50) using 
colonoscopy as the recommended screening method. Screening guidelines vary slightly 
by professional medical groups, but in general, United States national guidelines 
recommend that persons with a family history of colorectal cancer (one FDR or two or 
more second-degree relatives) undergo cancer screening by colonoscopy beginning at age 
40 or 10 year younger than the age at diagnosis of the youngest affected relative, 
whichever is earlier. FDR screening should occur every five years for normal exams, and 
more frequently if findings are present.55, 171 The Alaska Native Medical Center (ANMC) 
has further guidelines that if there are documented adenomatous polyps in a FDR or 
multiple second-degree relatives then those persons should be screened with colonoscopy 
starting at age 50 continuing every five years, or more frequently if findings are present 
(Alaska Area Native Health Service CRC Screening Guidelines, revised June, 2008).  
 
Predictors of Family History Screening Adherence  
Healthcare professionals in the United States have long used family history information 
collected from individuals as a risk assessment tool.172 However, family histories are 
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rarely used to identify and provide systematic outreach to those at increased risk for 
disease, especially for colorectal cancer,173 and studies have shown that documentation of 
family cancer history in medical records is inconsistent, and lacking in over half of 
primary care patients.174-178 Incorporating family history into clinical practice is 
challenging due to the lack of standardized methods for collection and reporting of family 
history.179 There is also a dearth of  information on the extent to which clinicians use 
family history information to drive discussions and provide recommendations to their 
increased risk patients, although it has been found that those with a family history are 
more likely to report healthcare provider recommendation to undergo screening.180 
Studies of physician knowledge and practice patterns have found that many providers are 
not aware of the recommended guidelines regarding screening intervals for FDRs or 
provide notification to their at-risk patients.181 For the most part, when used, these FDR 
screening referral decisions are based on self-reported pedigree information. Several 
studies have compared self-reported history of colorectal cancer among patients with 
medical record data. While some studies found that FDR-reported colorectal cancer 
family history is fairly accurate and may be relied upon for colorectal cancer risk 
assessment, other studies have found underreporting of family history.182-185 One study 
reported that 25% of FDRs did not know that their parent or sibling had histologically 
confirmed diagnoses of colorectal cancer.186 In general, FDRs are less likely to be aware 
of early stage (in situ or localized) colorectal cancers among their family members than 
later stage or more severe colorectal cancers.186 
 
Despite the number of published recommendations for screening individuals at increased 
risk of CR colorectal cancer due to their family history, a review by Rees et al. (2008) 
found few studies that had specifically investigated screening adherence in this 
population, and none had assessed FDR patient preference as a factor in screening 
adherence.167 The studies that exist have found that many of the demographic and 
behavioral factors that influence screening adherence among the average risk population 
also influence colorectal cancer screening by FDRs of colorectal cancer patients. One 
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study reported that FDR barriers included lack of awareness of colorectal cancer and the 
need for screening, concerns about concerns about efficacy of screening tests, fear of 
finding cancer, embarrassment and lack of provider recommendation.93 Additionally, 
sociodemographic factors including income, education and insurance status also play a 
role in screening adherence by FDRs. However, reported associations have been 
inconsistent among studies. For example, some studies reported higher screening uptake 
among older FDRs,177, 187, 188 while other studies reported that younger cohorts were more 
likely to obtain screening by colonoscopy than older cohorts,189 and others reported no 
association between age and screening behavior.190  Similar inconsistencies have been 
found among sex, educational level and income and FDR screening adherence.167, 191 
However, similarly to the general population, provider recommendation and awareness of 
the benefits of screening have been found across studies of FDRs to be positively 
associated with screening adherence.93, 177, 180, 187, 192, 193  
 
Family-related factors have been associated with increased screening by FDRs, including 
the number and proportion of affected FDRs in the family.177, 187, 194 Additionally, some 
studies found that family support and sibling closeness were significantly associated with 
screening adherence by siblings of affected colorectal cancer cases.111 Knowledge of risk 
for family members by the colorectal cancer patient might also be important for screening 
among their FDRs. In one study, FDR screening colonoscopy adherence was 
significantly higher (27%) when the colorectal cancer patients were aware of the 
increased risk for their family members in contrast to screening adherence among siblings 
of colorectal cancer patients who were not aware of the risk (20%).The authors conclude 
that informing colorectal cancer patients about the potential risk for their relatives may 
increase participation in screening by those family members.195 
 
Of note, these studies have shown that perceived risk for colorectal cancer is not 
necessarily associated with receipt of recommended colorectal cancer screening by 
FDRs,93, 109, 191 as shown by a quote from a focus group of African American women: 
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“When my sister died, we agreed we would go get tested. So far only one of us has, and 
there are five of us. I guess I have a fear they’ll find something.”196 However, other 
studies have shown greater screening receipt by those with a family history compared to 
those without a family history.180, 197 Of note, one study found that 84% of FDRs were 
interested in having a genetic test if one were available; although only 59% of the FDRs 
in the study were adherent to current colorectal cancer screening guidelines.198 A 
difficulty with the FDR screening adherence literature is that many of the earlier studies 
included fecal occult blood test, sigmoidoscopy and colonoscopy as screening options, 
and so less is known about screening adherence to colonoscopy specifically, starting at 
least at age 40 and continuing every five years, which presents greater demands upon 
patients for completion than other screening methods. To date no studies have been 
published on predictors of screening adherence among Alaska Native FDRs. 
 
Screening Prevalence among First-degree Relatives 
It is difficult to get a true screening prevalence among FDRs as many studies in the 1990s 
and early 2000s only used fecal occult blood test or sigmoidoscopy as a screening 
outcome measure, which are not currently recommended for screening this increased-risk 
population. Data reported from the 2000 U.S. National Health Interview Survey showed 
that of individuals with a positive family history, only 28% of Whites and 9% of African 
Americans had been screened by endoscopy. This racial disparity persisted even after 
adjustment for age, gender, educational level, insurance status, and usual source of 
care.199 Another study a few years later in 2002 reported a screening adherence rate of 
57% among siblings of colorectal cancer patients,111 and a cross sectional study in 1995 
of twin sisters found that 69% of the cotwins reported receiving a sigmoidoscopy, 
compared with 27% of the general population, although none of the cotwins in the study 
reported receiving a colonoscopy.190  
 
United States screening rates among FDRs have increased over the past decade: the 2005 
National Health Interview Survey found that reported colorectal cancer screening 
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(endoscopy) had increased to 65% of those with a known family history. However, 13% 
reported being screened by fecal occult blood test, which is not considered adequate for 
screening this increased risk population.105 Additionally, only participants over age 50 
were asked their screening history, which may over represent the true screening rate 
among FDRs, many of whom need to be screened at much earlier ages. Results vary 
among other countries. A Canadian study published in 2009 found that 60% of FDRs 
were adherent to current screening guidelines.106 An Australian study by Ryan et al. 
(2013) found that 69% of FDRs had ever received any colorectal cancer testing (i.e. 
FOBT, sigmoidoscopy or colonoscopy), although only 25% of ‘slightly above risk” (1 
FDR with colorectal cancer diagnosed age 55 or older), 47% of those at “moderately 
increased risk” (1 or more FDR with colorectal cancer diagnosed before age 55), and 
49% of “potentially high risk” FDRs (FAP, HNPCC, or colorectal cancer before the age 
of 50) were up-to-date with screening according to Australian guideline 
recommendations (biennial fecal occult blood test for ‘slightly above risk’ and 
colonoscopy every five years for ‘moderately’ and ‘high risk’).200 This is in contrast with 
a 1997 study in New South Wales, Australia, which found only 1% of FDRs were 
screened in accordance with Australian recommendations at the time.201 Another study 
from Spain (2007) found low screening adherence among FDRs, with only 38% screened 
for colorectal cancer.202 However, a study from Italy that used an educational intervention 
(letters, phone calls, face-to-face interactions) was able to increase colonoscopy use 
among FDRs ages 45-75 to 78% compared with the control group population rate of 
8%.194 In summary, the available evidence suggests that screening rates of FDRs of 
colorectal cancer patients in accordance with guideline recommendations is increasing 
but remain much lower than would be optimal to reduce colorectal cancer incidence and 
mortality on a population level. 
 
Screening Prevalence among Alaska Native First-degree Relatives 
Because of the overall disproportionate colorectal cancer incidence and mortality rates 
among Alaska Native people, it is important to identify those at highest risk and 
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encourage them to receive appropriate screening.16 Although no Alaska BRFSS data are 
available on family history of colorectal cancer, data from a supplemental questionnaire 
included in the 2008 Oregon BRFSS found that 8% of respondents had a FDR with 
colorectal cancer.180 In Alaska, the only published data available on Alaska Native family 
history of colorectal cancer comes from the Alaska Education and Research Towards 
Health (EARTH) Study, which found 13% of Alaska EARTH Study participants (2004-
2006) reported one or more FDRs diagnosed with colorectal cancer before age 50.143 Of 
those who knew the age of diagnosis of their relative, 38% reported that their family 
member was diagnosed with colorectal cancer before age 50.203 Study participants who 
reported a family history of colorectal cancer were twice as likely to report receipt of a 
colonoscopy or flexible sigmoidoscopy in the past five years (44.1% vs. 26.2%).204 
However, this still represents a low screening rate for a population at increased risk. 
 
Evidence Base for Colorectal Cancer Prevention 
Systematic evidence-based reviews by the U.S. Community Preventive Services Task 
Force outlined in the Guide to Community Preventive Services have identified effective 
public health strategies that support increased colorectal cancer screening.205 Currently, 
the Community Guide has found sufficient to strong evidence to recommend small media 
(such as brochures with tailored messages targeted to specific under-screened minority 
groups), client reminders (such as post cards, phone calls, or reminders at the point of 
care), one-on-one education, provider reminder systems,  including office-based 
systems,206 provider assessment and feedback, and the reduction of structural barriers 
(such as those associated with procedure access, scheduling, or transportation) as 
effective strategies for increasing colorectal cancer screening. It is important to note that 
these strategies are often recommended to be used to increase use of flexible 
sigmoidoscopy and colonoscopy for colorectal cancer screening, even though the 
evidence base comes from studies which only used fecal occult blood tests as the 
screening modality. Interventions that use newer colorectal cancer screening methods, 
such as fecal immunochemical tests and stool DNA tests, have not yet been evaluated and 
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it is unknown whether effects differ for these tests.207 The Task Force found that there 
was insufficient evidence for the use of mass media, client incentives, group education, 
and reducing client out-of-pocket expenses to increase colorectal cancer screening in 
their October, 2009 assessment.208, 209  
 
The Community Guide recommended interventions for cancer screening are based on 
review of the published literature and where available, National Cancer Institute (NCI) 
research-tested intervention programs. There is a growing body of literature around 
colorectal cancer screening interventions, but much is still unknown, especially for 
interventions that promote endoscopy (flexible sigmoidoscopy and colonoscopy) as 
screening modalities. The Task Force notes in their reviews that absence of evidence or 
insufficient evidence is not indicative that a specific program or intervention does not 
work; rather that the overall evidence base is not strong enough or more information is 
needed to make recommendations about intervention benefits, particularly where there is 
a dearth of research studies, for example for reducing client out-of-pocket expenses, 
where no colorectal cancer screening research studies were found by the Task Force 
using this type of intervention.207, 210 It can be especially challenging to evaluate the 
effectiveness of multi-component programs, especially ones that use broad population-
based strategies, although the Task Force did find some evidence that implementing a 
multicomponent intervention can provide incremental benefits. The Task Force cautioned 
against implementing multicomponent interventions when there are not adequate 
resources and infrastructure to deliver all components with fidelity.208  
 
One form of educational media not addressed by the Community Guide is interactive 
exhibits. Such exhibits have been increasingly used by general and science museums to 
promote public participation and engagement.211 However, limited data exists on the 
extent to which interactive exhibits leads to greater understanding among the public. The 
studies that have been done have primarily examined how people interact with the 
exhibits,212 not whether interaction with exhibits lead to knowledge and behavior change. 
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A few studies have been conducted on special events as tools for behavior change, such 
as health fairs, community celebrations, educational parties, and Readers’ theatre. These 
special events promoting increased access to health services and cancer screening include 
breast health educational parties, where use of breast health knowledge games led to 
increased screening among underserved and uninsured women in New Jersey;213 a project 
which provided limousine service to and from screenings to encourage mammography 
use;214 as well as cultural events (‘Ohana Day Project in Hawaii)215 and more traditional 
health fair events to promote awareness and increase knowledge.216, 217 In Alaska, a 
colorectal cancer-focused script was developed for use in Alaska Native communities as 
Readers’ theatre, a community event in which participants read aloud from a non-
memorized script. Use of the Readers’ theatre script was shown to increase comfort with 
cancer screening and interest in making health changes among theatre participants, and a 
giant inflatable colon was used to promote colorectal cancer screening knowledge, 
intention to get screened, and comfort talking about screening with friends and family 
among community members statewide.218, 219  
 
Less is known about the effectiveness of interventions targeting systems-level changes in 
healthcare systems, such as in primary care settings, but these might also be an effective 
method to improve colorectal cancer screening and follow-up.207, 220 For example, from 
2005 to 2009, Kaiser Northern California doubled its up-to-date colorectal cancer 
screening from 35% to 69% among commercially insured enrollees and increased 
screening for Medicare enrollees from 46% to 75% by implementing a highly organized 
screening program.221 Other recommendations to increase colorectal cancer screening are 
for state health departments to design systems that allow linkage of Medicaid enrollee 
data to other datasets, if such linkages are allowed. This would enable identification and 
active recruitment for screening, and develop program registries to monitor participation, 
diagnostic follow-up, treatment initiation and long-term outcomes.9 Overall, it is 
important to consider the characteristics of the priority population carefully, including 
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what factors impact their screening behaviors when determining which type of 
interventions to initiate to promote colorectal cancer screening.  
 
Centers for Disease Control and Prevention (CDC) Social Ecological Model 
In order to understand the myriad factors that influence an individual’s likelihood of 
obtaining colorectal cancer screening it is helpful to visualize these factors in the context 
of a model. There has been a growing understanding that many public health challenges 
are too complex to be understood adequately from single levels of analysis, and instead, 
require more comprehensive approaches that integrate interpersonal, organizational, 
community planning, and regulatory perspectives.222 This has led to the development of 
several perspectives on health promotion, including social ecological analyses of health 
promotion. The social ecological model of health promotion is a systems model with 
multiple bands of influence and the individual at the core.223-225 The model assumes that 
appropriate changes in the social environment will produce changes in individuals and 
that the support of individuals in the population is essential for implementing 
environmental changes.226, 227  
 
The Centers for Disease Control and Prevention has adapted the social ecological model 
to represent a multi-level systems approach to colorectal cancer prevention, and suggest 
the range of potential types of screening promotion activities (see Figure 1-11).223 At the 
core of the model is the individual, surrounded by four other bands of influence 
representing the interpersonal, organizational, community, and policy levels. The second 
band represents the most immediate influence on the individual-family and healthcare 
professionals (Interpersonal Level). Studies have shown that health provider 
recommendation is consistently one of the pivotal reasons for why people chose to get 
screened.102, 228-230  The third band is the Organizational Level, which includes healthcare 
systems, health departments, and professional organizations that aim to facilitate 
individual behavior change through organizational systems and policies. The fourth band 
represents the Community Level, and represents activities that occur at the community 
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level, often by institutions such as comprehensive cancer control coalitions, tribal health 
departments, media, and community advocacy groups. The final band represents the 
Policy Level, which seeks to influence the individual indirectly through systems and 
policy changes at the local, state, and federal level.  
 
Figure 1-11: Centers for Disease Control and Prevention Social Ecological Model 
(SEM)225 
 
The social ecological model is broad, and as such can be applied to colorectal cancer 
screening interventions among Alaska Native populations. Most interventions to promote 
colorectal cancer screening among Alaska Native people have occurred at the 
Interpersonal and Organizational levels. This has played to two key strengths, namely, 
the importance of family and community in Alaska Native culture, and the ability of 
regional tribal health organizations to make direct changes to promote screening among 
the populations that they serve. The band of the social ecological model that is not as 
easily influenced in the Alaska Native colorectal cancer screening context is the Policy 
Level, as this often involves state and federal policy changes, such as requirements for 
increased financial coverage for colorectal cancer screening by insurance companies. 
These do not appear to factor into Alaska Native individual decision making on 
colorectal cancer screening as much as other forms of influence such as family and 
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healthcare providers, including affiliated healthcare staff like case managers and patient 
navigators.  
 
However, policy changes can be made at the regional tribal health organization level, 
which would have beneficial impacts on patient screening outcomes. This can be 
illustrated more generally by another model which focuses specifically on the primary 
care setting, which represents elements of both the Organizational and Interpersonal level 
(see Figure 1-12 below). This model outlines leverage points for increasing colorectal 
cancer screening in primary care practices. 
 
 
Figure 1-12. Factors affecting improved CRC screening in primary care.231 
 
Patient Navigation 
One type of intervention recommended by the Community Guide for increasing 
colorectal cancer screening is one-on-one education with the goal of informing, 
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encouraging and motivating patients to seek recommended screening.205 These messages 
can be delivered by a variety of healthcare workers or other health professionals, lay 
health advisors, such as promotoras or even volunteers. To this end, there has been an 
increase over the last two decades in the use of patient navigation for colorectal cancer 
screening.232, 233 Patient navigation is a way to improve effectiveness of care and increase 
screening rates, especially among low-income, minority, and medically underserved 
populations.196, 234-236 Patient navigators have a multitude of backgrounds, from lay 
community members, to community health workers, to case managers and nurses. The 
job duties, education, and experience required for these positions often vary widely by 
location and organization. colorectal cancer screening patient navigation provides 
individualized assistance to help overcome healthcare system and patient-level barriers to 
care and helps guide individuals into action by getting needed cancer screening.196, 232, 237 
Outreach is usually conducted by sending mailed reminder letters and phone calls to 
patients or community members encouraging them to get colorectal cancer screening, as 
well as face-to-face approaches.233 These approaches are often accompanied by the use of 
small media (e.g., brochures) as well as client reminders and follow-up to complete 
screening. Patient navigators are also increasingly being seen as key for managing 
referrals, helping patients navigate the healthcare system, and facilitating follow up 
surveillance of abnormal screening, such as adenomatous polyp surveillance.4, 234, 236  
 
The benefits of patient navigation in improving client screening adherence has been 
studied in several populations, although there had not been many studies of the overall 
economic effect of using patient navigators in the colorectal cancer screening context. 
One such study that examined use of patient navigators to increase colonoscopy volume 
and completion rates in an urban public hospital system found the patient navigator 
program cost-effective and yielded a net financial benefit, although cost analysis has not 
been studied more widely to determine net benefit among other types of healthcare 
organizations and settings.238 Although use of the patient navigation model for increasing 
colorectal cancer screening among the general population has been on the rise, there has 
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been little or no use of patient navigation for focused outreach to patients at increased 
risk of colorectal cancer such as to those with a family history of the disease. Patient 
navigation has been identified as a key component for increasing colorectal cancer 
screening in general among Alaska Native people,26 and is currently being used for 
targeted outreach to first-degree relatives of colorectal cancer patients.72  
 
National Policy Related to Colorectal Cancer Screening 
On March 23, 2010, Congress passed and the President signed the Affordable Care Act 
(ACA), healthcare reform legislation giving greater access to colorectal cancer screening 
through a requirement for private health insurers to cover recommended preventive 
services without any patient cost sharing such as copays and deductibles. As of 
September 23, 2010, all new private health plans are required to cover colorectal cancer 
screening tests with a U.S. Preventive Services Task Force (USPSTF) rating of “A” or 
“B” without any out-of-pocket costs to patients. Currently, the USPSTF recommends 
screening for colorectal cancer using fecal occult blood testing, sigmoidoscopy, or 
colonoscopy in adults beginning at age 50 and continuing until age 75.  
 
As of 2011, in the United States Medicare program, preventive services, such as 
colonoscopies, have no out-of-pocket costs and are exempt from deductibles. The 
deductible will be waived for colorectal cancer screening tests even when polyps are 
detected and removed. Additionally, starting 2013, states will be given a one percent 
increase in the Federal Medical Assistance Percentages for Preventive Services if they 
offer Medicaid beneficiaries all preventive services recommended by the USPSTF, offer 
immunizations recommended by the Advisory Committee on Immunization Practices, 
and remove cost sharing for all these services.4 This is important as patients can 
encounter unexpected cost sharing for screening colonoscopy. This occurs under three 
different circumstances: 1) when a polyp is detected and removed during a screening 
colonoscopy; 2) when a colonoscopy is performed as part of a two-step screening process 
following a positive stool blood test; and 3) when the individual is at increased risk for 
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colorectal cancer due to family or personal history and may receive earlier or more 
frequent screening compared with average risk adults. One study conducted in 2012 by 
the Henry J. Kaiser Family Foundation, the American Cancer Society, and the National 
Colorectal Cancer Roundtable collected interview data in eight states to determine how 
private insurers were approaching cost sharing for colorectal cancer screening. The study 
found that cost sharing varies widely based on those three circumstances depending on 
the insurer and how physicians code the colonoscopy procedure. Consumer complaints 
on unexpected colorectal cancer screening cost sharing have led to additional state-level 
legislation to clarify the intent of ACA.239  
 
Recent history shows that as colonoscopy becomes a covered procedure for screening, 
use by beneficiaries increases. For example, screening by colonoscopy increased rapidly 
following implementation by the Medicare program in 2001 of coverage for colorectal 
cancer screening colonoscopy for average-risk enrollees.118 Therefore, if present trends in 
screening preference continue and greater coverage is available from insurance plans, it 
can be projected that screening by colonoscopy will increase nationwide, unless other 
screening methods are developed as alternatives, such as stool DNA testing.  
 
Alaska Native Policy Related to Colorectal Cancer Screening 
Even prior to ACA, the Alaska Tribal Health System (ATHS) had made colorectal cancer 
screening a priority, and colorectal cancer screening, including colonoscopy, is generally 
an entirely covered benefit for Alaska Native people receiving care at tribal health 
facilities statewide. Several regional tribal health organization Board of Directors have 
also made colorectal cancer screening a priority area. ANTHC passed an organizational 
level resolution in 2009 to support the development of projects and/or programs to 
increase colorectal cancer screening statewide (ANTHC Resolution 09-04). However, 
coverage of patient and escort travel costs are not always covered by regional tribal 
health organizations within the ATHS, which can result in significant cost sharing for 
Alaska Native people who have to travel from remote villages into hub communities or 
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into Anchorage to obtain colorectal cancer screening. There are currently practice 
guidelines for appropriate screening and follow up intervals for Alaska Native people 
(Alaska Area Native Health Service CRC Screening Guidelines, June 2008), but no 
Alaska Tribal Health System-wide guidelines for what portion of colorectal cancer 
screening (procedure, travel, escort travel) is covered by the healthcare system for Alaska 
Native people, which is left up to individual tribal health organizations to determine.  
 
Alaska Native Tribal Health System 
Alaska Native people are concerned about the increasing burden of cancer, which has led 
to a focus on cancer prevention within tribal health organizations statewide, collectively 
called the Alaska Tribal Health System (ATHS). As will be discussed in Chapter 3, the 
ATHS represents more than 140,000 Alaska Native and American Indian people through 
a number of federally recognized tribes and tribal health organizations. Each tribal 
organization retains its autonomy with regard to health priorities, services, and policies in 
their respective service areas. Formed in 1997, the Alaska Native Tribal Health 
Consortium (ANTHC) is a statewide non-profit health services organization owned and 
operated by Alaska Native people to provide health services to tribal members throughout 
Alaska and to support the THOs that comprise the ATHS. The ATHS is a hub and spoke 
network of small village-based clinics, sub-regional clinics, regional hospitals, and a 
large urban secondary and tertiary care facility (see Figure 1-13 below). The tribal village 
clinics are staffed by Community Health Aides/Practitioners (CHA/Ps), laypeople who 
are trained as first responders for emergencies and provide basic primary and preventive 
healthcare. Sub-regional clinics are staffed by CHA/Ps, physician assistants, and nurse 
practitioners. Regional hospitals provide inpatient, outpatient, and emergency services 
and are staffed by physician assistants, nurse practitioners, and physicians.240 The ATHS 
comprises cradle-to-grave comprehensive care for eligible Alaska Native people. This 
integrated system of care has the potential for significant impact on colorectal cancer 
disease burden by allowing for a systematic focus on colorectal cancer prevention and 
control.  
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Figure 1-13. Alaska Tribal Health System referral patterns map.  
 
Colorectal Cancer Prevention Efforts 
Efforts to increase colorectal cancer screening rates in the ATHS have been undertaken 
by various tribal health organizations throughout Alaska. In the late 1990s, ANTHC 
began endoscopy training for nurse practitioners and physician assistants in order to 
improve access to screening flexible sigmoidoscopy and colonoscopy. Over the past 
decade, ANTHC has worked to improve colorectal cancer screening prevalence through 
various pilot projects and the creation of a Tribal Comprehensive Cancer Control 
Program. Some projects to reduce structural barriers in the Alaska Tribal Health System 
have included the development and implementation of a flexible sigmoidoscopy training 
program for rural mid-level providers; the provision of itinerant endoscopy services at 
rural tribal health facilities; the development and implementation of a colorectal cancer 
screening patient navigator project; the creation and use of a colorectal cancer first-
degree relative database to identify and screen relatives of colorectal cancer patients; a 
study to test the specificity and sensitivity of immunochemical fecal occult blood test as a 
screening method, especially in H. pylori positive patients, and a study on the 
effectiveness of a screening method that detects colorectal cancer genetic molecular 
markers exfoliated in stool (sDNA test).26, 72, 74 Along with these efforts state and tribal 
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health organizations have created multiple small media community health education 
tools, including brochures, posters, videos, health fair display boards, Readers’ theatre 
scripts, and digital stories.241 These tools are increasingly designed to be interactive and 
engaging and include multimedia components, such as theater events, personal stories, 
and videos.218, 242, 243 
 
An internal review of medical records at the Alaska Native Medical Center (ANMC) in 
1999 found that only 10% of the age-eligible Alaska Native population had been 
screened for colorectal cancer. To address this issue, the Alaska Native Medical Center 
Surgery Department trained a physician assistant to perform screening with flexible 
sigmoidoscopy. In 2000, colorectal cancer screening services were expanded by 
recruiting and training a nurse practitioner for a dedicated screening flexible 
sigmoidoscopy clinic. As a result of these combined efforts, the percentage of age-
eligible Alaska Native people in the Anchorage area screened for colorectal cancer 
increased rapidly to 47% by December 2003, representing a five-fold increase.244 Based 
on this success ANTHC developed a flexible sigmoidoscopy training program for nurse 
practitioners and physician assistants from regional hub communities across the state. 
The curriculum included didactic and clinical skills components. Seven providers were 
trained from 2005-2009 and as a result 205 rural patients received screening flexible 
sigmoidoscopies in that period. However, by the end of 2012 only one trainee continued 
to perform screening exams. Factors affecting attrition included staff turnover, competing 
clinical priorities, and a general shift to colonoscopy as the preferred screening modality 
for this increased-risk population.74  
 
Because of the limited success of the flexible sigmoidoscopy training program, ANTHC 
shifted focus in 2007 to supporting itinerant screening colonoscopy field clinics. In this 
model an endoscopist from the Alaska Native Medical Center travels out to remote areas 
of Alaska to conduct three to five day colorectal cancer screening clinics at regional 
hospitals with clinical space available for endoscopy. Priority is given to patients who 
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have never been screened and to those individuals who have a family history of colorectal 
cancer or adenomatous polyps in one or more first-degree relatives. Patients in whom 
colorectal cancer is found are referred to Alaska Native Medical Center in Anchorage for 
further care. This model has shown greater success in getting patient screened, but is 
subject to issues including a lack of support staff at regional facilities, including trained 
sedation nurses, endoscopy technicians, and sterile processing technicians, and weather 
related travel delays, which can reduce a planned five day clinic to only two or three days 
of procedures when patients are unable to fly from their home community to the hub 
community where the screening clinics are being held. Despite these issues, this model is 
being used throughout the state for regions that do not have trained endoscopist staff on-
site.72  
 
In 2009, ANTHC was accepted as one of the three Alaska tribal grantees of the Centers 
for Disease Control and Prevention (CDC) National Colorectal Cancer Control 
Program.26 As shown in Figure 1-14, ANTHC has six formal partner sites but provides 
technical assistance, including small media, training opportunities, and data request 
responses to an additional seven regional tribal health organizations. The goal of the 
ANTHC Colorectal Cancer Control Program (CRCCP) is to increase screening among 
Alaska Native and American Indian people through the provision of direct screening 
services, public outreach, provider education, and policy and systems improvements in 
the Alaska Tribal Health System. At the regional tribal health organizations with formal 
partnerships with the ANTHC CRCCP, Government Performance and Results Act 
(GPRA) data showed that screening rates increased by an average of 73% (range 4% to 
177%) since the 2009 program initiation.  
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Figure 1-14. Alaska Native Tribal Health Consortium Colorectal Cancer Control 
Program (CRCCP) activities in Alaska.  
 
Challenges for Colorectal Cancer Screening  
There are a number of challenges to the delivery of colorectal cancer screening among 
Alaska Native populations. First, about 40% of Alaska Native people live in widely 
dispersed remote communities which are not connected by road. Most of these 
communities are only accessible year round by air, with seasonal access by boat or 
snowmobile. Endoscopy (colonoscopy and flexible sigmoidoscopy) services are available 
in Anchorage and at a few of the regional hospitals. Therefore, obtaining colorectal 
cancer screening for Alaska Native people residing in remote communities requires long 
distance, high cost air travel to access screening services, as well as overnight lodging in 
order to complete the colonic preparation prior to the screening procedure. It is important 
to note that because of the limited endoscopic capacity, the endoscopy that is performed 
is generally for symptomatic patients, not for screening. Additionally, the few regional 
physicians who are trained in endoscopy generally have competing clinical 
responsibilities and often limited support staff.74 All of these factors have presented 
significant barriers to improving screening rates. 
 
Furthermore, as elsewhere in the U.S.121, 245 endoscopic capacity is limited in Alaska, 
particularly at the regional health facilities that serve the Alaska Native population. For 
many Alaska Native people living in remote communities, obtaining screening 
endoscopy requires travel to one of the seven regional health facilities with endoscopic 
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capacity or to Anchorage.74 Due to a shortage of trained local personnel, only four of 
these regional facilities provide endoscopy on a continuous basis, while three hold 
intermittent screening clinics staffed by itinerant endoscopists.  
 
A further challenge is the heterogeneous nature of the Alaska Tribal Health System, 
which includes multiple tribal groups with differing cultural traditions and histories. This 
heterogeneity makes it more difficult to draw conclusions as to best practices in 
promoting colorectal cancer screening among all Alaska Native men and women. 
However, previous ATHS studies have found that even if screening and/or travel for 
screening are financially covered, other barriers, such as systems level issues, still exist. 
Because of this the ATHS has increasingly focused on expanding patient navigation, 
education, and outreach efforts to ensure higher numbers of patients received 
recommended colorectal cancer screening.72 
 
Colorectal Cancer Screening Research 
 
Stool Test Studies 
Additional research is needed to identify and test effective colorectal cancer screening 
among Alaska Native people. There are two major areas of research inquiry that exist for 
increasing colorectal cancer screening among the Alaska Native population, particularly 
for those living in rural regions of the state. The first is to expand the screening options 
available. The current recommendation of colonoscopy as the first line of screening for 
Alaska Native people presents challenges in the form of high cost to the Alaska Tribal 
Health System, higher risks for patients from surgical complications of colonoscopy, and 
the reluctance of some patients to make long and costly trips away from their home 
communities in order to access colorectal cancer screening services. Because of these 
geographic and health system barriers, there is a critical need to expand colorectal cancer 
screening options for Alaska Native people. Better tools are needed to overcome the 
logistical barriers to screening in this population at increased risk of colorectal cancer. 
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Effective screening tests which are simple, convenient, relatively inexpensive, and 
minimally invasive would be especially helpful to increase colorectal cancer screening 
rates and prioritize endoscopy for higher risk and symptomatic patients. However, 
because the colorectal cancer incidence and mortality rates are so high among Alaska 
Native people, it is important to carefully choose tests that have greater effectiveness in 
this population.  
 
A first step in that direction is the Alaska Native Tribal Health Consortium’s Evaluation 
of the Fecal Immunochemical Test for Colorectal Cancer Screening in the Alaska Native 
Population Study (2008-2012), which enrolled 300 participants in a study comparing 
guaiac-based fecal occult blood test (gFOBT) with the newer fecal immunochemical 
fecal occult blood test (iFOBT) in patients receiving screening and surveillance 
colonoscopies to assess the accuracy (sensitivity and specificity) of gFOBT and iFOBT 
for detection of screen-relevant neoplasia (colorectal cancer and advanced precancer) in 
Alaska Native people. Previously there has been widespread reluctance to use gFOBT for 
colorectal cancer screening in Alaska Native people due to a concern that the high 
prevalence of H. pylori infection and other factors lead to excessive false positive tests 
and poor specificity. 
 
Preliminary results from the study show that the iFOBT had a significantly higher 
specificity than gFOBT, especially in patients with current H. pylori infection. Sensitivity 
between the two tests was comparable. The false positive rate was significantly higher for 
gFOBT compared with iFOBT, especially in patients with current H. pylori infection. 
Among participants who were able to adhere to gFOBT-required dietary and medication 
restrictions, specificity of gFOBT increased but was still significantly lower than iFOBT. 
The study data suggest that iFOBT offers advantages that may help increase colorectal 
cancer screening rates in Alaska Native people, and allows for prioritization of 
colonoscopy for diagnostic and surveillance examinations. However, iFOBT is primarily 
a test that detects cancer, not precancerous lesions, and so is not as effective as 
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colonoscopy in preventing cancer in this increased-risk population. However, for patients 
who refuse colonoscopy or do not want to travel for an initial screening test it represents 
a potential strategy for expanding colorectal cancer screening. A manuscript is in 
preparation detailing the results of the study (Redwood D, Provost E, Asay E, Roberts D, 
Haverkamp D, Perdue D, Bruce M, Sacco F, Espey D. Comparison of guaiac-based and 
immunochemical fecal occult blood tests for colorectal cancer screening in an Alaska 
Native population with high prevalence of Helicobacter pylori infection. Prevent Chronic 
Dis (in review) 2013).  
 
A follow-up pilot study is planned to start in 2014 to evaluate the feasibility and 
acceptability of iFOBT in at least two rural/remote regions of Alaska, especially among 
persons who have previously refused screening by endoscopy. This pilot study aims to 
lay the groundwork for broader implementation of the use of iFOBT throughout the 
Alaska Tribal Health System. Objectives will include developing and implementing 
healthcare system policy changes in those regions in order expand colorectal cancer 
screening options available to Alaska Native people.  
 
A second cross-sectional stool test study at ANTHC began in 2012: “Stool DNA 
Screening for Detection of Colorectal Neoplasia in Alaska Native People: An Initial 
Appraisal (2012-2015).” The objective of this study is to examine next generation stool 
DNA (sDNA) testing (sensitivity, specificity) in comparison with iFOBT in patients 
receiving screening or surveillance colonoscopies. Early studies have shown that the stool 
DNA test detects both colorectal cancer and polyps that lead to cancer, including right-
sided colorectal cancers in the colon, more accurately than stool blood tests, but it has not 
been evaluated in Alaska Native people. Over 600 participants are expected to join the 
study over the next three years. If the stool DNA test proves more effective than other 
types of stool tests, then it has the potential for markedly increasing access to colorectal 
cancer screening among Alaska Native populations living in remote locations, 
particularly among those unwilling or unable to get colorectal cancer screening by 
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colonoscopy. Increasing the availability and types of tests for colorectal cancer screening 
may increase uptake of screening and decrease colorectal cancer incidence and mortality.  
 
Facilitators and Barriers to Screening 
The second area of research inquiry is exploring the facilitators and barriers to screening 
among Alaska Native people. This information can be used to design interventions that 
target barriers to increase patient willingness to get screening tests completed. 
Discussions with Community Health Aides who provide the primary care for patients in 
their communities at the 2008 Annual Community Health Aide Forum identified 
common barriers to colorectal cancer screening, including discomfort, financial issues 
(travel costs), lack of knowledge/information about the importance of screening, and 
logistic issues (time away from family, need for escort for screening colonoscopies due to 
sedation). A follow up discussion at the 2011 Annual Community Health Aide Forum 
identified facilitators to getting community members screened: increasing use of health 
education materials, professional speakers, knowing the current screening rates by 
community, making improvements in scheduling referrals, appointments, and patient 
travel, as well as bundling colorectal cancer screening with other wellness appointments. 
Community Health Aides who completed follow up interviews reported more comfort in 
promoting cancer screening among their patients once they had gotten cancer education 
themselves.246 
 
Social ecological theory emphasizes influential behaviors, roles and environmental 
conditions that act as high-impact “leverage points” for enhancing people’s well-being.222 
To this end more research is needed on the use and effectiveness of patient navigators. A 
pilot project in 2009 by the Alaska Native Tribal Health Consortium in collaboration with 
a regional tribal health organization involved the creation of a colorectal cancer screening 
patient navigator position to test the benefits of patient navigation for increasing 
colorectal cancer screening. Although the project was successful at outreaching to 
patients to encourage them to get screened, fewer patients completed screening than was 
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hoped. Healthcare system barriers were identified as a major impediment to screening 
completion.72 More research is needed to identify how patient navigators can be 
integrated into existing Alaska Tribal Health systems of care to enhance the success of 
colorectal cancer screening efforts.  
 
Likewise, more research is needed on the use of community-level interventions for 
promoting colorectal cancer screening in the Alaskan setting. One such study was 
completed in 2013 by the ANTHC Epidemiology Center on the use of a giant inflatable 
interactive colon exhibit as an educational tool for increasing community members’ 
knowledge, intention, and social support for colorectal cancer screening and prevention. 
Alaskan adults (n=880) attending community events statewide between March, 2011- 
March, 2012 completed a short questionnaire before and after walking through a giant 
colon model (see Figure 1-15 below). The model depicted colorectal cancer stages from 
normal tissue to advanced adenocarcinoma and included display signs with colorectal 
cancer prevention tips. Adult community members significantly improved their colorectal 
cancer knowledge, intention to get screened, and comfort with talking to friends and 
family about colorectal cancer screening. Furthermore, the giant colon appeared to be 
equally effective for men and women, those over and under age 50, and Alaska Native 
and non-Native community members in all three construct domains surveyed 
(knowledge, intention and social support).219  
 
Figure 1-15. ‘Nolan’ the giant colon.  
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Lastly, there needs to be more research into how to evaluate the effectiveness of 
screening interventions, including economic analysis, and measuring the scope of 
effectiveness and sustainability of intervention outcomes over time. The expansion of 
colorectal cancer screening test methods, understanding more about effective and 
sustainable ways to encourage patients to get colorectal cancer screening, and decreasing 
systems-level barriers all will contribute to promoting colorectal cancer screening among 
Alaska Native people. These efforts will increase colorectal cancer screening prevalence 
and, ultimately, decrease the excess morbidity and mortality caused by colorectal cancer 
among the Alaska Native population. 
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CHAPTER 2 
 
Executive Summary 
 
Colorectal cancer (CRC) is the second leading cause of cancer mortality and the leading 
cause of new cases of cancer among Alaska Native people. First-degree relatives (FDRs) 
of CRC patients have twice the risk as the average population. Therefore, first-degree 
relatives are an increased risk sub-population within the larger Alaska Native population 
that experiences a significant health disparity due to CRC. Efforts to increase CRC 
screening rates have been undertaken by various tribal health organizations throughout 
the Alaska Tribal Health System (ATHS). Some projects have included training rural 
mid-level providers in flexible sigmoidoscopy; provision of itinerant endoscopy services 
at rural tribal health facilities; increasing patient navigator services; and stool test 
research studies. There have also been some efforts to increase screening specifically by 
Alaska Native first-degree relatives of CRC patients. However, no program evaluations 
have been conducted of these activities, nor have any studies previously assessed the 
extent to which these activities have been occurring throughout the ATHS.  
 
As will be discussed in detail in Chapter 4, program evaluation uses social research 
methods to investigate the effectiveness of health interventions. Program evaluation 
includes evaluation design, data collection, data analysis and interpretation, and report 
dissemination. Program evaluations can be completed at all stages of a program’s 
existence, from pre-implementation, currently implemented, or outcome and impact 
evaluations of long-standing programs. Findings about program design and 
implementation provide valuable feedback that can be used to improve program 
operations.1  
 
This study used the Framework for Program Evaluation in Public Health developed by 
the Centers for Disease Control and Prevention,2 as a primary structure for developing the 
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research aims, hypotheses and methodology. Elements of participatory research and 
evaluation were also used to inform the research structure, including the community-
based participatory research (CPBR) model.3-6 The CBPR approach reflects a profound 
shift to a more egalitarian balance between program evaluators and communities. Some 
of the important CBPR principles for program evaluation include an emphasis on 
building capacity, translating findings into sustainable action, and disseminating results in 
respectful ways.7-11 Furthermore, the tribal participatory research and evaluation model 
was used to increase the cultural relevancy of the program evaluation with the ultimate 
goal of improving the health care services for Alaska Native people.12-17  
 
Research Aims, Hypotheses and Methodology 
 
Research Aim I 
The first research aim of this study was to perform a survey of all Alaska Tribal Health 
System facilities for use of family history for CRC screening. Although a few studies 
have been done on collection of family history for cancer outreach,18, 19 no systematic 
survey has been conducted on the use of family histories for increasing CRC screening 
among Alaska Native people. Two sub-aims included surveying providers at Alaska 
tribal health facilities on the types of outreach used for encouraging family members of 
CRC patients to get screened as well as determining barriers to CRC screening and 
potential tools to improve CRC screening throughout the Alaska Tribal Health System. 
The research hypothesis for this aim was that conducting a survey of Alaska Tribal 
Health System facilities could provide information on current outreach practices and 
identify areas of need for further training and education.   
 
A study design which incorporated key informant interviews was chosen to provide 
insight into the programs and screening outreach practices available at the regional 
level.20 The study design for the family history outreach key informant interviews was a 
census of all ATHS tribal health organizations that either provide CRC screening or refer 
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patients to other facilities for screening. Regional THO representatives who were 
knowledgeable about CRC outreach at their tribal health facilities were asked to 
participate in the key informant interviews.21 An initial email describing the project was 
sent to ATHS regional contacts requesting that they participate in the interview or 
identify another individual who would be better able to provide the information 
requested. If participants did not respond to the initial or follow-up emails, follow-up 
phone calls were made to elicit response. Interviews were conducted by telephone and 
recorded on paper data collection sheets prior to entry into an electronic database (SPSS 
for Windows, Version 16.0 (IBM, Chicago, Illinois). The key informant moderator’s 
guide was developed specifically for this study based on previous ATHS surveys on CRC 
tracking and surveillance. The survey was reviewed by an outside expert in questionnaire 
design (Dr. B. Rogers, Tufts University) and pilot tested before the initiation of data 
collection with members of the priority population. The interview was designed so that 
the administration time would range from 15-25 minutes to allow enough time to gather 
the relevant information but not overly burden participants. The interview questionnaire 
was semi-structured and included a mix of quantitative (yes/no) and qualitative (open-
ended) questions to allow participants the opportunity to provide more in-depth 
responses. Statistical software (SPSS for Windows, Version 16.0 Chicago, Illinois, 2007) 
was used to analyze quantitative data (counts, frequencies). A manuscript on the study: 
“Use of Family History for Colorectal Cancer Outreach in the Alaska Tribal Health 
System,” details the survey results of ATHS providers on CRC screening outreach 
activities and barriers and facilitators, which found that CRC screening outreach was 
common in the ATHS, but significant barriers still exist, especially for outreach to FDRs, 
predominately a lack of dedicated staff and resources. This manuscript appears as 
Chapter 3 of the present work. 
 
Research Aim II 
The second research aim of this study was to assess the efforts of the Alaska Native CRC 
Family Outreach Program by conducting a process evaluation of the program.2, 20, 22 A 
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process evaluation design was chosen to explore how the program was developed and 
implemented, in order to disentangle the factors involved in the success and challenges of 
the program, and to help identify the key components involved.1, 23 The essential function 
of process evaluation is to provide insight into why a program or intervention does or 
does not work. Some key process evaluation components include the larger social context 
that the program is situated within; the reach, or proportion of the intended audience that 
actually participates in the intervention; the dose delivered and dose received of the 
intervention; the program fidelity, or how well the program was delivered as planned; 
implementation, which describes the extent to which the intervention was implemented, 
and recruitment, or how the program participants were actually approached and 
encouraged to join the program. All of these components relate to the eventual success or 
failure of a given program.1, 24 In addition to providing descriptive information for 
analyzing the effects of a given program, process evaluation as a tool offers a way to 
potentially avoid Type III errors in the evaluation analysis plan.25 Many public health 
evaluators are aware of Type I errors (rejecting a “true” null hypothesis (e.g. a false 
positive), or Type II errors (failing to reject a “false” null hypothesis (e.g. a false 
negative). Fewer evaluators and researchers take into account Type III errors, which are 
sometimes referred to as “providing the right answer to the wrong question,” or 
“correctly rejecting the null hypothesis for the wrong reason.”1 Type III errors have 
important consequences for understanding the benefits of a given intervention or 
program, including potentially misinterpreting the true effects of that intervention.26 By 
examining whether the program was carried out as intended and if not, how it varied from 
the original plan, the potential for Type III errors can be lessened.25  
 
No theoretical framework was used to originally design the Alaska Native CRC Family 
Outreach Program, nor was a community assessment done prior to program initiation. 
Over the ten years that the program has been in existence there has not been a program 
evaluation conducted. The research hypothesis was that a process evaluation of the 
Alaska Native CRC Family Outreach Program could provide qualitative data for 
99 
 
 
informing future outreach efforts to this increased-risk population. The goal of the 
process evaluation was to identify themes within key components of the program. The 
process evaluation sought to answer the following questions within the key components 
of the program: What led to the formation and evolution of the program? What were 
participant outreach responses? What were the successes and strengths of the program, 
and what were some of the program barriers and challenges? 
 
The evaluation plan used qualitative research methods27 including key informant 
interviews with past and present program Alaska Native and non-Native stakeholders. 
Key informant semi structured interviews formed a central line of evidence in this 
evaluation to provide in-depth qualitative data. Key informants were selected to ensure 
that historical and current program staff and managers, as well as key stakeholders 
involved in the creation of the Alaska Native CRC Family Outreach Program were 
represented. A snowball sampling technique28 was used to identify past or present 
informants who might have relevant information to share. Interviews were conducted 
until all potential informants had given an interview or declined at which point it was 
determined that saturation had been reached. The interview guide was developed in 
consultation with the program director and included 21 semi structured open-ended 
process evaluation questions. All interviews were conducted in person. The interviews 
were audio taped and transcribed verbatim. The transcripts were thematically coded using 
established qualitative methodology and software (QSR International NVivo Version 10, 
Burlington, MA). Document review was used in conjunction with the key informant 
interview to fill in dates for when key program changes or decisions occurred as well as 
providing additional insights into the program development, evolution, strengths, and 
challenges. Document sources included the CRC screening program coordinator’s email 
archive, hard copies of historic meeting minutes, reports to funders and program progress 
reports, and other correspondence and program notes. A manuscript on the study: “A 
Process Evaluation of the Alaska Native Colorectal Cancer Family History Outreach 
Program,” provides the process evaluation results of the Alaska Native CRC Family 
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Outreach Program (2000-2012) including its formation, evolution, and successes and 
challenges. A logic model was built of the program, and key themes included an 
incremental approach which led to a fully formed unique outreach program and the need 
for dedicated staff to provide culturally competent patient navigation. Challenges 
identified included differing FDR responses to screening outreach, health system data 
access and coordination, and the impact of reliance on grant funding for program 
sustainability. Program participant data, such as surveys of FDRs, were not included in 
the current study as the focus was on the program development, successes and challenges 
and opportunities for improvement in outreach efforts. Further research is needed to 
address participant level barriers to screening, in conjunction with the data compiled as 
part of this program of study. This manuscript appears as Chapter 4 of the present work. 
 
Research Aim III 
The third research aim of this study was to perform an outcome evaluation of the Alaska 
Native CRC Family Outreach Program to assess whether the program helped increase 
screening rates among family members of Alaska Native people with CRC. The research 
hypothesis was that the Alaska Native CRC Family Outreach Program increases the 
likelihood that first-degree relatives will get screened for CRC. The program database of 
CRC patients and their FDRs was used to provide the data source for the study. Statistical 
software (SPSS for Windows, Version 16.0 Chicago, Illinois, 2007) was used to analyze 
quantitative outcome evaluation data (counts, frequencies, chi-square tests of association, 
linear regression). All analyses were 2-tailed, and significance was set at p<0.05.  
 
A manuscript detailing the results of the study analysis: “Colorectal Cancer Screening 
Adherence among Alaska Native First-degree Relatives of Colorectal Cancer Patients,” 
provides the results of the outcome evaluation of the Family History Outreach Program 
which found despite increasing programmatic outreach and FDR screening rates, a large 
proportion of Alaska Native FDRs were still due for screening, especially rural-dwelling 
and older FDRs. This study found that overall, CRC screening and awareness is 
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increasing among the Alaska Native population, including among FDRs. However, many 
Alaska Native FDRs remain unscreened. There is a critical need for more research into 
FDR barriers and facilitators to CRC screening, as well as how the ATHS can more 
systematically promote screening among this increased-risk population and reduce 
morbidity and mortality due to this preventable disease. This manuscript appears as 
Chapter 5 of the present work. 
 
Research Aim IV 
The last research aim was to use the results of the ATHS survey and the case study to 
provide recommendations for Indian Health Service, tribal, or urban Indian facilities on 
the use of family history to improve outreach for CRC screening for AI/AN populations.     
The research hypothesis was that the Alaska Native CRC Family Outreach Program can 
provide a model for other Indian Health Service/Tribal/Urban Indian Health (I/T/U) 
facilities seeking to improve screening of populations at increased risk for CRC. Findings 
relevant to this research aim are included in the three manuscripts detailed above. In 
order to disseminate the research findings a presentation will be made to Alaska tribal 
health representatives in August, 2013. Once published, the three manuscripts will be 
widely distributed to representatives working in CRC screening at Alaska tribal health 
organizations, as well as to the Indian Health Service Task Force on CRC, for discussion 
and promotion among the IHS Task Force members and member organizations.  
 
Research Review Process 
The Alaska Area Institutional Review Board (IRB) (Reference #2011-02-003), the 
University of Alaska Fairbanks IRB (Reference #234570-1) and the Alaska Native Tribal 
Health Consortium and Southcentral Foundation research and ethics committees as well 
as the relevant tribal privacy officers reviewed and approved the study protocol. It was 
also approved for clearance by the Centers for Disease Control and Prevention Division 
of Cancer Prevention and Control, which funded the study. 
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The main role of the Alaska Area Institutional Review Board (IRB) is to protect the 
interests of research participants in the Alaska Native Health Care System and to ensure 
that the research projects meet the requirements of federal regulations. All researchers 
wanting to conduct studies among Alaska Native people must get permission from this 
board. Furthermore, if the Alaska Area IRB determines a project to be research, then 
researchers must get permission from the applicable human protections committee of the 
tribal health organizations in the regions in which they wish to conduct their research. 
Multiple Tribal review and approvals may need to be obtained prior to initiation of 
research projects.  
 
Research Timeline 
The program evaluation proposal was submitted to the Alaska Area IRB in February, 
2011, and a final approval letter of “Exempt Research” was received seven months later. 
The Tribal review process (which included concept proposal approval) started in June, 
2011, and final Tribal approvals were received five months later in November, 2011. The 
entire process from start to finish took ten months for final approval. It is important to 
note that at no point in the process was this project seen as anything more than minimal 
risk by each of the review bodies; nonetheless, the approval process still took a 
significant amount of time for completion due simply to the steps required in the process 
and review committee schedules. See Appendix E for a graphic timeline display of the 
Alaska Area IRB and Tribal review process for the study. Two subsequent study 
modifications also went through the AAIRB review and approval process but are not 
detailed here. The PhD dissertation defense presentation and written dissertation also 
went through the relevant tribal review and clearance processes.  
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2011 
• February 9: Submitted proposal to Alaska Area IRB 
• April 19: AAIRB reviewed proposal 
• June 2: Received AAIRB modifications required letter 
• June 23: Submitted PI response to AAIRB 
• June 23: Submitted proposal to ANTHC Research Abstracts Manuscripts Proposals 
(RAMP) Committee  
• June 23: Submitted proposal to SCF tribal concept review  
• July 19: AAIRB reviewed PI response letter 
• July 27: Concept proposal reviewed and approved by SCF Research Oversight 
Committee (ROC) 
• August 1: Submitted proposal to ANTHC Privacy Officer (as per AAIRB 
requirements) 
• August 1: Submitted proposal to SCF Privacy Officer (as per AAIRB requirements) 
• August 3: Submitted proposal to CDC Project Officer for review and approval 
• August 9: Concept proposal reviewed and approved by SCF Executive Committee 
• August 16: Received concept proposal approval letter from SCF Executive 
Committee 
• August 17: Received AAIRB approval letter (determination of Exempt Research) 
• August 24: ANTHC Privacy Officer determined that a Waiver of Authorization 
required 
• August 25: Submitted proposal to SCF Executive Committee for full proposal review 
• August 25: Submitted proposal to ANTHC Abstracts Manuscripts Proposals (AMP) 
Research Review Committee for review 
• August 30: Submitted draft Waiver of Authorization to ANTHC Privacy Officer for 
review 
• August 30: Proposal approved by CDC Project Officer 
• September 2: Received ANTHC Privacy Officer review and approval 
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• September 2: ANTHC Privacy Officer determines that Waiver of Authorization NOT 
required, as AAIRB determined project to be Exempt Research, and if Exempt 
Research then Waiver of Authorization cannot apply.  
• September 2: Received Southcentral Foundation Privacy Officer review and approval 
• September 20: Submitted to UAF IRB for review and approval 
• September 23: Reviewed and approved by ANTHC Abstracts Manuscripts Proposals 
(AMP) Research Review Committee 
• September 30: Received UAF IRB  approval as Exempt Research 
• October 4: Reviewed and approved by Southcentral Foundation Executive Committee 
• October 17: Received Southcentral Foundation Executive Committee approval letter 
• November 9: ANTHC Health Research Review Committee (HRRC) reviewed and 
approved on behalf of ANTHC Board of Directors 
• November 15: Received ANTHC Health Research Review Committee (HRRC) 
approval letter 
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CHAPTER 3 
 
Use of family history for colorectal cancer outreach in the Alaska Tribal Health 
System1 
 
Abstract 
Background: Colorectal cancer (CRC) is the second leading cause of cancer mortality 
and the leading cause of new cases of cancer among Alaska Native people. First-degree 
relatives (FDRs) of CRC patients have twice the risk as the average U.S. population.  
Purpose: This study assessed the prevalence of CRC screening outreach to FDRs at 
Alaska tribal health organizations (THOs), use of family history information, barriers to 
CRC screening, and potential tools to improve CRC screening throughout the Alaska 
Tribal Health System (ATHS). 
Methods: Key informant interviews were conducted by telephone with regional THOs 
using a semi-structured moderator’s guide from October to December, 2012. 
Results: Fourteen THOs (82%) participated, of whom 93% provided some type of CRC 
screening outreach to patients. More than three-quarters (79%) used brochures/patient 
educational handouts; 71% used mailed patient reminders or phone patient reminders; 
and 50% used provider reminders. Other types of outreach included health fairs, Alaska 
Native-specific CRC prevention videos, radio and TV public service announcements, 
patient birthday cards, and advertisements in local newspapers and tribal newsletters. 
Phone patient reminders were considered the most useful for encouraging CRC screening 
(90%). Only half (50%) said their facility provided outreach to increase FDR screening. 
Conclusions: CRC screening outreach is common in the ATHS, but significant barriers 
still exist, especially for outreach to FDRs, including lack of time and dedicated 
personnel, as well as opportunistic versus systematic CRC screening and limited medical 
records functionality. Potential tools included more Alaska Native-specific educational 
materials and provider training on screening guidelines and age-appropriate referrals.  
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Background 
Alaska Native people are indigenous persons whose ancestors, prior to European contact, 
occupied lands that are now part of the state of Alaska. Alaska Native people are a 
culturally and geographically heterogeneous population with over 230 federally 
recognized widely dispersed tribes. These tribes represent major cultural groups: in the 
north are the Inupiaq people, in the interior of the state, the Athabascan people, in the 
southwest live Yup’ik and Cup’ik people, along the Aleutian Chain are the Aleut and 
Alutiiq people, and along the southeast panhandle live Tlingit, Haida, and Tsimshian 
people. Approximately half of the 143,000 Alaska Native people in the state live in rural 
and remote communities that are off the road system and are accessible only by small 
aircraft, snow machines, or boats.29, 30 Traditional Alaska Native values vary throughout 
the state, but share a common thread of respect for others, caring for the land, sharing 
with family and community members, and honoring the wisdom of Elders.31 
 
Western contact in Alaska began in the mid-1700s with Russian explorers and fur 
hunters, and continued with the purchase of Alaska by the United States government in 
1867. During the past 200 years Alaska Native people experienced significant cultural 
disruption, including prohibitions on the practice of Native language and cultural 
traditions, conflicts with Western immigrants, as well as  considerable population loss 
through epidemics and forced relocation.32 Infectious diseases such as measles and 
influenza were the primary cause of death among Alaska Native people through the 
1950s.33, 34 In 1954, the Parran Report documented significant health disparities among 
Alaska Native people compared with other United States populations. This led to the 
initiation of research studies and health programs focusing on tuberculosis, other 
infectious diseases, and infant and maternal morbidity and mortality.33, 35 Since the 1950s, 
infectious disease rates have declined, and rates of chronic diseases have increased. 
Chronic diseases are now responsible for five out of the ten leading causes of death 
among Alaska Native people.36   
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Cancer is the leading cause of death among Alaska Native (AN) people.36 Colorectal 
cancer (CRC) is the second leading cause of cancer mortality and the leading cause of 
new cases of cancer among Alaska Native people.37 For the period, 2005 to 2009, the 
CRC incidence rate in Alaska Native people was two times the rate in U.S. Whites (84 
vs. 43/100,000), and mortality rates are also about twice that of U.S. Whites.38, 39 Most 
CRCs begin as polyps which generally progress slowly into cancers. The average time 
from progression of a polyp to cancer is 10 to 15 years.40 This long lead-time presents a 
window of opportunity for screening and intervention. Screening tests, including 
colonoscopy, flexible sigmoidoscopy, and fecal occult blood tests, can be used to detect 
CRC, prevent it through removal of precancerous polyps, or treat it if detected early in 
the disease progression.41, 42 It has been estimated that if all precancerous polyps were 
identified and removed before becoming cancerous, CRC incidence and mortality could 
be reduced by 76% to 90% and 70% to 90%, respectively.40, 43 This has profound 
personal and social consequences for patients and their families, as well as financial 
implications for healthcare systems.44, 45  
 
Alaska Native people are concerned about the increasing burden of cancer which has led 
to a focus on cancer prevention within tribal health organizations statewide, collectively 
called the Alaska Tribal Health System (ATHS). The ATHS consists of 143,131 Alaska 
Native and American Indian people in 229 federally recognized tribes organized into over 
30 Tribal Health Organizations (THOs) providing direct patient care. The ATHS provides 
cradle-to-grave comprehensive care for tribal members, including CRC screening. The 
ATHS is a hub and spoke network of small village-based clinics, sub-regional clinics, 
regional hospitals, with one tertiary care hospital located in Anchorage, Alaska. The 
tribal village clinics are staffed by Community Health Aides/Practitioners (CHA/Ps), who 
are laypeople trained as first responders for emergencies and provide basic primary and 
preventive village-based healthcare under supervision of physicians within the ATHS. 
Sub-regional clinics are generally staffed by CHA/Ps and midlevel providers. Regional 
hospitals provide inpatient, outpatient, and emergency services and are staffed by 
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midlevel providers and physicians.46 In many parts of Alaska the regional THO is the 
only healthcare provider available for both Native and non-Native residents.  
 
Because of the disproportionate burden of CRC among Alaska Native people, it is 
important to identify those at highest risk and encourage them to receive appropriate 
screening.47 First-degree relatives (FDRs: parents, siblings, children) of patients with 
CRC are almost twice as likely to experience CRC themselves, especially if their family 
member was affected before age 45.48-50 National guidelines recommend that people with 
a family history of CRC undergo cancer screening beginning at age 40 or 10 years before 
the youngest diagnosed FDR, whichever is earlier.42, 51, 52 Although the field of molecular 
epidemiology and genomics is rapidly expanding the potential for identifying persons at 
risk of CRC; including the discovery of new genetic biomarkers, whole genome 
association studies (GWAs), and expression profiling and proteomics;53-55 family history 
is still one of the most valuable tools which provides predictive value to identify 
individual patients at increased risk of CRC.56 
 
Improving outreach to persons at increased risk of CRC due to family history is critical to 
efforts to reduce CRC morbidity and mortality.57 Healthcare professionals in the United 
States have long used family history information collected from individuals as a risk 
assessment tool.58 However, family histories are rarely used to identify and provide 
systematic outreach to those at increased risk for disease, especially for CRC,59 and 
studies have shown that documentation of family cancer history in medical records is 
lacking in over half of primary care patients.60, 61   
 
Purpose 
Although a few studies have been done on collection of family history for cancer 
outreach,18, 19 no systematic survey has been conducted on the use of family histories for 
increasing CRC screening among Alaska Native people. The primary objective of this 
study was to assess the prevalence of CRC screening outreach based on family history in 
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the Alaska Tribal Health System (ATHS), as well as how family history information was 
collected and used for outreach. Lastly, the study elicited responses from regional tribal 
health providers on barriers to CRC screening and potential tools and activities that could 
improve family member outreach and screening more systematically throughout the 
ATHS.  
 
Methods 
The study design for the family history outreach key informant interviews was a census 
of all ATHS tribal health organizations that either provide CRC screening or refer 
patients to other facilities for screening (n=17). Regional THO representatives who were 
knowledgeable about CRC outreach at their tribal health facilities were asked to 
participate in the key informant interviews (October to December 2012). An initial email 
describing the project was sent to ATHS regional contacts requesting that they participate 
in the interview or identify another individual who would be better able to provide the 
information requested. If participants did not respond to the initial or follow-up emails, a 
follow-up phone call was made to elicit response. Interviews were conducted by 
telephone and recorded on data collection sheets prior to entry into a database (SPSS for 
Windows, Version 16.0 (IBM, Chicago, Illinois). The key informant moderator’s guide 
was developed specifically for this study based on previous ATHS surveys, and pilot 
tested before the initiation of data collection with members of the priority population. 
Interview administration time ranged from 15-25 minutes. The interview design was 
semi-structured and included a mix of quantitative (yes/no) and qualitative (open-ended) 
questions to allow participants the opportunity to provide more in-depth responses.  
 
The interview instrument included questions regarding CRC screening outreach methods 
used at the THO, such as patient wellness handouts, provider reminders, mailed or 
telephone patient reminders, or other tools for CRC screening outreach. The interviewer 
then asked whether the THO provided CRC screening outreach specifically to family 
members of patients with CRC, what types of outreach were used for those family 
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members, and whether there was outreach provided specifically to FDRs of CRC 
patients. The interviewer also queried how family members of CRC patients were 
identified, such as by histories in the electronic health record, in the patient chart, asking 
CRC patients directly for lists of their family members, taking family histories when 
patients came to the tribal health facility, or other methods. For each method, the 
informant was asked who at the THO collects the family history information, where the 
information is stored, and how (or if) that information is used for outreach. Any THO 
which reported not offering CRC screening outreach to patients was queried as to their 
perceived barriers to providing that service. All respondents were asked what they 
thought would help their THO expand CRC screening outreach to patients. Lastly, 
informants provided feedback on what types of CRC screening materials and continuing 
education they thought would be most helpful for their THO and which staff would be 
most able to use the information, especially for outreach to patients at increased risk of 
CRC due to family history. The Alaska Area Institutional Review Board (IRB), the 
University of Alaska Fairbanks IRB and the Alaska Native Tribal Health Consortium and 
Southcentral Foundation research and ethics committees reviewed and approved the 
study protocol. It was also approved for clearance by the Centers for Disease Control and 
Prevention Division of Cancer Prevention and Control, which funded the study. 
 
Results 
Fourteen THOs (82%) provided interview data (see Figure 3-1). Two regions elected to 
provide a written response to the interview instead of by telephone. The regional THOs 
interviewed serve an estimated 139,118 Alaska Native people, representing 97% of the 
total Alaska Native population living in Alaska (Data source: IHS 2012 Draft Active 
User Population Report). At least one staff member was interviewed; however, two 
THOs had two staff members participate in the interview. Of the 16 people that 
participated in the key informant interviews; 44% (7) were medical or clinic directors or 
case managers, 25% (4) were patient navigators, 19% (3) were program coordinators, and 
13% (2) were health education staff. Of the THOs surveyed, 8 (57%) provide CRC 
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screening at their regional tribal health facility, while the remaining THOs refer patients 
for CRC screening to the Alaska Native Medical Center in Anchorage, Alaska.  
 
 
Figure 3-1. Map of Alaska Tribal Health System tribal health organizations 
surveyed, 2012 (dark shaded areas indicate colorectal cancer outreach interview 
areas completed).   
 
Of the THOs surveyed, 13 (93%) provided at least some CRC screening outreach to 
patients. A total of 11 (79%) used brochures and patient educational handouts, 10 (71%) 
used mailed patient reminders, 10 (71%) used phone patient reminders, and 7 (50%) used 
provider reminders. Of all the outreach tools used, phone patient reminders were 
considered the most useful for encouraging CRC screening (90%), followed by provider 
reminders (86%), mailed patient reminders (80%) and brochures (64%). However, 
respondents felt that these collective methods were not used much by providers at their 
facilities, and none of the methods were considered sufficient on their own to encourage 
screening, but rather a variety of methods was better to reach the intended audience.  
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Respondents were asked to describe other types of CRC screening outreach used by their 
facility. All but one THO said that they did other types of outreach, including provision 
of CRC screening information at health fairs and community events, displaying 
 ‘Nolan the Giant Inflatable Colon’,62 Alaska Native specific CRC prevention videos, 
public service announcements on radio and TV, patient birthday cards, medical staff in-
services, and advertisements in local newspapers and tribal newsletters. Additionally, 
many THOs use Centers for Disease Control and Prevention supported CRC Control 
Program.63 patient giveaway items, including calendars, water bottles, veggie bags, tee-
shirts, berry buckets, and coffee sleeves with CRC prevention messages to help spread 
the word about screening. 
 
Although general CRC screening outreach is conducted to varying degrees through the 
ATHS, only half (50%) of the respondents said that they do any sort of outreach 
explicitly focused on encouraging family members of CRC patients to get screened. A 
total of 4 (29%) said that they ask CRC patients for a list of their FDRs to provide 
outreach to them. At 9 (64%) THOs, medical providers take family history if a patient 
comes in for a health concern. Family history information is entered into the electronic 
medical record at 7 (50%) THOs. Other types of outreach based on family history varied, 
including using a database or log to keep track of FDRs in need of screening, sending a 
specially designed letter outreach letter to FDRs due for screening, distributing family 
tree worksheets to patients, and provider review of medical records for FDRs to 
determine their need for screening referral at an earlier age than average-risk patients.  
 
Respondents described many barriers and challenges to increasing CRC screening 
outreach at their facility to patients at average risk, and even more so for FDRs. The most 
commonly cited issue was lack of time and dedicated personnel. Respondents said that 
their tribal health facility generally provides care to patients who come in for a specific 
medical complaint and then a screening referral might be offered if the provider thinks it 
is appropriate. For most facilities CRC screening outreach is not part of usual clinical 
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duties, and if performed is carried out by just one or two individuals, who generally have 
other additional job responsibilities. Some respondents also pointed to the challenge that 
most Alaska Native people live in communities where CRC screening is not locally 
available. Patients therefore have to travel far distances, which involve airplane flights, 
out of town stays, and weather-related travel delays. This travel is generally costly, time-
consuming and makes patients reluctant to complete the screening procedure. Some 
respondents also gave examples of systemic barriers to increasing outreach, including 
only having paper medical charts or electronic medical records that lack functionality to 
create a list of patients who are due for screening or who have a family history of CRC. 
Lastly, respondents said that patients are oftentimes unaware of the benefits and 
importance of screening, and that it is difficult to convince some patients to complete 
CRC screening, especially those who are healthy or asymptomatic or who do not access 
the medical system very often.  
 
Respondents were also asked what would help them increase screening outreach among 
the population they serve. Responses varied, from wanting information on how 
traditional wild foods might assist with cancer prevention, to more Alaska Native-specific 
materials, to needing templates for outreach letters, telephone scripts, and provider 
notations in the medical records. One item needed that was mentioned by all respondents 
was more training for ATHS healthcare providers on CRC screening guidelines and age-
appropriate referrals. Respondents reiterated that the most beneficial way to increase 
screening would be dedicated staff time to talk with patients, attend community events 
and work with multiple departments within each THO to encourage CRC screening 
among their specific patient populations (diabetes, tobacco control, etc.). However, 
respondents did not feel that this had to be a doctor per se, but other types of mid-level or 
allied healthcare professionals (patient navigators, case managers, etc.) could also 
effectively provide these types of outreach. 
 
 
115 
 
 
Conclusion 
Due to the high incidence and mortality among Alaska Native people, three Alaska THO 
grantees were funded in 2009 for a five-year grant supported by the Centers for Disease 
Control and Prevention (CDC) as part of the National CRC Control Program.63 The 
financial support of these grants and other funding mechanisms has led to the creation 
and staffing of CRC screening patient navigator or equivalent positions in 9 of the 17 
main regional THOs. These patient navigators provide screening outreach to patients and 
help decrease behavioral and structural barriers to screening.64-69 Although dedicated staff 
time was rated by all respondents as important for increasing outreach, funding for the 
screening navigation positions is entirely grant-funded, which has important implications 
for future sustainability of CRC outreach and prevention efforts.  
 
These activities are even more crucial in light of respondent comments that a great deal 
of the screening done is opportunistic care, that is, healthcare facilities in the ATHS do 
not have systems in place to facilitate CRC screening. Only if a patient comes in for 
another reason and it is somehow recognized that the patient is due, then that patient will 
be scheduled for screening. Family history information was also opportunistically 
updated in the medical records if a patient came in for care, but most facilities did not 
provide outreach to FDRs based on that information. This is in contrast to a organized 
approach, where a healthcare facility has a system in place to notify providers whether 
average risk and increased risk patients are due for CRC screening along with a method 
to notify patients that they are due at the age-appropriate interval.70 This is known 
collectively as provider reminder systems, and is listed as one of the five recommended 
best practices for increasing CRC screening by The Guide to Community Preventive 
Services.71, 72  
 
Alaska, like the rest of the United States, faces challenges in addressing increasing 
healthcare costs, improving access to medical care, and ensuring and improving quality 
medical care for patients. Timely access to essential medical information by providers at 
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the point of care is critical to good outcomes for patients and to improving quality and 
coordination of patient care. Computerized health records have a long history in the 
ATHS. Each THO maintains health records for users of their system. The majority of 
these health record systems are electronic, which has the potential for increasing provider 
ability to note family history in the medical record and use it for outreach to family 
members. Previously, the main medical record used by all Alaska THOs was the 
Resource and Patient Management System (RPMS). However, many regional THOs have 
now moved to using other electronic health records systems, which do not interface with 
one another and which are not consistent in where family history and previous cancer 
screening information is placed within the electronic medical record. Some respondents 
reported trying to set up provider reminders in their electronic medical records system, 
but lack of staff time to enter accurate data into the system, as well as inconsistency in 
where information was located in the medical record, has led to widespread inability to 
use family history and previous cancer screening information for systematic outreach to 
patients due for screening within the ATHS.  
 
Furthermore, provider reminder is one of the strongest predictors of CRC screening 
completion among patients.73-75 Respondents noted that it would be helpful to expand 
training opportunities for ATHS healthcare providers at all levels of care. This would 
address knowledge gaps on CRC screening guidelines and age-appropriate referrals,76 
especially for FDRs and other increased risk groups, to help improve screening rates 
among the Alaska Native population.  
 
Limitations of this study include a study design in which only one or two respondents per 
regional THO completed the key informant interview. This individual potentially might 
not have been the best person to answer interview questions on the behalf of the THO. 
However, potential respondents were selected on the basis of prior knowledge of their 
THO responsibilities, including CRC screening management. Also, respondents were 
asked at the beginning of each interview if they felt they were the best person to answer 
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the questions, and to provide another individual’s name if they felt another would be a 
better candidate for the interview. Only one respondent gave another name, but it was 
solely to provide additional information on sub-regional outreach efforts. Another 
potential study limitation is that these results might be subject to social desirability 
response bias in that respondents may have said that their organization was doing more to 
promote CRC screening than they actually were. ATHS CRC screening rates might be 
used to further assess the veracity of self-reported screening outreach efforts. Lastly, 
although a census sampling design was used to identify organizations for participation, 
the final sample size was still small, and limits the generalizability of the findings. 
 
This study was conducted to better understand how CRC outreach occurs across the 
ATHS, and whether family history information is being collected and used for outreach 
to FDRs of CRC patients. Although reported CRC screening outreach was common in the 
ATHS, significant barriers to increasing screening were noted; predominately lack of 
dedicated staff. These study findings may provide insight for Indian Health Service, 
tribal, or urban Indian facilities seeking to increase screening, especially among family 
members of CRC patients, and may also have relevance to improving CRC screening for 
increased risk patients in other healthcare delivery systems nationwide.  
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CHAPTER 4 
 
A process evaluation of the Alaska Native Colorectal Cancer Family Outreach 
Program1  
 
Abstract 
Objectives: This article presents the results of a process evaluation of the Alaska Native 
(AN) Colorectal Cancer (CRC) Family Outreach Program, which encourages CRC 
screening among AN first-degree relatives (FDRs: parents, siblings, children) of CRC 
patients. AN incidence and mortality rates for CRC are the highest of any ethnic/racial 
group in the United States. FDRs of CRC patients are at increased risk. CRC can be 
prevented through screening and early detection.  
Methods: The evaluation included key informant interviews (August-November, 2012) 
with AN and non-AN stakeholders and program document review. 
Results: Five key process evaluation components were identified: program formation, 
evolution, outreach responses, strengths, and barriers and challenges. Key themes 
included an incremental approach which led to a fully formed program and the need for 
dedicated culturally competent patient navigation. Challenges identified included 
differing FDR responses to screening outreach, health system data access and 
coordination, and the impact of reliance on grant funding for program sustainability. 
Conclusions: This program evaluation indicates a need for more research into motivating 
screening behaviors, electronic medical records systems quality improvement projects, 
and program sustainability planning to continue the dedicated efforts to promote 
screening in this increased risk population. 
 
1Redwood D, Provost E, Lopez E, Skewes M, Johnson R, Garcia G, Christensen C, Sacco 
F, Espey E. A process evaluation of the Alaska Native Colorectal Cancer Family 
Outreach Program. Prepared for Health Promotion Practice 2013.   
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Background 
 
Colorectal cancer prevention and first-degree relatives 
Colorectal cancer (CRC) is the second leading cause of cancer mortality and the leading 
cause of new cases of cancer among Alaska Native people.1 For the period, 2004-2008, 
the Alaska Native age-adjusted CRC mortality and incidence rates were nearly twice that 
of United States (U.S.) Whites.2, 3 Colorectal cancer can be successfully treated if 
detected early or even prevented through removal of precancerous (adenomatous) polyps. 
Nationally recommended screening tests include colonoscopy, flexible sigmoidoscopy 
and fecal occult blood tests.4, 5 People with a family history of CRC or adenomatous 
polyps in one or more first-degree relatives (FDRs: parents, siblings, or children) are 
almost twice as likely to experience CRC themselves, especially if their family member 
was affected before age 45.6-8 Screening strategies targeting FDRs of affected cases could 
contribute to the prevention or early detection of 15% to 20% of CRCs.9, 10 Alaska Native 
FDRs are an increased risk population, within a larger Alaska Native population that 
experiences a significant health disparity due to CRC. Based on national guidelines,11, 12 
the Alaska Tribal Health System CRC Screening Guidelines (June 2008) recommend that 
Alaska Native people with a first-degree relative or two or more second-degree relatives 
receive a colonoscopy every five years beginning at age 40 or 10 years before the 
youngest diagnosed family member, whichever is earlier.  
 
Program overview 
The Alaska Native CRC Family Outreach Program is located at the Alaska Native Tribal 
Health Consortium (ANTHC) in Anchorage, Alaska. ANTHC was formed in 1997 as a 
statewide non-profit health services organization owned and operated by Alaska Native 
people to provide health services to members of the 237 tribes throughout Alaska, 
primarily through small clinics in each community. ANTHC has a Self-Governance 
Agreement (the Alaska Tribal Health Compact) with the federal Indian Health Service for 
management of all statewide health services formerly provided by that agency. ANTHC 
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co-manages the Alaska Native Medical Center (ANMC) in Anchorage, Alaska along with 
Southcentral Foundation, which is the regional tribal health organization for Anchorage 
and surrounding communities.  
 
The goal of the Alaska Native CRC Family Outreach Program is to encourage FDRs of 
CRC patients to get screened for CRC themselves (see Figure 4-1: Program Logic 
Model). The program activities include asking to CRC patients seen at ANMC for a 
contact list of their FDRs. CRC patients either are approached for these lists while still in 
the hospital for cancer treatment, when coming back for follow-up appointments, or are 
sent a form with a business reply envelope to fill out at home. Furthermore, CRC cases 
are ascertained annually from the ANTHC Alaska Native Tumor Registry. The contact 
information given by the CRC patient is entered into a Microsoft Office Access database. 
A CRC screening patient navigator uses the information to provide direct outreach to 
Alaska Native family members encouraging them to get screened for CRC using 
telephone and mailed reminders, scheduling them into the screening clinic, and guiding 
them through the cancer screening process. First-degree relative lists are also sent 
annually to regional Tribal Clinical Directors for use by their facilities in identifying 
patients at increased risk of CRC.  
 
Figure 4-1. Logic model of the Alaska Native Colorectal Cancer Family Outreach 
Program, 2012. 
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The program does not currently provide outreach to high risk family members such as 
those with defined familial syndromes associated with extremely high risks of CRC, such 
as hereditary non-polyposis colorectal syndrome (HNPCC, or Lynch syndrome) or 
familial adenomatous polyposis (FAP),13 which require and receive specialized case 
management services at ANMC. Likewise, management of surveillance in patients with a 
personal history of adenomas or CRC is provided by the main CRC screening clinic at 
ANMC.  
 
Program evaluation 
Public health programs have been developed to address some of the significant health 
disparities experienced by Alaska Native people, such as cancer screening promotion to 
reduce morbidity and mortality related to breast, cervical and colorectal cancer. Cancer 
screening program components often include community outreach and education, 
provider education, direct screening services, and policy and systems changes.14 Cancer 
screening provision in Alaska can be challenging due to geographic and health systems 
access issues.15-17 
 
Program evaluation is the “use of social research methods to systematically investigate 
the effectiveness of social intervention programs […]”.18 Program evaluation can be 
appreciated as a progression of steps which include designing the evaluation, collecting 
the data, analyzing and interpreting the data, and reporting the findings (see Figure 4-2: 
Framework for Program Evaluation in Public Health, Centers for Disease Control and 
Prevention). Program evaluation can encompass many aspects and occur at many stages 
of the life of a program; from formative evaluation of programs that are still in the 
planning phase; to process monitoring and evaluation of currently implemented 
programs; to outcome and impact evaluation of programs to determine their overall net 
worth and broader effect.19 Process evaluation specifically examines how a program was 
actually implemented, by monitoring program activities and the priority populations 
131 
 
 
served.20 Findings about program design and implementation provide valuable feedback 
that can be used to improve program operations.21 This study describes the process 
evaluation of the Alaska Native Colorectal Cancer (CRC) Family Outreach Program, 
which collects contact information on family members of CRC patients for purposes of 
outreach and CRC screening. The goal of the process evaluation was to identify themes 
within key components of the program. The process evaluation sought to answer the 
following questions: What led to the formation and evolution of the program? What were 
participant outreach responses? What were the successes and strengths of the program, 
and what were some of the program barriers and challenges? 
 
 
Figure 4-2. Framework for program evaluation in public health, 1999.22 
 
Methods 
No theoretical framework was used to design the Alaska Native CRC Family Outreach 
Program, nor was a community assessment done prior to program initiation. Over the ten 
years that the program has been in existence there has not been a program evaluation 
conducted. The evaluation plan used qualitative methods23 including key informant 
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interviews with past and present program Alaska Native and non-Native stakeholders and 
program document review, including program progress reports and correspondence. Key 
informant semi structured interviews formed a central line of evidence in this evaluation. 
Key informants were selected to ensure that historical and current program staff and 
managers, as well as key stakeholders involved in the creation of the Alaska Native CRC 
Family Outreach Program were represented. A snowball sampling technique24 was used 
to identify past or present informants who might have relevant information to share. 
Interviews were conducted until all potential informants had given an interview or 
declined. The interview guide was developed by the lead evaluator in consultation with 
the program director and included 21 semi structured open-ended process evaluation 
questions. All interviews were conducted in person. The interviews were audio taped and 
transcribed verbatim. The transcripts were coded using established qualitative 
methodology and software (QSR International NVivo Version 10, Burlington, MA). 
 
The Alaska Area Institutional Review Board (IRB), the University of Alaska Fairbanks 
IRB and the Alaska Native Tribal Health Consortium and Southcentral Foundation 
research and ethics committees as well as the relevant tribal privacy officers reviewed 
and approved the study protocol. It was also approved for clearance by the Centers for 
Disease Control and Prevention Division of Cancer Prevention and Control, which 
funded the study. 
 
Results 
A total of eight interviews with key informants were conducted between 30 July and 5 
September, 2012, including hospital administrators (1), patient navigators (2), program 
managers (1), data analysts (1), and clinicians (3). All those who declined (n=5) self-
reported that it was due to insufficient knowledge of the program. The findings of the key 
informant interviews were delineated into five key components of the process evaluation. 
Key components included program formation, evolution, outreach responses, successful 
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components and strengths of the program, and program barriers and challenges (Table 4-
1).  
 
Table 4-1. Key themes of the Alaska Native Colorectal Cancer (CRC) Family 
Outreach Program process evaluation, 2012. 
Key Component Themes 
Program formation  • Incremental approach to program development 
Program evolution • Additional funding used to hire dedicated outreach staff 
(patient navigators) 
• Improved outreach tracking system and patient materials 
• Improved endoscopic access for patients 
Outreach responses • Increased awareness of CRC and the need for screening 
among population served 
• Fear of finding cancer 
• Wanting to prevent cancer by getting screened 
• Needing help navigating the system to get screened 
• Familial support for screening 
Strengths  • Geographically and ethnically defined patient population 
• Screening costs covered by Alaska Tribal Health System 
• Support by hospital leadership (Chief of Surgery) 
• Only program collecting this information and using it for 
outreach among Alaska Native people 
• Dedicated staff time 
• Alaska Native patient navigators who receive intensive 
training in motivational interviewing and patient outreach 
techniques 
Barriers and 
challenges 
• Culturally heterogeneous population from across state 
• Still patients due for screening  
• Need for more education on benefits of screening (patients) 
and screening referral guidelines (providers) 
• Reliance on grant funding for program operations 
• Need for improved data sharing and reporting in Alaska 
Tribal Health System 
 
Program formation 
The Alaska Native Tumor Registry, which monitors cancer incidence and mortality for 
all Alaska Native people, has data going back to 1969 that documents a rise in both CRC 
incidence and mortality among the Alaska Native population which is significantly 
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higher than the U.S. White population. Those data coupled with the literature showing 
that FDRs have a higher prevalence of CRC than the average-risk population led to an 
interest in the late 1990s by the ANMC Chief of Surgery in collecting family information 
from the Alaska Native CRC patients seen at the hospital. Furthermore, the clinicians 
who were involved in care of patients with CRC at the time noticed they were seeing 
more and more patients from the same family, either first- or second-degree relatives, 
who were also experiencing CRC.  
I think, as a clinician taking care of patients with colorectal cancer, I think it 
became clear that we were seeing people from the same family. And when we 
talked to people, the more we talked to them, we found that there were multiple 
instances where there were people who had first-degree family members or 
second-degree family members with colon cancer. So I think it started out 
basically as a clinical impression, and I think that because of that clinical 
impression and because of the fact that the literature shows higher risks for first-
degree relatives that we thought that this was something that we should be 
pursuing since this is a potentially preventable disease (Hospital Administrator). 
 
The Alaska Native CRC Family Outreach Program began very slowly, first just as a 
spreadsheet in the late 1990s of 200-300 newly diagnosed Alaska Native CRC patients. 
In early 2001, a nurse practitioner in the ANMC Surgery Clinic was assigned the task of 
getting in touch with CRC patients to ask them for contact information for their FDRs. 
CRC patients were identified either by the surgeons who had diagnosed the CRC or from 
the weekly hospital Tumor Board. CRC patients were approached either in person if they 
had not yet left the hospital, or by mailed letter. The hospital’s risk management and legal 
departments reviewed the project and the outreach letter to ensure patient privacy and 
confidentiality concerns were met. The nurse practitioner was primarily providing 
screening endoscopy procedures so was not able to dedicate time to outreaching to the 
identified FDRs. However, a registered nurse was available who sent out some letters to 
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FDRs. However, no attempt was made to keep track of how many FDRs were getting 
screened.  
 
At the beginning of the program, much of the relevant family history and screening 
information was in free text fields in the electronic medical record surgery package which 
was difficult to navigate and had great variability in where information was put and how 
it was entered. No funding was available for additional computer programming. There 
was also a belief at the time that the hospital was going to be changing medical records 
systems, and so it would not make sense to put more data into the current system. 
Therefore, a decision was made to collect information outside of the electronic medical 
record.  
 
Originally kept as a three-ring binder full of FDR contact information, a Microsoft Office 
Access database was created in 2002 to better manage the collected information. 
Although beneficial in that the database could be used immediately and contained exactly 
the variables required, because it was free standing and unconnected to the hospital’s 
medical record systems keeping patient contact and screening information current was 
difficult and required a lot of staff time that wasn’t available in the early years of the 
program. One key informant stated:  
And then to go through and figure out if the person had actually already had a 
procedure done; how would we find that out? Where would we find that 
information? So having it freestanding was a problem but the only way we had 
right then of keeping track (Clinician).  
A further issue was that the data collected were not always complete. Some CRC patients 
would say they had four children, but they could not remember their birth dates. Others 
would not know the addresses of their FDRs as they had lost touch over the years, or they 
gave names that were the same as other names in the medical records system, such that it 
was not possible to verify the identity of a FDR.  
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A CRC tracking package within the medical records system was created in 2003 and used 
briefly to keep track of patients due for screening. This package had the benefit that it 
could leverage the patient registration and previous screening information from the 
electronic medical record. It was also able to produce letters to patients, including FDRs, 
in need of screening. However, all information had to be hand entered, similar to the 
database; it did not have as many useful fields; it was difficult for staff to navigate; and it 
was difficult to pull aggregated reports. 
It was difficult at first because it was a free-text environment. So sifting through 
all the different ways of documentation for colorectal cancer screening and results 
and other information like family history were there, but the noise surrounding 
them was significant. The variation in ways of saying the same thing was also 
significant. And I think that that helped us realize that we needed a better tracking 
system (Data Analyst).  
For these reasons, the CRC tracking package was not used for very long at ANMC, 
although a version of it is used at one of the regional tribal health organizations to keep 
track of patients for surveillance colonoscopies.  
 
The Access database is still the primary data management tool used for the program. The 
database can be used by multiple staff members conducting outreach simultaneously. All 
patient contact information is kept on a secure research server, and access to the server is 
password protected. In 2008, a programmer analyst was tasked with increasing the 
capability of the Access database, most notably by adding fields on FDR screening dates 
and results, a tracking log to record and display outreach activities and patient notes, and 
report functions for those activities (number of phone calls made, number of letters sent, 
appointments kept, etc.). That was the first point at which outcomes of the program could 
be tracked and evaluated. One program staff member said:  
Well the family history database has undergone--in fact, I don’t know if I would 
recognize it anymore because I know [programmer analyst] made a lot of really 
good changes to it to make it more user friendly and useful. So I know there are a 
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lot of changes that have happened as far as notifications […] keeping track of that 
is very, very helpful (Clinician). 
 
Program evolution 
In April 2007, using funding from the Centers for Disease Control and Prevention, a 
program assistant was hired to identify FDRs, maintain the FDR database and provide 
outreach to FDRs to encourage them to get screened, including taking over sending 
letters from the nurse who had been doing it previously. Along with these FDR project 
duties the program assistant also performed other duties for the screening colonoscopy 
clinic, including making appointment reminder and rescheduling calls to patients, 
maintaining records for surveillance and follow-up, and sending results letters to patients 
who had completed their screening colonoscopies. The program assistant did not have 
previous experience in patient outreach and found it difficult initially to know how to 
motivate FDRs to come in for screening. Additionally, by having multiple job duties, the 
program assistant was not able to devote as much time to the FDR outreach as had been 
originally envisioned. Despite this, as shown in Figure 4-3, FDR screening rates 
increased when the first CRC screening patient navigator was hired from about 25 FDRs 
screened per year in the early 2000s to 90 screened in 2008. Also, in October 2009, the 
program assistant’s job title was changed to patient navigator to better reflect the job 
duties associated with the position.  
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Figure 4-3. First-degree relatives screened from the Alaska Native Colorectal 
Cancer Family Outreach Program, 2000-2012.  
 
In 2009, the screening endoscopist also started allowing direct referrals, so that low-risk 
patients did not have to go through a primary care provider in order to schedule a 
screening colonoscopy. In addition to facilitating direct access, the program also lets 
providers know that their patients are due for screening due to their FDR increased risk 
for CRC. The FDR outreach letter was also refined and a picture of the screening 
endoscopists and patient navigators was added to the letter so that patients would feel 
more comfortable when the patient navigators contacted them by phone or they came in 
for screening. A greater emphasis also was placed on sending out lists to regional tribal 
health organizations of the Alaska Native FDRs living in their areas who were due for 
screening so that these increased-risk patients could be invited to complete their 
screening. 
 
In 2012, a second patient navigator was added using research grant funding. The 
additional staff time almost doubled the number of FDRs screened to 228 from 117 in 
2011. At the same time there was also a shift such that CRC screenings no longer 
occurred in the surgery department, but were moved into a new dedicated space with a 
screening clinic offering both flexible sigmoidoscopy and colonoscopy services. This 
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shift brought additional case manager assistants, who were able to take over the clinical 
duties the patient navigator had been performing previously.  
 
Outreach responses 
The original concept for the outreach program was to systematically work from a list of 
patients at increased risk due to family history in order to help reduce CRC on a 
population level. The program has found that the most effective way to obtain family 
history lists from CRC patients is face-to-face interactions. It can be difficult since the 
cancer patient may be sick, may just had surgery or have just been told they have cancer 
and need time to deal with their diagnosis and treatment plan. However, in that personal 
interaction it is possible to sit with the cancer patient and explain that the information 
collected will be used to help their family members. Sometimes their FDRs are also there 
helping to take care of the cancer patient, so they can be scheduled for screening at that 
time.  
 
The patient navigators work to lower barriers to screening, such as helping FDRs find 
transportation and lodging before the procedure if they are homeless. All key informants 
reported that dedicated staff time for outreach was the most critical element to increasing 
screening rates. However, patient beliefs and attitudes also play a role in screening 
adherence. In general many Alaska Native people are motivated to come in for screening 
because somebody they know has CRC.  
We would keep records of how many times we've contacted the patients over the 
years. And then you see someone who calls you up after you've been trying to call 
them for four years. And you just ask that question, ‘So what made you change 
your mind?’ And they'll tell you their Uncle George or their best friend at work or 
somebody had colon cancer (Clinician).  
Several key informants pointed out that over the last 15 or 20 years there has been an 
increased awareness about CRC in the Alaska Native population due to increased 
education throughout the state and increased availability of screening services. The 
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Native population as a whole is much more aware of family history as a risk factor, and 
the need for CRC screening. As more Alaska Native people have gotten screened, the 
more likely that any given patient who hasn't been screened will be able to talk to 
somebody who's actually gone through the screening process, who may have had 
precancerous polyps removed, or who had a cancer found early when it was more easily 
treated and cured.  
 
For Alaska Native FDRs, there are an additional set of issues that play into screening 
adherence. FDRs experience conflicting emotions including fear or anger about getting 
cancer, especially if they are the primary care taker for the cancer patient and see what 
they are experiencing, particularly if the treatment is unsuccessful and the family member 
dies from a disease that was diagnosed too late to cure. Sometimes the FDRs do not want 
to do the procedure and find out that they also have cancer. Sometimes they do not 
believe that they are at risk themselves. One patient navigator reported:  
I've had people who were just absolutely upset that I called. I told them, “Your 
family member had colon--.” They're like, “Who?” “Oh, yeah, I guess she did.” 
And I say, "Well, you are more likely to develop these precancerous polyps.” And 
they say, "Oh, bunch of baloney! (Patient Navigator) 
For other FDRs it is a very strong impetus for them to get screened if they saw a loved 
one delay seeking care for symptoms.  
Mom just never went in. She was having problems for a long, long time, and she 
either wouldn't go in, or she just kept putting it off (Clinician).  
If they see their family member have the cancer caught early and still be alive and disease 
free, that can also be a push towards getting screened.  
 
Sometimes the CRC patient will tell their family members that they are at higher risk and 
encourage them to get screened. Sometimes family relationships can help wherein one 
FDR will come in for screening to get another FDR in the family to complete their 
screening, or two siblings will come in for screening at the same time to provide support 
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and encouragement to one another.  
Often we'll see somebody who has cancer, and when one of the siblings get 
screened and they kind of push the others to get screened. So I mean I think 
there's family pressure which works to help, and I think that that makes a 
difference. I think that the more people that are screened, the more likely any 
given patient who hasn't been screened will be able to talk to somebody who's 
actually gone through it (Hospital Administrator).  
After screening many FDRs reported feeling a sense of relief, which ends up outweighing 
the anxiety they experienced before the procedure. FDRs are often relieved to have the 
program contact them because they know they need to get screened but do not know 
where to start. Sometimes their primary care doctor does not know they have a family 
history, which makes it even more important that the program provide outreach 
encouraging FDRs to get screened.  
 
Even the FDRs who are nonresponsive at first sometimes are more receptive later when 
they have had time to think about it more or their life circumstances have changed. One 
clinician noted:  
It’s not that they're not interested or that they will never be interested, it's just that 
there are different phases in individual humans' willingness to change or be able 
to actually face change […] They may be going through some kind of crisis, other 
things going on in their lives, or fishing is going on or berry-picking is going on. 
But you offer this in November, and they say, ‘Well, when can I get this done? 
Can I come in? Can I come in tomorrow? Can we do it now?’ I've actually had 
people say that (Clinician). 
 Additionally, because the screenings occur within the Alaska Tribal Health System, it 
gives all Alaska Native FDRs equal access to care, regardless of financial status. By 
removing the financial burden, it reduces a common barrier to screening experienced by 
other U.S. populations. However, the colonoscopy preparation and procedures requires 
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time away from work and/or care of family members, which can be challenging for some 
patients.  
 
Successful components and strengths of the program 
One of the most successful components of the program is the dedication of resources 
(staff and otherwise) to actively obtaining information on FDRs and then providing 
outreach to those relatives, especially multiple phone calls, to schedule them for 
screening. Key informants highlighted that if the program didn’t collect the FDR 
information from CRC patients, then there would be no way of knowing which Alaska 
Native patients need earlier CRC screening, and at what age they need to be screened. 
I think the main strength of the program is, I don't know of any other program 
around the country that is actually dedicating resources to going out and finding 
people that are at risk this way. Most of them are leaving it up to families and 
people to show up themselves rather than to actually have people dedicated to 
gathering that information (Program Manager).  
For FDRs as well, without the program’s efforts many would not know they need to be 
screened, or how to schedule a screening appointment. And for those who do not follow 
through with the screening appointments, the program provides outreach to encourage 
them to reschedule and complete the screening. All of these efforts provide a valuable 
service to help reduce Alaska Native morbidity and mortality due to this disease. 
 
A further strength is that patient navigators (one male, one female) are Alaska Native 
themselves, and so have a better perspective on culturally competent ways to motivate 
patients to obtain screening. One patient navigator commented:  
I think of Native people as a whole family, in a way, whether they're close 
together or far apart. So that's what kind of drives me to call people and be 
passionate about talking to people because I think of them as family members 
(Patient Navigator).  
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Staff providing outreach have also received annual training in motivational interviewing, 
social marketing and patient navigation to help increase their ability to convince patients 
to get screened and follow through with screening exams. Leadership and support at the 
highest level by the ANMC Chief of Surgery has also played a key role in the on-going 
vitality of the program.  
 
Another element that benefits the program is that the Alaska Native population is an 
ethnic group that is geographically defined and a patient population that is well defined, 
unlike many other U.S. healthcare systems. There also exists a tribal health system 
responsibility to provide the best healthcare possible to this population, such that the FDR 
outreach is seen as a natural outgrowth of that obligation. Many regional tribal health 
organizations have also started to place a priority on CRC screening in general, which has 
made them more interested in getting their patient populations at increased risk (such as 
due to family history) screened.  
 
Program barriers and challenges 
The program outreaches to Alaska Native FDRs who come from diverse cultures 
throughout the state, and who may be at very different stages of behavior change and 
readiness to undergo screening. As mentioned previously responses can range from ready 
acceptance of the need for screening to anger and distrust, which can be a challenge to 
increasing screening in this population. Also, despite the increased education and 
awareness of CRC screening and prevention by Alaska Native people throughout the 
state, there are still misconceptions about screening; that it's either only for women or 
only for men, or that there is no need for screening if there are no physical signs and 
symptoms. Many Alaska Native people are unaware that FDRs are an increased risk sub-
population within the larger Alaska Native population that experiences a significant 
health disparity due to CRC. Furthermore, due to some of the previous cultural barriers 
against mentioning the word cancer, some family members were unaware that their 
sibling or parent had cancer, or what type it was. Lack of discussion within families can 
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be a significant barrier to awareness of the important and need for screening. For Alaska 
Native people, additional barriers, including geographic distances and cost of travel may 
also play a role in CRC screening underutilization.  
 
To be successful the program requires on-going identification of CRC patients, outreach 
to patients to obtain lists of their FDRs, database maintenance, and outreach to FDRs to 
promote screening. One key informant pointed to the on-going challenge of maintaining 
the database. 
I think that we don’t really have a good way of cross [referencing]… one of the 
things is it’s not integrated in our medical records system. So a patient may have 
had a procedure somewhere else, or they may have just had it done for diagnostic 
reasons by a surgeon, and we don’t know that, and they’re still in our database. So 
there’s no real linkage to say, ‘We don’t need to screen this person anymore for 
another five years’ (Clinician).  
 
A further challenge is staff time. At various points in the implementation of the program 
the staff members responsible for family history outreach have had other clinical duties 
and so have not been able to devote attention to outreach activities. Furthermore, 
although the Alaska Area Native Health Service CRC Screening Guidelines (June, 2008) 
state that patients with two or more second-degree relatives should be screened starting at 
age 40, the program does not keep track of or outreach to second-degree relatives due to 
limitations in staff time. While the program has been successful at increasing outreach to 
FDRs, there are still many who have not been screened. Of the FDRs in the database due 
for screening, 44% have been screened. This is lower than the Alaska Native population 
average screening rate of 58.5%.25 One key informant stated:   
The biggest challenge now is getting us up the next 20 percent. And that’s going 
to take different approaches, whether that's different techniques of screening or 
making better use of the navigator program to do outreach […] Unless we do 
something different, we're going to stay where we are (Hospital Administrator).  
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A major challenge for the program mentioned by all key informants is the continued 
reliance upon grant and research (soft) money and the impact that may have on program 
sustainability. 
I've seen this many, many times in the Indian Health Service and now in the 
Alaska Native Health System is that when the grant for a program starts to shrink, 
the program also begins to shrink. And when the grant goes away, the program 
goes away and it has nothing to do with how important that program is to the 
health of the population or how successful the program is (Clinician).  
 
Another issue identified is implementing a coordinated statewide focus, which is 
hampered by a lack of data sharing and reporting throughout the Alaska Tribal Health 
System. For example, the medical record information for FDRs who have completed 
screening at one of the regional facilities is not transmitted to ANMC and vice versa, 
such that a primary care provider at the regional facility might recommend screening not 
knowing that the patient was screened elsewhere, or the Alaska Native CRC Family 
Outreach Program database may show FDRs are due who have already been screened.  
Since it’s a huge state, a statewide program, I mean--and the colon cancers we’re 
getting now are not local people that have been screened before; they are way out 
there in rural communities. And so when we do get those family history lists, 
many times they have people on them, the first-degree relatives, who we know 
nothing about, medically. They may have not accessed the medical system. They 
may stay in their village or in a place where we don’t have access to their record 
[...] (Clinician).  
There is also not any mechanism within the electronic medical record system for letting 
providers at regional facilities know about FDRs living in their region who are in need of 
screening, so that the FDRs could be screened more conveniently at their regional 
facility, other than the outreach lists compiled and distributed periodically to regional 
facilities by the Alaska Native CRC Family Outreach Program. More coordinated data 
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management and system efficiencies would improve the overall outreach to Alaska 
Native FDRs at risk for CRC. There also needs to be more coordination and education for 
providers and case managers so that they understand the importance of CRC screening 
for their increased-risk patients, and know the appropriate age to refer FDR patients in for 
screening. Primary care providers already have relationships built with their patients, and 
their recommendations could help improve screening adherence among this  
population.26-31 One key informant noted:  
I think the education efforts are just--I mean they really set the stage for the 
navigators or for the primary-care people to be a success. So I think that all of the 
education stuff that's been done with the health aids, with the public, with the 
primary-care docs and things are just really, really important (Hospital 
Administrator). 
 
Conclusions 
It is vital that public health programs that seek to benefit Alaska Native people by 
reducing health disparities are evaluated. Evaluation allows for program improvement 
through assessment and modification. It allows for the results from successful programs 
to be promulgated for others to use as a basis for expanded efforts. It also builds the 
evidence base for emerging best practices. To the investigators’ knowledge, the Alaska 
Native CRC Family Outreach Program is unique in the United States in its sustained 
gathering of information and outreach to FDRs of CRC patients, and is the only one of its 
kind for Alaska Native or American Indian people. There are some existing programs that 
provide outreach to family members of patients with HNPCC or FAP, and there has been 
an increased focus in the United States on CRC screening in the general population, most 
notably through the 25 state and four tribal Centers for Disease Control and Prevention-
funded Colorectal Cancer Control Programs.14 However, the national CRC Control 
Program focuses on average risk individuals, not those with an increased risk due to 
family history or personal history of CRC, and does not include systematic outreach to 
these increased-risk sub-populations.   
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Participatory research approaches provide a framework for increasing the cultural 
relevancy of evaluation of programs designed to improve the health of Native people, and 
have been further refined as the tribal participatory research model.32-40 Along with the 
tribal participatory research model, this evaluation used an empowerment evaluation 
framework, which seeks to involve stakeholders throughout the evaluation process.41 
Representation from multiple groups of stakeholders, including clinical staff, program 
staff, and hospital leadership, helped make this process evaluation a strong and valuable 
source of information. 
 
This qualitative study was undertaken to explore some of the initial factors that gave rise 
to the Alaska Native CRC Family Outreach Program, key elements of program success, 
and challenges to the continued growth and sustainability of the program. Process 
evaluation is a critical piece in determining whether a program has been implemented as 
conceived. It appears that the program design is well conceived and logically sound, and 
is being implemented as intended. However, full implementation took some time to 
develop, and the program did not hit full stride until the past two or three years when full-
time funded patient navigators were able to devote dedicated time to the program 
activities. As a result of the process evaluation, five key components were identified 
including: program formation, program evolution, outreach responses, strengths of the 
program, and program barriers and challenges, which had a number of key themes within 
each component (see Table 4-1). 
 
Within the program creation and implementation component, it was notable that an 
incremental approach, whereby the program came into being piece by piece, actually led 
to a well-developed program, despite not having been initiated as such. Indeed, there was 
no dedicated funding or staffing available in the earliest days of the program. However, 
the need was identified (Alaska Native FDRs at higher risk) and a clearly defined 
potential solution (collect contact information for FDRs and provide CRC screening 
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outreach to them). Based on those core activities the program was able to progressively 
grow and thrive. Within the outreach responses component, key themes include the 
increasing trend in CRC screening awareness among the Alaska Native population and 
the increasing number of Alaska Native FDRs screened for CRC. However, many FDRs 
report a range of responses which impact their participation in screening efforts. Within 
the successes and strengths component, a key theme was that having dedicated patient 
navigators was vital for increasing screening in this population, especially who are 
themselves Alaska Native, and so can provide more culturally competent outreach to the 
patients that they serve. Weaving through the strengths and successes component was the 
support for program activities exhibited by key leadership within the organization which 
was critical to the expansion of the program, along with successful attainment of program 
funding. However, within the barriers and challenges component, notable themes were 
the reliance on grant funding for program continuation, the need for dedicated staff time 
to perform outreach activities, the need for more provider education, and health system 
data access and coordination issues.  
 
Several limitations of this study should be noted. Although the key findings can be used 
by other health organizations seeking to improve CRC screening outreach, especially for 
FDRs of CRC patients, due to the uniqueness of the Alaska Native CRC Family Outreach 
Program there was no comparison group to use to contrast with the activities and 
processes of the program. Also, creation of key components was conducted by one coder, 
although all interviews were audio recorded and two key informants were recontacted a 
week after the interview to reconfirm key points made during the interview.  
 
Overall, this process evaluation provided a rich source of information on the 
development, successful components and strengths, and barriers and challenges of a 
program to increase CRC screening among Alaska Native FDRs of CRC patients. These 
findings have relevance for other programs and organizations working to increase health-
seeking behaviors among populations experiencing significant health disparities. 
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CHAPTER 5 
 
Colorectal cancer screening adherence among Alaska Native first-degree relatives of 
colorectal cancer patients1 
 
Abstract 
Background: Alaska Native (AN) people experience twice the incidence and mortality 
due to colorectal cancer (CRC) as U.S. Whites. CRC can be prevented through screening 
and early detection. First-degree relatives (FDRs: parents, siblings, children) of CRC 
patients are at increased risk and screening colonoscopy is recommended every five years 
starting at age 40.  
Purpose: This study assessed screening adherence and outcomes among AN FDRs. 
Methods: Review of a database of AN CRC patients and their FDRs containing 
information on demographic characteristics, screening adherence and outcomes.  
Results: From January 1, 2000 to December 31, 2012, information on 691 CRC patients 
and 1979 of their FDRs (90 parents, 942 siblings, and 919 children) was compiled and 
used for screening outreach across the Alaska Tribal Health System. Over 80% of FDRs 
who had been screened were adherent to CRC screening guidelines. A total of 44% had 
been screened, compared to the AN population average of 58.5%. The advanced 
adenoma and adenocarcinoma detection rate was 34%. FDRs living in rural areas were 
significantly less likely to have been screened (38% vs. 59%, p<0.001). Children of CRC 
patients were more likely to have gotten screened than parents of CRC patients (46% vs. 
30%, p<0.05) and younger FDRs were more likely to be adherent to current screening 
guidelines than older FDRs (p<0.001). 
Conclusions: Preventing CRC among FDRs is vital. This study found an increase in AN 
FDR screening rates over the past ten years, corresponding with an increase in 
programmatic outreach to this increased risk population. Further research is needed to 
identify barriers and facilitators to CRC screening among Alaska Native people to reduce 
morbidity and mortality due to this disease.  
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Background 
In contrast to the declining United States (U.S.) death rate from cancer, the Alaska Native 
cancer death rate has not been declining.1 For the period 2004-2008, the age-adjusted 
CRC mortality rate for Alaska Native people was nearly twice that of U.S. Whites (30.2 
vs. 16.6 per 100,000). Alaska Native people also have about twice the incidence of CRC 
as U.S. Whites (97.2 vs. 50.1 per 100,000).1 Furthermore, Alaska Native people 
experience the highest incidence rates of all American Indian groups compared to non-
Hispanic Whites with the rate varying 5-fold between Alaska Native people and 
American Indian people from the Southwest U.S.2-4  
 
Colorectal cancer can be treated or prevented if detected early through the use of 
screening tests, including colonoscopy, flexible sigmoidoscopy, and fecal occult blood 
tests.5, 6 Because of the disproportionate burden of CRC among Alaska Native people, it 
is important to identify those at highest risk and encourage them to receive appropriate 
screening.2 Family history is a critical component of CRC risk stratification.7-9 People 
with a family history of CRC or adenomatous polyps in one or more first-degree relatives 
(FDRs; parents, siblings, or children) are at almost twice the risk for CRC.7, 8, 10, 11 A 
prospective study of participants in the Nurses' Health Study and the Health Professionals 
Follow-up Study found that FDRs of CRC patients had a 1.7-fold increase in risk of 
CRC.12 Furthermore, for persons who had two or more affected FDRs or who were 
younger than age 44 the relative risk increased substantially.12 This association held even 
after adjustment for other known or suspected risk factors for CRC.7 A total of 10% to 
30% of cases of CRC occur in people who have a relative with a history of an 
adenomatous polyp or CRC. This family history may increase CRC risk by influencing 
adenoma formation or enhancing the formation of new lesions.13  
 
FDRs of CRC patients are the largest groups of individuals at increased CRC risk. 
Overall, it is believed that screening strategies targeting FDRs of affected cases could 
contribute to the prevention or early detection of 15% to 20% of CRCs.14, 15 Therefore, 
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FDRs are an increased risk sub-population within the larger Alaska Native population 
that experiences a significant health disparity due to CRC. Based on national 
guidelines,16, 17 the Alaska Tribal Health System CRC screening guidelines (June 2008) 
recommend that Alaska Native people with a first-degree relative or two or more second-
degree relatives receive a colonoscopy every five years beginning at age 40 or ten years 
before the youngest diagnosed family member, whichever occurs earlier.  
 
CRC screening rates among the Alaska Native population are lower than U.S. White 
rates, but have been steadily increasing, from 29.0% in 2000 to 58.5% in 2012 of age-
appropriate Alaska Native people being up to date with CRC screening (colonoscopy in 
last 10 years or flexible sigmoidoscopy in last 5 years).18 Data from the Alaska 
Behavioral Risk Factor Surveillance System (BRFSS) in 2011 showed that 68.1% of 
Alaska Native adults reported ever having a sigmoidoscopy or colonoscopy. This 
screening rate was a notable increase from 50.0% in 2010 and 51.8% in 2008. The 2011 
rate is the first time that the Alaska Native rate has been above the rate for all Alaskans or 
Alaska Whites (65.0%).19 Through substantial efforts, CRC screening rates among 
Alaska Native people are close to the Healthy People 2020 target (70.5%) but are still 
below the CDC National CRC Control Program 2014 goal of 80%.20 Additionally, 
statewide aggregated rates hide the wide variation in CRC screening by tribal health  
region, which varies from 30% to 72% statewide.18  
 
Although no statewide data are available on family history of CRC in Alaska, data from a 
supplemental questionnaire included in the 2008 Oregon BRFSS found that 8% of 
respondents reported having a FDR with CRC.21 In Alaska, the only published data 
available on Alaska Native family history of CRC comes from the Alaska Education and 
Research Towards Health (EARTH) Study, which found a total of 13% of Alaska 
EARTH Study participants (2004-2006) reported one or more FDRs diagnosed with 
CRC.22 Of those who knew the age of diagnosis of their relative (n=209), 38% reported 
that their family member was diagnosed with CRC before age 50.23 Study participants 
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who reported a family history of CRC were twice as likely to report receipt of a 
colonoscopy or flexible sigmoidoscopy in the past five years (44.1% vs. 26.2%).24 
However, this still represents a low screening rate for a population at increased risk. 
 
In 1997, the Alaska Native Tribal Health Consortium (ANTHC), a statewide non-profit 
health services organization owned and operated by Alaska Native people was formed to 
provide health services to members of the 229 tribes throughout Alaska and support the 
tribal health organizations that comprise the Alaska Tribal Health System (ATHS). The 
Alaska Tribal Health System is a spoke-and-hub system consisting of small tribal village 
clinics, sub-regional clinics, and regional hospitals, with one tertiary care hospital 
(Alaska Native Medical Center, ANMC) in Anchorage. The size and geography of 
Alaska can present formidable barriers to obtaining healthcare, including cancer 
screening. In 2004, ANMC hospital administrators decided to start collecting FDR 
contact information from CRC patients treated at ANMC. These patients are approached 
for a contact list of their FDRs either while still in the hospital, when coming back for 
follow-up appointments or via a form sent with a business reply envelope to their home. 
The FDR contact information is entered into a computerized Microsoft Access database. 
Direct outreach using a CRC screening patient navigation began in 2007. In 2012, 
another patient navigator was added to the program, which greatly increased the number 
of FDRs screened (see Figure 5-1). The patient navigators provide direct outreach (phone 
calls, mailed letters, and one-on-one interactions) to encourage CRC screening among 
Alaska Native family members who receive care in the Anchorage area. Lists of FDRs 
living in other parts of the state in need of screening are also sent annually to regional 
tribal Medical and Clinical Directors for outreach efforts. Defined familial syndromes 
associated with extremely high risks of CRC, such as hereditary non-polyposis colorectal 
syndrome (HNPCC) or familial adenomatous polyposis (FAP),25 require and receive 
specialized case management services at ANMC. 
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Figure 5-1. Impact of CRC screening patient navigators on number of first-degree 
relatives screened, Alaska Native Colorectal Cancer Family Outreach Program, 
2000-2012. 
 
The purpose of this study was to examine the prevalence of screening adherence among 
Alaska Native FDRs of CRC patients, and characteristics associated with screening 
patterns in this increased-risk population. The Alaska Area Institutional Review Board 
(IRB), the University of Alaska Fairbanks and the Alaska Native Tribal Health 
Consortium and Southcentral Foundation research and ethics committees as well as the 
relevant tribal privacy officers reviewed and approved the study protocol. It was also 
approved for clearance by the Centers for Disease Control and Prevention Division of 
Cancer Prevention and Control, which funded the study. 
 
Methods 
Screening outcomes data were entered into the FDR database from medical records and 
combined with outreach data included in the FDR database for the study analysis. 
Summary statistics were calculated to provide an overview of Alaska Native CRC 
patients and their FDRs. The demographic variables analyzed for CRC patients included: 
sex, age at CRC diagnosis, and year of CRC diagnosis. FDR characteristics analyzed 
included age, relationship (parent, sibling child), screening status, screening type, and 
resident community size (urban area was based on 2010 U.S. Census definition of a 
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population of 50,000 or greater). Analysis of years since colorectal screening, screening 
adherence by region and screening adherence by relationship were restricted to those 
FDRs who were currently alive. Statistical software (SPSS for Windows, Version 16.0 
Chicago, Illinois, 2007) was used to analyze quantitative data (frequencies, chi-square 
tests of association, linear regression). All analyses were 2-tailed, and significance was 
set at p<0.05.  
 
Results 
Between January 1, 2000 and December 31, 2012, there were 691 CRC patients (52% 
women) included in the program database, along with 1,979 FDRs (see Table 5-1). Of the 
1,951 FDRs for whom the relationship was specified, 90 (5%) were parents, 942 (48%) 
were siblings, and 919 (47%) were children. On average about 3 FDRs were identified 
per CRC patient, and the mean age of CRC diagnosis was 61.7 years old (range 20-94). 
Since the project began only 9 (1%) CRC patients have declined to give contact 
information for their FDRs, although 95 CRC patients were lost to follow-up and thus 
had no relatives listed for them (data not shown). Case ascertainment for CRC patients 
was very high; of the 53 newly diagnosed CRC patients at ANMC in 2012, 45 (89%) 
were in the program database. The FDR mean age was 53.1 years old (range 3 to 98), and 
the mean age due for screening was 38.3 years old (range 11 to 40). Over 80% of FDRs 
were at or over age 40.  
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Table 5-1. Alaska Native colorectal cancer patient and first-degree relative 
demographic characteristics, 2000-2012. 
Characteristic No. (%) 
CRC Patients 691 (100) 
Female 359 (52) 
Deceased 249 (36) 
Age at diagnosis (mean) (range: 20-94) 61.7 
Diagnosis year  
   Pre-1999 166 (24) 
   2000-2009 361 (52) 
   2010-2012 164 (24) 
  
First-degree Relatives (FDRs) 1979 (100) 
Relationship (n=1951)  
   Parent 90 (5) 
   Sibling  942 (48) 
   Child 919 (47) 
Age, years (n=1890)  
   Mean age (range: 3-98) 53.1 
   Mean age due screening (range: 11-40) 38.3 
   <40 374 (20) 
   ≥40 1516 (80) 
 
As shown in Table 5-2, 319 (18%) of FDRs were not due for screening yet (too young), 
637 (36%) were screened previously by flexible sigmoidoscopy or colonoscopy, and 820 
(46%) were due for screening. A total of 824 FDRs had ever received a CRC screening 
exam of any type, 95% of which were colonoscopies. Of the living FDRs screened by 
colonoscopy for whom screening date was recorded (n=781), the majority (80%) were 
adherent to screening guidelines (screened by colonoscopy within the last 5 years), an 
additional 12% had been screened between 6 to 9 years prior, and 8% had been screened 
10 or more years prior. There was a significant difference in screening status by rural or 
urban community (38% vs. 59%, chi-square=57.68, df=1, p<0.001) as well as by familial 
relationship. Children of CRC patients were much more likely to have gotten screened 
than parents (46% vs. 30%, chi-square=5.65, df=1, p<0.05). Additionally, among FDRs 
who had already been screened, younger FDRs were more likely to be adherent to current 
screening guidelines than older FDRs (t= -7.79, df=3, p<0.001) and children (87%) were 
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more likely to be adherent than siblings (76%) or parents (61%) (chi-square=19.17, df=2, 
p<0.05). 
 
Table 5-2. Alaska Native colorectal cancer first-degree relative screening outcomes, 
2000-2012. 
Characteristic No. (%) 
First-degree Relatives (FDRs) 1979 (100) 
Screening status (n=1776)  
   Too young 319 (18) 
   Screened by flexible sigmoidoscopy or colonoscopy 637 (36) 
   Due for screening 820 (46) 
Screening type, ever had (n=824)  
   Barium enema  4 (1) 
   Flexible sigmoidoscopy  33 (4) 
   Colonoscopy 787 (95) 
Screening by colonoscopy, years (n=781)  
   ≤5 622 (80) 
   6-9  94 (12) 
   ≥10 65 (8) 
Screening adherence by region (% screened)*  
   Rural  363 (38) 
   Urban  252 (59) 
Screening adherence by relationship (% screened)  
   Parent  20 (30) 
   Sibling  340 (42) 
   Child 257 (46) 
Screening adherence to guidelines by relationship (% screened)*  
   Parent  20 (61) 
   Sibling  340 (76) 
   Child 257 (87) 
Screening histology (n=788)  
   Normal, non-polyp, or non-adenomatous polyps  424 (54) 
   Hyperplastic polyps 97 (12) 
   Adenomas, not otherwise specified 31 (4) 
   Tubular adenomas 159 (20) 
   Tubulovillous, villous or serrated adenomas 41 (5) 
   Adenocarcinomas or adenomas with high grade dysplasia 36 (5) 
*p<0.05. 
Note: All shaded categories were considered advanced neoplasia. 
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Of the 788 (95%) persons screened for whom results were available, 54% had normal or 
non-adenomatous polyp histology, 12% had hyperplastic polyps, 4% had adenomas of 
unknown type, 20% had tubular adenomas, 5% had tubulovillous, villous or serrated 
adenomas, and 5% had adenocarcinomas or adenomas with high grade dysplasia. The 
overall adenoma detection rate was 34%. 
 
Discussion 
This study is the first examination of CRC screening adherence and characteristics among 
Alaska Native FDRs of CRC patients. The results showed that the number of Alaska 
Native FDRs screened for CRC increased significantly over the past decade. However, 
only 44% of FDRs due had been screened. This is lower than the Alaska Native 
population average screening rate of 58.5%.18 An encouraging finding was among FDRs 
screened, 80% were adherent to current guidelines (colonoscopy within the past 5 years). 
U.S. screening rates among FDRs have increased over the past decade. According to the 
National Health Interview Survey (2005), CRC screening (endoscopy) had increased to 
65% among those with a family history. However, only participants over age 50 were 
asked their screening history, which may over represent the true screening rate among 
FDRs, many of whom need to be screened at much earlier ages when they may not be 
aware of the need for screening.26  In the current study the adenoma detection rate among 
Alaska Native FDRs was 34%, which is much higher than a national study of Medicare 
beneficiaries (24%).27  
 
Despite the number of published recommendations for screening individuals at increased 
risk of CRC due to their family history, a review by Rees et al. (2008) found few studies 
that had specifically investigated screening adherence patterns among FDRs.28 In this 
study of Alaska Native FDRs, adherence to current screening guidelines was higher 
among urban Alaska Native populations than rural FDRs. Of the FDRs due for screening 
known to be living in Alaska, the majority (78%) were located in rural areas, which may 
reflect the challenges of access to higher levels of health services. This finding warrants 
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further investigation. This study also found that younger FDRs and FDRs who were 
children of CRC patients were more likely to have gotten screened and to be up-to-date 
with screening. These results are consistent with some studies which found that younger 
cohorts were more likely to obtain screening by colonoscopy than older cohorts.29 Yet, 
other studies have reported higher screening uptake among older FDRs,30-32 and some 
have reported no association between FDR age and screening behavior.33   
 
There are several theoretical constructs that may influence CRC screening behavior, 
including perceived susceptibility, self-efficacy, and social influence.34, 35 For Alaska 
Native people, additional barriers, including geographic distances and cost of travel may 
also play a role in underutilization of CRC screening. In recent years there has been a 
national trend towards use of patient navigation for CRC screening promotion to help 
address barriers to screening.36, 37 CRC screening patient navigation provides 
individualized assistance to help overcome healthcare system and patient-level barriers to 
care and helps guide individuals into action.36 The Alaska Native Colorectal Cancer 
Family Outreach Program works to increase screening among FDRs by sending mailed 
reminder letters and making phone calls to encourage FDRs to get CRC screening, as 
well as using face-to-face approaches.37 To the investigators knowledge this sort of 
sustained outreach to increased risk family members of CRC patients is unique in the 
United States, and is the only one of its kind for Alaska Native or American Indian 
people. An informal survey of FDR outreach among the 25 state and four tribal Centers 
for Disease Control and Prevention-funded Colorectal Cancer Control Programs resulted 
in responses from six states and one tribe. One state reported that their results letter sent 
to patients identified with CRC or adenomatous polyps includes a sentence encouraging 
the patient to notify their FDRs that they are also at increased risk for CRC and polyps 
and to consult their primary care physicians regarding screening colonoscopy. However, 
none of the respondents reported that they provide active outreach to family members of 
CRC patients, nor did any program managers know of other programs doing such 
outreach. One way to more sustainably conduct FDR outreach would be to have family 
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member name, date of birth and contact information included in central cancer tumor 
registries for patients with confirmed CRC diagnoses. This information could then be 
used for outreach by CRC prevention programs to promote screening among this 
increased-risk population. 
 
Several limitations and strengths of this study should be emphasized. One limitation of 
this study is that colonoscopic results among FDRs in the program were limited to the 
most recent exam, and do not include prior abnormal findings. Therefore, a FDR could 
have had CRC or advanced polyps on a previous exam, but the results of the five-year 
surveillance colonoscopy were normal, which therefore may have led to an 
underestimation of the true adenomatous polyp detection rate. A retrospective medical 
record review would be necessary to more accurately categorize these patients on the 
basis of total clinical findings. Additionally, FDRs could have been screened outside of 
the Alaska Tribal Health System (ATHS), and thus the FDR screening rate presented here 
may be lower than the true prevalence. However, efforts were made to elicit information 
from FDRs as to prior screenings whenever possible, and CRC screening is a fully 
covered benefit for Alaska Native beneficiaries who receive their care within the ATHS. 
Lastly, the study sample was not able to be restricted to asymptomatic patients, thus 
patients may have been screened for diagnostic, not screening purposes. A strength of the 
study was that family history and screening test type and adherence to interval guidelines 
were objectively assessed through use of ATHS medical records, instead of relying on 
retrospective self-reports of screening behavior and family history.28, 38 
 
In summary, the available evidence suggests that screening rates of Alaska Native FDRs 
of CRC patients in accordance with guideline recommendations is increasing but remain 
lower than would be optimal to reduce CRC incidence and mortality on a population 
level. First-degree family members are an increased risk population, within a larger 
Alaska Native population that experiences nearly twice the incidence and mortality due to 
CRC as the U.S. White population. Further research is needed to inform interventions to 
167 
 
 
support sustained screening participation in this population and help reduce morbidity 
and mortality due to this disease.   
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CHAPTER 6 
 
Conclusions 
 
Alaska Native (AN) people experience twice the incidence and mortality due to 
colorectal cancer (CRC) as U.S. Whites. CRC can be prevented through screening and 
early detection. Besides age, family history of CRC is a key risk factor in CRC 
pathogenesis, with first-degree relatives (FDRs: parents, siblings, children) of CRC 
patients experiencing twice the risk as the general population. Therefore, FDRs are an 
increased risk sub-population within the larger Alaska Native population that experiences 
a significant health disparity due to CRC. Improving outreach to persons at increased risk 
of CRC because of their family history is critical to efforts to reduce CRC morbidity and 
mortality. This can be especially challenging in the Alaska healthcare setting, which 
requires Alaska Native patients seeking CRC screening to travel far distances involving 
airplane flights, out of town stays, and weather-related travel delays.  
 
Despite the number of published recommendations for screening individuals at increased 
risk of CRC due to their family history, there are few studies that  have specifically 
investigated screening adherence patterns among FDRs, and none have explored CRC 
screening trends and characteristics among Alaska Native FDRs.1 Use of active outreach 
to encourage CRC screening among FDRs is likewise rare to non-existent in the U.S., 
and no data exist on the extent and types of outreach occurring for this sub-population 
within the Alaska Tribal Health System (ATHS).  
 
This study assessed the prevalence of CRC screening outreach to FDRs at Alaska 
regional tribal health organizations (THOs), use of family history information, barriers to 
CRC screening, and potential tools to improve CRC screening throughout the Alaska 
Tribal Health System (ATHS). The study also included a process and outcome evaluation 
of the Alaska Native Colorectal Cancer Family Outreach Program, which encourages 
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CRC screening among Alaska Native FDRs of CRC patients. The process evaluation 
included a qualitative study of themes related to the program using key informant 
interviews and program document review. The outcome evaluation included an 
examination of the prevalence of screening adherence among Alaska Native FDRs of 
CRC patients, and characteristics associated with screening patterns in this increased-risk 
population. 
 
The main empirical findings are chapter specific and were summarized within the 
respective empirical chapters: “Use of Family History for Colorectal Cancer Outreach in 
the Alaska Tribal Health System,” “A Process Evaluation of the Alaska Native Colorectal 
Cancer Family History Outreach Program,” and “Colorectal Cancer Screening Adherence 
among Alaska Native First-degree Relatives of Colorectal Cancer Patients”. The survey 
of CRC screening outreach at ATHS facilities study found that CRC screening outreach 
is common in the ATHS, with over 90% of tribal health organizations surveyed reporting 
providing at least some sort of CRC screening outreach to patients. However, significant 
barriers still exist, especially for outreach to FDRs, for which only half of survey 
respondents (50%) said they do any sort of outreach to encourage screening among 
FDRs, and only half (50%) had a mechanism for keeping track of family history in the 
facility medical record system. Patient level barriers to screening were also noted, 
including a lack of awareness of the benefits and importance of screening, especially 
among patients who are healthy and who don’t often access the medical system. 
Respondents felt that more Alaska Native-specific health education materials and training 
for ATHS healthcare providers on screening guidelines would help increase CRC 
screening and referrals. The most significant challenge cited among all respondents was 
lack of time, resources and dedicated personnel.  
 
The Alaska Native Colorectal Cancer Family Outreach Program process evaluation 
elicited information within a number of themes, including program formation, evolution, 
outreach responses, strengths, and barriers and challenges. Key findings included an 
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incremental approach which led to a fully formed program and the need for dedicated 
culturally competent patient navigation. Challenges identified included differing FDR 
responses to screening outreach, health system data access and coordination, challenges 
in maintaining dedicated staff time to the program, and the use of grant funding for 
program operations. The Alaska Native Colorectal Cancer Family Outreach Program 
outcome evaluation found despite increasing programmatic outreach and FDR screening 
rates, a large proportion of Alaska Native FDRs were still due for screening (56%). 
Screening adherence was significantly lower among Alaska Native FDRs living in 
rural/remote areas compared with urban areas (38% screened vs. 59%, chi-square=57.68, 
df=1, p<0.001) as well as older Alaska Native FDRs compared with younger FDRs (t= -
7.79, df=3, p<0.001). However, of FDRs who had been screened, the majority (80%) 
were adherent to currently recommended interval guidelines (colonoscopy every five 
years). In summary, the study data suggest that screening rates of Alaska Native FDRs of 
CRC patients in accordance with guideline recommendations are increasing but remain 
much lower than would be optimal to reduce CRC incidence and mortality on a 
population level. 
 
Study Implications 
The results of this study have a number of policy and research implications. In the 
framework of the social ecological model, these results point to three avenues along 
which to approach increasing Alaska Native CRC screening, especially among FDRs. On 
the Interpersonal level, there is a need for culturally competent CRC screening outreach 
by medical paraprofessionals, such as patient navigators, as well as an expansion of 
training opportunities for all healthcare providers in use of appropriate screening referral 
guidelines. On the Organizational level, improving ATHS electronic medical records 
systems to facilitate CRC screening reminders and coordination is needed. On the Policy 
level, expansion is needed in the resources devoted to CRC screening beyond the current 
substantial reliance on grant funding to support outreach activities. Specific activities for 
implementing these recommendations are detailed below.  
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The ATHS is made up of multiple regional THOs, all of whom are dedicated to 
improving cancer prevention and care for the patients that they serve. In recent years 
there has been a national trend towards use of patient navigation to improve patient 
adherence to screening guidelines and assist patients with barriers to screening. Grants 
for improving CRC screening in the ATHS have led to the creation and staffing of CRC 
screening patient navigator or equivalent positions in nine of the 17 main regional THOs. 
These patient navigators provide screening outreach to patients and help decrease 
behavioral and structural barriers to screening.2-7 However, much remains unclear as to 
the best ways to implement patient navigation in tribal health settings, and how best to 
train navigators to provide culturally competent care.8  
 
Additionally, although provider recommendation has been found across studies to be a 
major facilitator of screening adherence,9, 10 surveys and claims data analysis of tribal and 
non-tribal healthcare providers find that knowledge gaps exist regarding the appropriate 
age to initiate screening, appropriate use of tests, and appropriate time intervals to repeat 
screening.11, 12 This is especially important for FDRs, who need to be screened earlier 
than the average-risk population, and with colonoscopy rather than other screening 
methods. Evaluation research is needed on the most effective ways to communicate 
screening guidelines to tribal providers and how to help them encourage screening 
referrals in their tribal health practice, for example by adapting national clinician 
toolkits13 for the Alaskan setting.  
 
Electronic medical records systems that do not facilitate CRC screening were also noted 
throughout this study as a barrier to more systematic CRC screening outreach. Alaska, 
like the rest of the United States, faces challenges in addressing increasing healthcare 
costs, improving access to medical care, and ensuring and improving quality medical care 
for patients. Timely access to essential medical information by providers at the point of 
care is critical to good outcomes for the patients and to improving quality and 
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coordination of patient care. Many studies, as well as the USPSTF guidelines, 
demonstrate strong evidence for use of provider reminder systems to improve screening 
rates.14-16 Computerized health records have a long history in the ATHS. Each THO 
maintains health records for users of their system. The majority of these health record 
systems are electronic, which has the potential for increasing provider ability to note 
family history in the medical record and use it for outreach to family members. However, 
this study found that systematic outreach using electronic health records as a tool was 
rare to non-existent in the ATHS, especially for FDRs. Previously one main electronic 
health record, the Indian Health Service Resource and Patient Management System 
(RPMS) was used within the ATHS, but over the last decade regional THOs have moved 
to using multiple electronic health records systems, which do not interface with one 
another and which are not consistent in where family history and previous cancer 
screening information is located within the medical record. Policy changes are needed at 
the tribal health organizational level to improve the use of electronic medical records 
systems for coordinated and efficient CRC screening and outreach within the ATHS. This 
could potentially include data sharing agreements among regional THOs to better 
organize the flow of screening and outcomes data across the entire ATHS. Another 
potential area for policy development is to include family member names, dates of birth 
and contact information in central cancer tumor registries for patients with confirmed 
CRC diagnoses. This information could then be used for FDR screening outreach by 
CRC prevention programs. Research in developing innovative provider and health system 
approaches in the ATHS is vital for improving CRC screening delivery, as well as 
follow-up care and cancer surveillance.   
 
Perhaps not surprisingly, uncertain funding and lack of dedicated resources and staff was 
an area noted throughout the study, especially in regards to future sustainability of CRC 
screening activities. The Alaska Native CRC Family Outreach Program is unique in its 
efforts to identify Alaska Native FDRs and provide patient navigation to guide them into 
appropriate CRC screening and follow-up. However, these activities are entirely grant-
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driven, which means that if future grants are not secured, this outreach activity will cease. 
In other areas, notably in New York, a pilot patient navigator program in urban public 
hospitals was evaluated for cost, cost-effectiveness, and cost-benefit analyses. The 
economic evaluation found that overall the program was cost-effective and actually 
yielded a net financial benefit, primarily through decreasing patient broken appointment 
rates, which increased overall colonoscopy volume,7, 17 and by improving patient bowel 
preparation quality, which reduced the number of colonoscopies that needed to be 
repeated.3  The results of the study were used to encourage hospitals to hire and train 
patient navigators as part of standard hospital operating costs. This type of economic 
analysis has never been conducted on patient navigation in Alaskan healthcare settings. 
Conducting economic analysis research in the tribal health setting could provide data for 
building the business case for adding patient navigation to the menu of healthcare 
delivery services that are currently provided in the ATHS. 
 
Some limitations of this study should be noted. No data were available on the sex of 
Alaska Native FDRs included in the Alaska Native CRC Family Outreach Program; 
therefore it was not possible to determine if there were differences between men and 
women in FDR screening behaviors. This study may also have underrepresented the true 
screening prevalence of Alaska Native FDRs as some patients may have been screened 
outside of the Alaska Tribal Health System (ATHS). However, efforts were made to elicit 
information from FDRs as to all prior screenings whenever possible, and CRC screening 
is a fully covered benefit for Alaska Native beneficiaries who receive their care within 
the ATHS. Additionally, although Alaska Native FDR screening rates increased over the 
years of the program, overall screening rates in the Alaska Native population were also 
increasing over the same period, thus it is not possible to attribute positive screening 
trends just to program outreach activities. Further research is needed to more fully 
explore screening characteristics, barriers, and facilitators to screening in this increased-
risk population.  
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Another issue is that much of the study data was qualitative in nature, derived primarily 
from key informant interviews and document review. These data provided a rich source 
of information, especially in regards to outreach activities across the ATHS and the 
formation, successes and challenges of the Alaska Native CRC Family Outreach 
Program. There are however, disadvantages to this type of research, including small 
study sample size and corresponding implications for study validity and reliability.18 A 
snowball sampling technique was used to identify as many stakeholder perspectives as 
possible for both the ATHS interviews as well as the Alaska Native CRC Family 
Outreach Program interviews to reduce potential measurement error due to selection bias, 
but which limited the evaluation generalizability. Reliability was addressed by aligning 
the research purpose and study design, and conducting key informant interviews using 
pilot-tested moderator’s guides and a trained interviewer. Lastly, the study focus was the 
Alaska Native population, which potentially limits the generalizability of the study 
findings to other racial/ethnic groups or to the broader U.S. population.  
 
Influences on screening behaviors are numerous and complex. Individual, interpersonal, 
organizational, community, and policy level factors all impact screening uptake. This 
study provided novel information on CRC screening outreach activities occurring across 
the ATHS, and challenges experienced by those working to increase CRC screening in 
the Alaska tribal health setting. It also explored the Alaska Native CRC Family Outreach 
Program, which is unique in providing active outreach to tribal FDRs of CRC patients. 
By closely examining the successes and barriers to increasing CRC screening 
experienced throughout the ATHS and within the Alaska Native CRC Family Outreach 
Program, the study was able to identify significant gaps and areas for research and policy 
improvement. The study findings highlight key issues that are faced by many tribal, 
urban Indian, and Indian Health Services facilities, as well as other healthcare delivery 
systems nationwide seeking to promote CRC screening among increased-risk patients. 
These data also have broader relevance for other programs working to increase health-
seeking behaviors among populations experiencing significant health disparities. Further 
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research is needed to inform CRC screening interventions among Alaska Native people to 
help reduce morbidity and mortality due to this preventable disease. 
  
181 
 
 
Literature Cited 
1. Rees G, Martin PR, Macrae FA. Screening participation in individuals with a 
family history of colorectal cancer: a review. Eur J Cancer Care (Engl). 2008 
May;17(3):221-32. 
2. Madlensky L, Esplen MJ, Gallinger S, McLaughlin JR, Goel V. Relatives of 
colorectal cancer patients: factors associated with screening behavior. Am J Prev Med. 
2003 Oct;25(3):187-94. 
3. Elkin EB, Shapiro E, Snow JG, Zauber AG, Krauskopf MS. The economic impact 
of a patient navigator program to increase screening colonoscopy. Cancer. 2012 Dec 
1;118(23):5982-8. 
4. Freeman HP, Rodriguez RL. History and principles of patient navigation. Cancer. 
2011 Aug;117(15 Suppl):3539-42. 
5. Lasser KE, Murillo J, Medlin E, Lisboa S, Valley-Shah L, Fletcher RH, et al. A 
multilevel intervention to promote colorectal cancer screening among community health 
center patients: results of a pilot study. BMC Fam Pract. 2009;10:37. 
6. Redwood D, Provost E, Perdue D, Haverkamp D, Espey D. The last frontier: 
innovative efforts to reduce colorectal cancer disparities among the remote Alaska Native 
population. Gastrointest Endosc. 2012 Mar;75(3):474-80. 
7. Nash D, Azeez S, Vlahov D, Schori M. Evaluation of an intervention to increase 
screening colonoscopy in an urban public hospital setting. J Urban Health. 2006 
Mar;83(2):231-43. 
8. Daley CM, James AS, Filippi M, Weir M, Braiuca S, Kaur B, et al. American 
Indian Community Leader and Provider Views of Needs and Barriers to Colorectal 
Cancer Screening. Journal of health disparities research and practice. 2012;5(2). 
9. Beydoun HA, Beydoun MA. Predictors of colorectal cancer screening behaviors 
among average-risk older adults in the United States. Cancer Causes Control. 2008 
May;19(4):339-59. 
10. Wilkins T, Gillies RA, Harbuck S, Garren J, Looney SW, Schade RR. Racial 
disparities and barriers to colorectal cancer screening in rural areas. J Am Board Fam 
Med. 2012 May-Jun;25(3):308-17. 
182 
11. Haverkamp D, Perdue DG, Espey D, Cobb N. A survey of Indian Health Service 
and tribal health providers' colorectal cancer screening knowledge, perceptions, and 
practices. J Health Care Poor Underserved. 2011 Feb;22(1):243-57. 
12. Klabunde CN, Frame PS, Meadow A, Jones E, Nadel M, Vernon SW. A national 
survey of primary care physicians' colorectal cancer screening recommendations and 
practices. Prev Med. 2003 Mar;36(3):352-62. 
13. Sarfaty M. How to Increase Colorectal Cancer Screening Rates in Practice: A 
Primary Care Clinician’s Evidence-Based Toolbox and Guide: The American Cancer 
Society 2008. 
14. Nease DE, Jr., Ruffin MTt, Klinkman MS, Jimbo M, Braun TM, Underwood JM. 
Impact of a generalizable reminder system on colorectal cancer screening in diverse 
primary care practices: a report from the prompting and reminding at encounters for 
prevention project. Med Care. 2008 Sep;46(9 Suppl 1):S68-73. 
15. Baron RC, Melillo S, Rimer BK, Coates RJ, Kerner J, Habarta N, et al. 
Intervention to increase recommendation and delivery of screening for breast, cervical, 
and colorectal cancers by healthcare providers a systematic review of provider reminders. 
Am J Prev Med. 2010 Jan;38(1):110-7. 
16. Klabunde CN, Lanier D, Breslau ES, Zapka JG, Fletcher RH, Ransohoff DF, et al. 
Improving colorectal cancer screening in primary care practice: innovative strategies and 
future directions. J Gen Intern Med. 2007 Aug;22(8):1195-205. 
17. Lacy NL, Paulman A, Reuter MD, Lovejoy B. Why we don't come: patient 
perceptions on no-shows. Ann Fam Med. 2004 Nov-Dec;2(6):541-5. 
18. Harris MJ. Evaluating public and community health programs. San Francisco, 
CA: Jossey-Bass; 2010. 
 
 
  
183 
 
 
Appendices 
 
Appendix A 
 
Use of Family History for Colorectal Cancer Screening Outreach Survey, 2012 
 
Introduction: Hello, my name is __________. I work in cancer prevention at the Alaska 
Native Tribal Health Consortium. In collaboration with the Indian Health Service, we are 
trying to learn how tribal health facilities manage outreach to encourage patients to get 
colorectal cancer screening.   
1.) Would you be the appropriate person to discuss colorectal cancer screening 
outreach at your facility?   
 
Yes (go to Background and Q. 2)    No       Don’t know  
 If no, who would you recommend speaking with about this? 
a. Name: 
____________________________________________________________ 
b. Contact Info: 
____________________________________________________________
____________________________________________________________ 
Thank you for your time. 
 
Background: We’d like to collect information from tribal health facilities in Alaska 
about how family history is being used for colorectal cancer screening outreach. Your 
input will help to make recommendations for improving CRC screening and should take 
about 5 minutes of your time. Is now a good time for you to answer a few questions on 
this? 
 
If not, when would be a better day and time to discuss this with you? ________________ 
 
I. Screening Outreach 
 
2.) Does your facility provide outreach to encourage patients to get CRC 
screening? 
 
Yes (go to Q. 3) No (go to Q. 11) Don’t know 
 
3.) What kinds of outreach do you do? 
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Now I am going to ask you about specific CRC screening outreach methods at your 
facility. 
  
4.) What materials do you use for CRC screening outreach? 
 
a. Patient Wellness Handouts (such as brochures) Yes   No (skip to b)   DK 
i. Do most of your providers use them?       Yes      No    DK  
ii. Are these useful for encouraging screening?      Yes      No    DK  
iii. Are these sufficient for encouraging screening?     Yes     No    DK 
b. Provider reminders?    Yes     No (skip to c)    DK 
i. Do most of your providers use them?       Yes      No    DK 
ii. Are these useful for encouraging screening?      Yes      No    DK 
iii. Are these sufficient for encouraging screening?     Ye       No    DK 
c. Mailed patient reminders?   Yes     No (skip to d)    DK 
i. Do most of your providers use them?       Yes      No    DK  
ii. Are these useful for encouraging screening?      Yes      No    DK  
iii. Are these sufficient for encouraging screening?  Yes       No   DK  
d. Phone patient reminders?   Yes     No (skip to e)    DK 
i. Do most of your providers use them?       Yes      No    DK  
ii. Are these useful for encouraging screening?      Yes      No    DK  
iii. Are these sufficient for encouraging screening?  Yes     No    DK 
e. Other types of CRC screening outreach (explain)? Yes  No    Don’t know 
____________________________________________________________
____________________________________________________________
____________________________________________________________ 
i. Do most of your providers use them?          Yes  No    Don’t know 
 
5.) Does your facility provide CRC screening outreach specifically to family 
members of patients with colorectal cancer? 
 
Yes (go to Q. 6) No (go to Q. 10) Don’t know 
 
6.) What type of outreach do you provide specifically for family members of CRC 
patients? 
 
a. Patient Wellness Handouts?  Yes     No (skip to b)    Don’t know 
i. Do most of your providers use them? Yes      No    Don’t know 
b. Provider reminders?   Yes     No (skip to c)    Don’t know 
i. Do most of your providers use them?  Yes      No    Don’t know 
c. Mailed patient reminders?  Yes     No (skip to d)    Don’t know 
i. Do most of your providers use them?    Yes    No    Don’t know 
d. Phone patient reminders?  Yes     No (skip to e)    Don’t know 
i. Do most of your providers use them?     Yes   No    Don’t know 
e. Other tools for CRC screening outreach purposes (explain)? Yes No DK 
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7.) Does your facility provide anything beyond that for first degree relatives 
(parents, siblings, children) of patients with colorectal cancer? 
 
Yes (go to Q. 8) No (go to Q. 10) Don’t know 
 
8.) What type of outreach do you do specifically for first degree relatives of patients 
with CRC beyond what you may do for family members in general? 
__________________________________________________________________
__________________________________________________________________ 
 
9.) Do you collect information on first degree family members of CRC patients? 
 
 
Yes (go to Q. 10) No (go to Q. 11) Don’t know 
 
10.) How do you identify first degree family members of CRC patients? 
 
a. Ask CRC patients for family history lists? Yes   No (skip to d)   DK 
i. How are CRC patients identified? 
______________________________________________________
______________________________________________________ 
ii. Who collects the family history information? 
______________________________________________________
______________________________________________________ 
iii. Where is that information put? 
______________________________________________________
______________________________________________________ 
b. Take family history when patient comes in to provider? Yes No (skip to e) 
DK 
i. Who collects the family history information? 
______________________________________________________
______________________________________________________ 
ii. Where is that information put? 
______________________________________________________
______________________________________________________ 
c. In the electronic medical record?    Yes   No (skip to b)   DK   No EMR 
i. How does information get into the electronic medical record? 
______________________________________________________
______________________________________________________ 
ii. Where is that information put? 
______________________________________________________
______________________________________________________ 
d. In the patient chart?    Yes     No (skip to c)    Don’t know 
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i. How does information get into the patient’s chart? 
______________________________________________________
______________________________________________________ 
ii. Where is that information put? 
______________________________________________________ 
 
iii. Other methods (explain)? Yes         No              Don’t know 
______________________________________________________
______________________________________________________ 
e. How often is the information updated (explain)?       
______________________________________________________
______________________________________________________ 
 
(Go to Q. 12) 
***If no to Q. 2: 
11.) If your facility does not offer CRC screening outreach to patients what are some 
of the reasons? 
_____________________________________________________________________ 
_____________________________________________________________________ 
 
12.) What do you think would help your facility expand CRC screening outreach to 
patients? 
_____________________________________________________________________
_____________________________________________________________________ 
 
13.) If the Indian Health Service was to develop a toolkit with CRC screening 
materials and outreach tips how might it be helpful for your facility?  
_____________________________________________________________________
_____________________________________________________________________ 
 
a. What types of items in a CRC screening outreach toolkit do you think 
would be most helpful for your facility?  
____________________________________________________________
____________________________________________________________ 
  
b. Who in your facility do you think would use it? 
____________________________________________________________
____________________________________________________________ 
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II. Demographics 
1.) Facility 
Name:___________________________________________________________ 
2.) Facility location (city, state): 
______________________________________________ 
3.) Facility Point Person: 
____________________________________________________ 
a. Facility Contact title: 
________________________________________________ 
b. Facility Contact email: 
_______________________________________________ 
c. Facility Contact phone number: 
_______________________________________ 
4.) Facility Contact address:  
_________________________________________________________________
_______________________________________________________ 
5.) Do you consider your facility a (circle one)? 
a. Indian Health Service 
b. Tribal 
c. Urban 
d. Other (explain): 
____________________________________________________ 
6.) Is there anyone else at your facility that you would recommend talking to about 
this? 
 
Yes No Don’t know 
 
If so, please list the name and contact information below 
_____________________________________________________________________ 
 
Thank you for your time and assistance. After we finish the survey we will compile an 
aggregated report which we will provide back to you at the end of the project. 
If you have any additional questions or comments please contact Diana Redwood at 
dredwood@anthc.org or 907-729-3959. 
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APPENDIX B 
 
CRC Family History Outreach Program Evaluation Key Informant Interview 
Moderator Guide, 2012 
Name:   Day:    
Position:   Time:    
The focus of this evaluation will be to better understand how the CRC Family History 
Outreach Program is operating in the Alaska Tribal Health System as well as learn what 
effect it has had on CRC screening among Alaska Native people. Input from this 
evaluation will be shared with staff and funders in order to make improvements in 
program implementation. 
My purpose in talking with you today is to learn more about your thoughts, feelings and 
experiences with the CRC Family History Outreach Program. 
Anything you tell me will not be personally attributed to you in any reports that result 
from this evaluation. All of the reports will be written in a manner that no individual 
comment can be attributed to a particular person.  
Your participation in this interview is completely voluntary. Are you willing to be 
interviewed?  
Do you have any questions before we begin? 
 (Note: Not all questions will be asked of all interviewees) 
 
Interview Questions 
1. What is your role with the program? 
2. How did you get involved with the program? When?  
3. How did the program come to exist? 
4. How have you seen it change? 
5. What do you think are the strengths of the program? Weaknesses? 
6. Was there a specific amount of funding available to run the program? How much? 
When did funding start? 
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7. Were staff assigned to the program outreach efforts actually able to spend time 
doing outreach, or were they pulled into other work activities? How many FTEs 
were devoted to the program? 
8. Was there continuous access to the electronic medical record available to program 
staff in order to identify first-degree relatives who had been screened? 
9. When did CRC patients start being contacted to obtain a list (“family history 
lists”) with contact information of their first degree relatives (siblings, parents, 
children)? 
10. Were family history lists that were obtained all entered into the database? 
11. Were first-degree relatives called/sent letters to encourage them to get screened? 
12. How many outreach efforts (phone calls/letters) were made? 
13. Were outreach efforts recorded/tracked in the database? 
14. Was the electronic medical record data merge with the family history database 
completed? 
15. How effective is the Program at getting AN people screened for CRC? 
16. Which program components have been the most successful for implementing the 
Program? 
17. Why did relatives who got screened make that health behavior change? 
18. What are your impressions of how Alaska Native first-degree relatives have been 
affected by the Program? (Probe: increased screening, knowledge of CRC—ask 
for examples) 
19. What were the barriers to program success previously, and what are the barriers 
now? 
20. What were the facilitators to program success previously, and what are the 
facilitators now? 
21. How has ANTHC ensured the sustainability of the Program? 
22. Do you have any additional comments about the Program that we have not 
already discussed? 
Thank you for your time! 
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